

CITATION REPORT

List of articles citing

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

DOI: 10.1126/science.1171362
Science, 2009, 324, 1457-61.

Source: <https://exaly.com/paper-pdf/45452080/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2279	Pancreatic cancer. 2004 , 363, 1049-57		1569
2278	Cancer. Breaching the cancer fortress. <i>Science</i> , 2009 , 324, 1400-1	33.3	46
2277	Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. 2009 , 8, 1893-901		28
2276	A combined, rational approach towards inhibition of the MEK-ERK and mTOR pathways in pancreatic ductal adenocarcinoma: promise or deja vu?. 2009 , 8, 1902-3		3
2275	The hedgehog pathway and pancreatic cancer. 2009 , 361, 2094-6		94
2274	Inflammation: a driving force speeds cancer metastasis. 2009 , 8, 3267-73		237
2273	Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?. 2009 , 11, e34		6
2272	Pancreatic cancer--could it be that simple? A different context of vulnerability. 2009 , 16, 7-8		30
2271	Genentech obtains proof of concept for hedgehog inhibition. 2009 , 27, 968-9		8
2270	Hedgehog inhibitor pokes tumor. 2009 , 15, 734-734		
2269	Two sides to cilia in cancer. 2009 , 15, 994-6		21
2268	Connecting obesity, aging and diabetes. 2009 , 15, 996-7		152
2267	Carbon nanotubes: A simple approach to superlattices. 2009 , 4, 545-6		1
2266	Nanomedicine: Silence the target. 2009 , 4, 544-5		32
2265	Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. 2009 , 8, 806-23		667
2264	Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. 2009 , 12, 114-26		167
2263	Finding and killing the CRABs of pancreatic cancer. 2009 , 137, 782-5		3

2262	Following the hedgehog to new cancer therapies. 2009 , 361, 1202-5	47
2261	Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. 2009 , 7, S68-78	54
2260	SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis. 2010 , 38,	1
2259	Pancreatic cancer: pathobiology, treatment options, and drug delivery. 2010 , 12, 223-32	84
2258	Epithelial-Mesenchymal Transition in Development and Diseases. 2010 , 187-211	1
2257	The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. 2010 , 50, 44-55	58
2256	Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer. 2010 , 59, 1389-400	24
2255	Modulators of the hedgehog signaling pathway. 2010 , 18, 6613-24	111
2254	Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis. 2010 , 395, 295-308	54
2253	Molekularbiologie des Pankreaskarzinoms. 2010 , 16, 557-567	
2252	Stemming cancer by Hedgehog pathway inhibition: from flies to bedside. 2010 , 3, 3-6	
2251	Stromal fibroblasts in digestive cancer. 2010 , 3, 117-25	37
2250	A digest on the role of the tumor microenvironment in gastrointestinal cancers. 2010 , 3, 167-76	23
2249	The extracellular matrix in digestive cancer. 2010 , 3, 177-85	12
2248	ABC transporters as molecular effectors of pancreatic oncogenic pathways: the Hedgehog-GLI model. 2010 , 41, 153-8	17
2247	New promising drug targets in cancer- and metastasis-initiating cells. 2010 , 15, 354-64	34
2246	Small molecule modulation of HH-GLI signaling: current leads, trials and tribulations. 2010 , 80, 712-23	75
2245	The benefits and challenges associated with the use of drug delivery systems in cancer therapy. 2010 , 80, 762-70	114

2244	Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. 2010 , 18, 499-509	126
2243	Dynamic interplay between the collagen scaffold and tumor evolution. 2010 , 22, 697-706	585
2242	Hallmarks of cancer: interactions with the tumor stroma. 2010 , 316, 1324-31	811
2241	Targeting histone deacetylases in pancreatic ductal adenocarcinoma. 2010 , 14, 1255-63	19
2240	Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice. 2010 , 51, 1712-23	136
2239	The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis. 2010 , 127, 1096-105	18
2238	Cyclopamin und der Hedgehog-Signaltransduktionsweg: Chemie, Biologie, medizinische Perspektiven. 2010 , 122, 3492-3502	5
2237	Cycloamine and hedgehog signaling: chemistry, biology, medical perspectives. 2010 , 49, 3418-27	91
2236	New developments in the discovery of small molecule Hedgehog pathway antagonists. 2010 , 14, 428-35	35
2235	Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. 2010 , 101, 882-8	20
2234	Y-box binding protein-1 is a novel molecular target for tumor vessels. 2010 , 101, 1367-73	35
2233	Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. 2010 , 29, 469-81	255
2232	Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells. 2010 , 29, 3146-52	12
2231	Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. 2010 , 103, 649-55	61
2230	CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. 2010 , 103, 1671-9	159
2229	Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo. 2010 , 88, 796-800	8
2228	Adeno-associated virus-mediated delivery of kringle 5 of human plasminogen inhibits orthotopic growth of ovarian cancer. 2010 , 17, 606-15	15
2227	Distant metastasis occurs late during the genetic evolution of pancreatic cancer. 2010 , 467, 1114-7	1834

2226	Finding the tumor copycat: approximating a human cancer. 2010 , 16, 976-7	17
2225	Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. 2010 , 10, 241-53	410
2224	KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. 2010 , 10, 683-95	431
2223	Serum tumor markers in pancreatic cancer-recent discoveries. 2010 , 2, 1107-24	38
2222	Transcriptome profiles of carcinoma-in-situ and invasive non-small cell lung cancer as revealed by SAGE. 2010 , 5, e9162	19
2221	Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. 2010 , 5, e9430	55
2220	Driver mutations: a roadmap for getting close and personal in pancreatic cancer. 2010 , 10, 588-91	23
2219	Targeting Notch signaling in pancreatic cancer. 2010 , 14, 541-52	39
2218	Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. 2010 , 9, 3052-64	202
2217	Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. 2010 , 62, 497-524	98
2216	Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice. 2010 , 70, 3515-25	50
2215	Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. 2010 , 3, 1427-34	72
2214	A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). 2010 , 15, 1310-9	56
2213	Overexpression of smoothed activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. 2010 , 16, 1781-9	141
2212	Hedgehog signaling controls mesenchymal growth in the developing mammalian digestive tract. 2010 , 137, 1721-9	129
2211	Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. 2010 , 24, 837-52	147
2210	Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. 2010 , 2, 84-95	200
2209	Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. 2010 , 16, 3684-95	62

2208	Deploying mouse models of pancreatic cancer for chemoprevention studies. 2010 , 3, 1382-7	23
2207	Protein kinase D2 is a crucial regulator of tumour cell-endothelial cell communication in gastrointestinal tumours. 2010 , 59, 1316-30	61
2206	Molecular biology and anticancer drug discovery. 2010 , 95, 9-29	2
2205	Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). 2010 , 28, 3617-22	659
2204	Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. 2010 , 107, 13432-7	248
2203	Intraperitoneal therapy for peritoneal cancer. 2010 , 6, 1625-41	117
2202	Genetically engineered mouse models in cancer research. 2010 , 106, 113-64	127
2201	A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. 2010 , 9, 311-8	34
2200	Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. 2010 , 70, 2644-54	75
2199	Hypoxia induced tumor metabolic switch contributes to pancreatic cancer aggressiveness. 2010 , 2, 2138-52	41
2198	Interaction of stellate cells with pancreatic carcinoma cells. 2010 , 2, 1661-82	31
2197	Contribution of epithelial-mesenchymal transition to pancreatic cancer progression. 2010 , 2, 2084-97	13
2196	Systemic therapy for metastatic pancreatic adenocarcinoma. 2010 , 2, 85-106	4
2195	Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy. 2010 , 70, 2141-5	28
2194	ERBB3: Multifunctional enabler or primary actor in pancreatic cancer?. 2010 , 10, 564-6	2
2193	Assessing the efficacy of the hedgehog pathway inhibitor vitamin D3 in a murine xenograft model for pancreatic cancer. 2010 , 10, 79-88	29
2192	Do predictive signatures really predict response to cancer chemotherapy?. 2010 , 9, 4836-40	46
2191	Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. 2010 , 10, 391-6	38

2190	Chemoprevention of pancreatic cancer: ready for the clinic?. 2010 , 3, 1375-8	6
2189	Challenges of drug resistance in the management of pancreatic cancer. 2010 , 10, 1647-61	38
2188	[Personalized therapy of gastrointestinal cancers--possibilities and limitations]. 2010 , 135, 1687-91	
2187	Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways. 2010 , 97, 41-78	22
2186	Novel therapies for pancreatic cancer: setbacks and progress. 2010 , 6, 1061-4	7
2185	Kinase signaling pathways as targets for intervention in pancreatic cancer. 2010 , 9, 754-63	23
2184	Tumor metabolism to blood flow ratio in pancreatic cancer: helpful in patient stratification?. 2010 , 6, 13-5	4
2183	The role of radiotherapy in locally advanced pancreatic carcinoma. 2010 , 7, 437-47	32
2182	Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. 2010 , 70, 2852-61	86
2181	Drug efficacy testing in mice. 2012 , 355, 19-38	10
2180	Recent Advances in Flow Cytometry: Platforms, Tools, and Challenges for Data Analysis. 2010 , 23-54	1
2179	Tyrosine kinase inhibitors to treat liver cancer. 2010 , 15, 13-26	19
2178	Gemcitabine intercellular diffusion mediated by gap junctions: new implications for cancer therapy. 2010 , 9, 141	32
2177	Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. 2010 , 9, 88	68
2176	25 Role of pharmacokinetics/Pharmacodynamics in dose selection of molecular targeted therapies. 2010 , 8, 17-18	
2175	26 Is a side effect of molecular targeted therapy a marker of efficacy?. 2010 , 8, 18	
2174	27 Drug response in a genetically engineered mouse: clinical implications. 2010 , 8, 18	
2173	27A Targeting the PI3K/mTOR pathway in genetically engineered mouse models of advanced prostate cancer. 2010 , 8, 18-19	

2172	Tracking down the hedgehog's lair in the pancreas. 2010 , 138, 823-5	6
2171	Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. 2010 , 139, 292-303	110
2170	Targeting of drugs and nanoparticles to tumors. 2010 , 188, 759-68	688
2169	Clinical experience with Hedgehog pathway inhibitors. 2010 , 28, 5321-6	161
2168	Drosophila as a novel therapeutic discovery tool for thyroid cancer. 2010 , 20, 689-95	28
2167	Delivering nanomedicine to solid tumors. 2010 , 7, 653-64	2279
2166	Learning from Jekyll to control Hyde: Hedgehog signaling in development and cancer. 2010 , 16, 337-48	174
2165	Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs. 2010 , 10, 397-404	7
2164	Tumors as organs: complex tissues that interface with the entire organism. 2010 , 18, 884-901	827
2163	Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. 2010 , 46, 2166-77	62
2162	Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy?. 2010 , 21, 2-10	116
2161	Stroma in breast development and disease. 2010 , 21, 11-8	87
2160	Role of pancreatic stellate cells in pancreatic cancer metastasis. 2010 , 177, 2585-96	257
2159	Pancreatic cancer. 2010 , 362, 1605-17	2151
2158	Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. <i>Science</i> , 2010 , 330, 827-30	333 756
2157	Targeting the Hedgehog pathway in cancer. 2010 , 2, 237-50	207
2156	Targeting Hedgehog--a cancer stem cell pathway. 2010 , 16, 3130-40	380
2155	Genetics of biliary tract cancers and emerging targeted therapies. 2010 , 28, 3531-40	164

2154	Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. 2010 , 9, 2255-64	156
2153	New frontiers in pancreatic cancer research. 2010 , 19, 431-51	2
2152	The Tumor Microenvironment. 2010 ,	4
2151	Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. 2010 , 7, 914-20	157
2150	Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P846, a new low-diffusible gadolinium-based contrast agent. 2011 , 175, 10-20	14
2149	New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy. 2011 , 25, 207-16	7
2148	Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. 2011 , 1, 291-6	145
2147	Pancreatic cancers require autophagy for tumor growth. 2011 , 25, 717-29	1003
2146	Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 2011 , 15, 1183-96	42
2145	Integrating pharmacogenetics into gemcitabine dosing--time for a change?. 2011 , 8, 439-44	53
2144	The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. 2011 , 2, 1139-45	84
2143	64-slice CT perfusion imaging of pancreatic adenocarcinoma and mass-forming chronic pancreatitis. 2011 , 18, 81-8	38
2142	Ectopic overexpression of Sonic Hedgehog (Shh) induces stromal expansion and metaplasia in the adult murine pancreas. 2011 , 13, 923-30	26
2141	Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt- β -catenin signaling to slow tumor progression. 2011 , 141, 1486-97, 1497.e1-14	234
2140	Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. 2010 , 10, 673-81	89
2139	Yet another nucleoside analog for pancreatic cancer. 2011 , 140, 400-4	2
2138	Timing is everything: Brca2 and p53 mutations in pancreatic cancer. 2011 , 140, 1143-6	5
2137	Drugging the cancer stem cell compartment: lessons learned from the hedgehog and Wnt signal transduction pathways. 2011 , 51, 289-310	41

2136	Cancer Associated Fibroblasts as Therapeutic Targets. 2011 , 383-401		
2135	Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. 2011 , 6, e27306		151
2134	FLIM-FRET imaging in vivo reveals 3D-environment spatially regulates RhoGTPase activity during cancer cell invasion. 2011 , 2, 239-244		25
2133	Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. 2011 , 2, 281-98		407
2132	Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research. 2011 , 6, 33-48		11
2131	Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. 2011 , 18, 1331-1335		281
2130	CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. <i>Science</i> , 2011 , 331, 1612-6	33:3	1177
2129	New targeted therapies for gastric cancer. 2011 , 20, 595-604		19
2128	Visualization of mouse pancreas architecture using MR microscopy. 2011 , 179, 610-8		6
2127	Tumor metastasis: molecular insights and evolving paradigms. 2011 , 147, 275-92		2474
2126	The role of Hedgehog signaling in fibrogenic liver repair. 2011 , 43, 238-44		91
2125	Interventions that induce modifications in the tumor microenvironment. 2011 , 15, 376-82		7
2124	[New perspectives for radiosensitization in pancreatic carcinoma: a review of mechanisms involved in pancreatic tumorigenesis]. 2011 , 15, 365-75		1
2123	Angiogenesis: a prognostic determinant in pancreatic cancer?. 2011 , 47, 2576-84		29
2122	The inverted pyramid of biomarker-driven trials. 2011 , 8, 562-6		14
2121	Targeting PDGFR- β in Cholangiocarcinoma. 2012 , 32, 400-9		27
2120	Cancer. Autophagy in tumor immunity. <i>Science</i> , 2011 , 334, 1501-2	33:3	23
2119	Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. 2011 , 8, 97-106		757

2118	Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. 2011 , 9, 433-46	314
2117	Development of targeted therapies for pancreatic cancer. 2011 , 12, 206-7	4
2116	Expression of L amino acid transport system 1 and analysis of iodine-123-methyltyrosine tumor uptake in a pancreatic xenotransplantation model using fused high-resolution-micro-SPECT-MRI. 2011 , 10, 30-7	8
2115	Pigment epithelium-derived factor associates with neuropathy and fibrosis in pancreatic cancer. 2011 , 106, 968-80	29
2114	Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. 2011 , 6, e24807	99
2113	Stromal biology and therapy in pancreatic cancer. 2011 , 60, 861-8	532
2112	In vivo delivery of RNAi with lipid-based nanoparticles. 2011 , 13, 507-30	142
2111	Pancreatic cancer. 2011 , 378, 607-20	1693
2110	Clinical implications of hedgehog signaling pathway inhibitors. 2011 , 30, 13-26	21
2109	Activation of the hedgehog pathway in gastroesophageal cancers. 2011 , 1,	0
2108	Signaling pathways in pancreatic cancer. 2011 , 21, 115-29	29
2107	Predictive biology of ovarian cancer. 41-54	
2106	RAS and Hedgehog--partners in crime. 2011 , 16, 2259-70	14
2105	Recent Patents on Liposomal-Based Chemotherapeutics with a Triggered Release Mechanism. 2011 , 1, 1-6	1
2104	The role of mirk kinase in sarcomas. 2011 , 2011, 260757	4
2103	Cancer stem cells: repair gone awry?. 2011 , 2011, 465343	14
2102	Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. 2011 , 16, 368-92	47
2101	A novel synthetic smoothed antagonist transiently inhibits pancreatic adenocarcinoma xenografts in a mouse model. 2011 , 6, e19904	25

2100	Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. 2011 , 6, e21573	104
2099	Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. 2011 , 6, e21684	53
2098	Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. 2011 , 6, e23943	119
2097	Reversion of pH-induced physiological drug resistance: a novel function of copolymeric nanoparticles. 2011 , 6, e24172	17
2096	Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. 2011 , 6, e26088	48
2095	Aberrant Hedgehog ligands induce progressive pancreatic fibrosis by paracrine activation of myofibroblasts and ductular cells in transgenic zebrafish. 2011 , 6, e27941	39
2094	Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma. 2011 , 27, 276-84	42
2093	Primary human tumor xenografted models ('tumorgrafts') for good management of patients with cancer. 2011 , 22, 827-41	39
2092	Advances in pancreatic cancer. 2011 , 27, 460-6	25
2091	Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms. 2011 , 254, 818-23; discussion 823	29
2090	Hedgehog inhibition with cyclopamine represses tumor growth and prolongs survival in a transgenic mouse model of islet cell tumors. 2011 , 253, 546-52	13
2089	Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. 2011 , 11, 254-84	170
2088	Precursor lesions in pancreatic cancer: morphological and molecular pathology. 2011 , 43, 183-200	48
2087	Hedgehog signaling pathway as a therapeutic target in various types of cancer. 2011 , 102, 1756-60	76
2086	Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. 2011 , 17, 320-9	1052
2085	Mouse models of advanced spontaneous metastasis for experimental therapeutics. 2011 , 11, 135-41	289
2084	The Hedgehog's tale: developing strategies for targeting cancer. 2011 , 11, 493-501	321
2083	G protein-coupled receptors: novel targets for drug discovery in cancer. 2011 , 10, 47-60	525

2082	Advances in the preclinical testing of cancer therapeutic hypotheses. 2011 , 10, 179-87	100
2081	Cytotoxic chemotherapy: clinical aspects. 2011 , 39, 717-722	22
2080	Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. 2011 , 21, 245-55	39
2079	Cell communication networks in cancer invasion. 2011 , 23, 621-9	61
2078	Hedgehog signaling in skin cancers. 2011 , 23, 1235-43	51
2077	Hallmarks of cancer: the next generation. 2011 , 144, 646-74	39819
2076	Overcoming drug resistance in pancreatic cancer. 2011 , 15, 817-28	157
2075	Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. 2011 , 17, 2502-11	431
2074	Mechanisms of Hedgehog signalling in cancer. 2011 , 29, 221-34	40
2073	Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 2011 , 17, 5822-32	73
2072	Chemical 'Jekyll and Hyde's: small-molecule inhibitors of developmental signaling pathways. 2011 , 40, 4318-31	26
2071	Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. 2011 , 6, 1605-20	67
2070	Pancreatic cancer stem cells: new insights and perspectives. 2011 , 46, 966-73	33
2069	Pancreatic cancer stem cell biology and its therapeutic implications. 2011 , 46, 1345-52	22
2068	Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. 2011 , 130, 93-101	12
2067	Cancer stem cells: a new framework for the design of tumor therapies. 2011 , 89, 95-107	57
2066	A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy. 2011 , 68, 1243-53	42
2065	Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma. 2011 , 42, 85-92	30

2064	Hedgehog Pathway Inhibitors: Potential Applications in Breast Cancer. 2011 , 3, 15-23	1
2063	Defining new paradigms for the treatment of pancreatic cancer. 2011 , 12, 111-25	33
2062	Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. 2011 , 10, 37	166
2061	The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. 2011 , 223, 295-306	38
2060	Overcoming in vivo barriers to targeted nanodelivery. 2011 , 3, 421-37	129
2059	Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. 2011 , 43, 565-74	76
2058	Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities. 2011 , 53, 695-704	54
2057	Hepatic stellate cells: partners in crime for liver metastases?. 2011 , 54, 707-13	114
2056	Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. 2011 , 54, 2076-88	114
2055	A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. 2011 , 117, 2620-8	21
2054	MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer. 2011 , 129, 2553-65	16
2053	MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF- β signaling. 2011 , 9, 1294-304	47
2052	Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice. 2012 , 5, 397-402	44
2051	Preclinical drug development for childhood cancer. 2011 , 6, 49-64	7
2050	Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients. 2011 , 11, 1555-65	12
2049	Establishment of murine basal cell carcinoma allografts: a potential model for preclinical drug testing and for molecular analysis. 2011 , 131, 2298-305	13
2048	The hedgehog knows many tricks. 2011 , 12, 2091-5	
2047	Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. 2011 , 131, 2467-76	78

2046	Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. 2011 , 71, 5182-93	75
2045	Tumoral and nontumoral pancreas: correlation between quantitative dynamic contrast-enhanced MR imaging and histopathologic parameters. 2011 , 261, 456-66	68
2044	Scaling rules for diffusive drug delivery in tumor and normal tissues. 2011 , 108, 1799-803	126
2043	Micro-ultrasound for preclinical imaging. 2011 , 1, 576-601	82
2042	Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells. 2011 , 10, 2104-14	45
2041	Targeting the tumor microenvironment by immunotherapy: part 2. 2011 , 3, 1385-408	5
2040	Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. 2011 , 39, 132-9	45
2039	Hedgehog-producing cancer cells respond to and require autocrine Hedgehog activity. 2011 , 71, 4454-63	38
2038	Pancreatic stellate cells radioprotect pancreatic cancer cells through α -integrin signaling. 2011 , 71, 3453-8	154
2037	Activation of Hedgehog Signaling in Human Cancer. 2011 , 85-104	5
2036	Targeting the Hedgehog pathway in cancer: can the spines be smoothed?. 2011 , 17, 2071-3	10
2035	Hedgehog signaling: networking to nurture a promalignant tumor microenvironment. 2011 , 9, 1165-74	53
2034	Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. 2011 , 17, 5793-800	175
2033	Hedgehog signaling and therapeutics in pancreatic cancer. 2011 , 32, 445-51	94
2032	Molecular Approaches To Target GPCRs in Cancer Therapy. 2011 , 4, 567-589	13
2031	New role of microRNA: carcinogenesis and clinical application in cancer. 2011 , 43, 831-9	34
2030	Oncolytic virotherapy for pancreatic cancer. 2011 , 13, e18	23
2029	In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging. 2011 , 108, 9945-50	73

2028	Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. 2011 , 71, 1019-28	124
2027	Opportunities and challenges in the development of experimental drug combinations for cancer. 2011 , 103, 1222-6	77
2026	Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53. 2011 , 71, 747-57	118
2025	Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells. 2011 , 108, 9589-94	89
2024	Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. 2011 , 108, E1275-84	55
2023	Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. 2011 , 10, 938-48	45
2022	Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. 2011 , 17, 4042-51	87
2021	PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF- κ B-cytokine network. 2011 , 1, 158-69	155
2020	Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. 2011 , 108, 2909-14	455
2019	Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. 2011 , 29, 4548-54	795
2018	Pathophysiology of pancreatic cancer. 2011 , 6-19	
2017	Imaging molecular dynamics in vivo--from cell biology to animal models. 2011 , 124, 2877-90	62
2016	How genetically engineered mouse tumor models provide insights into human cancers. 2011 , 29, 2273-81	97
2015	The many faces of wnt and pancreatic ductal adenocarcinoma oncogenesis. 2011 , 3, 3676-86	8
2014	Management strategies in pancreatic cancer. 2011 , 68, 573-84	20
2013	Membrane drug transporters and chemoresistance in human pancreatic carcinoma. 2010 , 3, 106-25	31
2012	Toxic plants. 2011 , 689-705	1
2011	Neoadjuvant therapy in patients with pancreatic cancer: a disappointing therapeutic approach?. 2011 , 3, 2286-301	2

2010	Pancreatic stellate cells: a starring role in normal and diseased pancreas. 2012 , 3, 344	198
2009	The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. 2012 , 3, 270	52
2008	nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. 2012 , 2, 260-269	309
2007	StellaTUM: current consensus and discussion on pancreatic stellate cell research. 2012 , 61, 172-8	298
2006	Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors. 2012 , 17, 1303-16	31
2005	Remodeling of tumor stroma and response to therapy. 2012 , 4, 340-53	13
2004	Role of hedgehog signaling in malignant pleural mesothelioma. 2012 , 18, 4646-56	47
2003	Pancreas cancer meets the thunder god. 2012 , 4, 156ps21	7
2002	Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. 2012 , 61, 1488-500	73
2001	How fibrosis influences imaging and surgical decisions in pancreatic cancer. 2012 , 3, 389	35
2000	TGF- β and α 5 integrin act in a common pathway to suppress pancreatic cancer progression. 2012 , 72, 4840-5	69
1999	GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells. 2012 , 72, 88-99	50
1998	Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. 2012 , 209, 437-44	78
1997	Targeting eNOS in pancreatic cancer. 2012 , 72, 4472-82	47
1996	Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. 2012 , 11, 1193-202	57
1995	Human correlates of provocative questions in pancreatic pathology. 2012 , 19, 351-62	23
1994	Genetically engineered mouse models of pancreatic cancer. 2012 , 18, 502-10	73
1993	Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persists or what?. 2012 , 2, 120066	129

1992	New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. 2012 , 23, 570-576	54
1991	The utility of hedgehog signaling pathway inhibition for cancer. 2012 , 17, 1090-9	36
1990	The pancreas cancer microenvironment. 2012 , 18, 4266-76	863
1989	Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells. 2012 , 7, 999-1013	56
1988	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. 2012 , 486, 266-70	253
1987	The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. 2012 , 12, 288-303	61
1986	Progress in pancreatic cancer: moving beyond gemcitabine?. 2012 , 12, 997-1000	1
1985	Immune system plays an important role in the success and failure of conventional cancer therapy. 2012 , 4, 125-8	12
1984	Aberrations and therapeutics involving the developmental pathway Hedgehog in pancreatic cancer. 2012 , 88, 355-78	4
1983	Arousal of cancer-associated stromal fibroblasts: palladin-activated fibroblasts promote tumor invasion. 2012 , 6, 488-94	28
1982	Combined modality treatments in pancreatic cancer. 2012 , 16 Suppl 2, S71-81	9
1981	Emerging roles of the tumor-associated stroma in promoting tumor metastasis. 2012 , 6, 193-202	44
1980	Development of an intrabiliary MR imaging-monitored local agent delivery technique: a feasibility study in pigs. 2012 , 262, 846-52	10
1979	Animal modeling of cancer pathology and studying tumor response to therapy. 2012 , 13, 1535-47	32
1978	Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. 2012 , 109, 15101-8	512
1977	Origins of tumor-associated macrophages and neutrophils. 2012 , 109, 2491-6	445
1976	The mesenchymal tumor microenvironment: a drug-resistant niche. 2012 , 6, 285-96	36
1975	N-cadherin haploinsufficiency increases survival in a mouse model of pancreatic cancer. 2012 , 31, 4484-9	24

1974	Hedgehog pathway activation in human transitional cell carcinoma of the bladder. 2012 , 106, 1177-86	45
1973	A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. 2012 , 31, 2535-44	57
1972	HIV-1 Env antibodies: are we in a bind or going blind?. 2012 , 18, 346-7; author reply 347-8	7
1971	The matricellular protein CCN1/Cyr61 is a critical regulator of Sonic Hedgehog in pancreatic carcinogenesis. 2012 , 287, 38569-79	41
1970	Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. 2012 , 72, 2695-700	103
1969	Development of NMR: Biological and Medical MR Spectroscopy. 2012 ,	
1968	Pancreatic cancer and premalignant tumors. 2012 , 123-134.e3	
1967	Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET. 2012 , 53, 275-80	20
1966	Selective targeting of interferon β to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth. 2012 , 11, 2419-28	39
1965	Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. 2012 , 10, 1403-18	357
1964	Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. 2012 , 61, 877-84	54
1963	Desmoplasia in pancreatic cancer. Can we fight it?. 2012 , 2012, 781765	41
1962	Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. 2012 , 4, 989-1035	25
1961	The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. 2012 , 109, E1038-47	95
1960	Emerging frontiers in pancreatic cancer research: elaboration of key genes, cells and the extracellular milieu. 2012 , 28, 516-22	13
1959	Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma. 2012 , 72, 6344-50	43
1958	Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?. 2012 , 17, 192-200	68
1957	Nuclear receptors as modulators of the tumor microenvironment. 2012 , 5, 3-10	22

1956	Molecular and genetic bases of pancreatic cancer. 2012 , 13, 731-43	21
1955	Neoadjuvant therapy for resectable and borderline resectable adenocarcinoma of the pancreas. 2012 , 13, 781-8	12
1954	Molecular pathology of pancreatic cancer: from bench-to-bedside translation. 2012 , 13, 744-52	26
1953	Monoclonal antibodies and other targeted therapies for pancreatic cancer. 2012 , 18, 653-64	16
1952	Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. 2012 , 122, 1734-41	53
1951	Therapeutic potential of Hedgehog signaling inhibitors in cancer: rationale and clinical data. 2012 , 2, 371-385	1
1950	Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. 2012 , 120, 2909-17	49
1949	Pancreatic cancer stem cells: regulatory networks in the tumor microenvironment and targeted therapy. 2012 , 19, 614-20	15
1948	Targeting pericyte differentiation as a strategy to modulate kidney fibrosis in diabetic nephropathy. 2012 , 32, 463-70	31
1947	Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. 2012 , 72, 897-907	62
1946	Nerve-cancer interactions in the stromal biology of pancreatic cancer. 2012 , 3, 97	76
1945	The mesenchyme in malignancy: a partner in the initiation, progression and dissemination of cancer. 2012 , 136, 131-41	15
1944	Small molecule inhibitors of the hedgehog signaling pathway for the treatment of cancer. 2012 , 35, 1317-33	33
1943	Hedgehog inhibition as an anti-cancer strategy. 2012 , 88, 507-22	8
1942	Treatment options for advanced pancreatic cancer: a review. 2012 , 12, 1327-36	32
1941	Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. 2012 , 23, 1613-21	171
1940	Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer. 2012 , 10, 1147-57	78
1939	What we have learned about pancreatic cancer from mouse models. 2012 , 142, 1079-92	129

1938	Everolimus for the treatment of pancreatic neuroendocrine tumors. 2012 , 13, 2073-84	6
1937	CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor B: implications for bidirectional tumor-stromal interactions. 2012 , 287, 39115-24	92
1936	A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. 2012 , 4, 156ra139	180
1935	Therapeutic effect of Bsecretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. 2012 , 22, 222-34	92
1934	EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. 2012 , 22, 318-30	272
1933	Hedgehog signaling: from the cuirass to the heart of pancreatic cancer. 2012 , 12, 388-93	8
1932	Pancreatic cancer: medical management (novel chemotherapeutics). 2012 , 41, 189-209	26
1931	STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases. 2012 , 14, 915-25	25
1930	Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. 2012 , 14, 410-9	34
1929	Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. 2012 , 109, 7859-64	99
1928	Enhancement of cyclopamine via conjugation with nonmetabolic sugars. 2012 , 14, 2454-7	20
1927	The extracellular matrix: a dynamic niche in cancer progression. 2012 , 196, 395-406	1999
1926	The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. 2012 , 31, 823-42	56
1925	The Valley of Death in anticancer drug development: a reassessment. 2012 , 33, 173-80	54
1924	A central role for RAF-MEK-ERK signaling in the genesis of pancreatic ductal adenocarcinoma. 2012 , 2, 685-93	202
1923	Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. 2012 , 4, 147ra112	135
1922	Nupr1-aurora kinase A pathway provides protection against metabolic stress-mediated autophagic-associated cell death. 2012 , 18, 5234-46	55
1921	Targeting the Hedgehog signaling pathway for cancer therapy. 2012 , 16, 49-66	61

1920	Heterogeneity and targeting of pancreatic cancer stem cells. 2012 , 18, 4277-84	61
1919	Stem Cell Characters in Primary and Metastatic Tumour Establishment. 2012 , 533-580	1
1918	Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid. 2012 , 61, 1377-9	39
1917	Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1. 2012 , 10, 183-96	34
1916	Vismodegib: a promising drug in the treatment of basal cell carcinomas. 2012 , 8, 915-28	8
1915	Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. 2012 , 13, 900-8	226
1914	Applying next-generation sequencing to pancreatic cancer treatment. 2012 , 9, 477-86	37
1913	Hedgehog-Gli pathway activation during kidney fibrosis. 2012 , 180, 1441-53	145
1912	Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method. 2012 , 172, 29-39	46
1911	Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. 2012 , 173, 105-12	68
1910	Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells. 2012 , 421, 349-54	127
1909	Combinational therapy: new hope for pancreatic cancer?. 2012 , 317, 127-35	70
1908	Pancreatic cancer: promise for personalised medicine?. 2012 , 318, 1-8	24
1907	Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. 2012 , 320, 138-49	61
1906	Life in the fast lane: mammalian disease models in the genomics era. 2012 , 148, 1099-109	60
1905	Drug resistance in the mouse cancer clinic. 2012 , 15, 81-9	27
1904	Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. 2012 , 22, 21-7	22
1903	The right time, the right place: will targeting human cancer-associated mutations to the mouse provide the perfect preclinical model?. 2012 , 22, 28-35	5

1902	The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. 2011 , 9, 77-87	75
1901	Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine. 2012 , 12, 354	46
1900	The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. 2012 , 12, 587-98	415
1899	New biomarkers and targets in pancreatic cancer and their application to treatment. 2012 , 9, 435-44	156
1898	Magnetic resonance spectroscopy of cancer metabolism and response to therapy. 2012 , 177, 398-435	10
1897	Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. 2012 , 18, 4249-56	65
1896	New insights into pancreatic cancer biology. 2012 , 23 Suppl 10, x135-8	56
1895	Targeting the hedgehog pathway: role in cancer and clinical implications of its inhibition. 2012 , 26, 565-88, viii	12
1894	Therapeutic targeting of hyaluronan in the tumor stroma. 2012 , 4, 873-903	72
1893	Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. 2012 , 441, 541-52	138
1892	Nakiterpiosin. 2012 , 25-37	2
1891	Anti-angiogenic drug discovery: lessons from the past and thoughts for the future. 2012 , 7, 723-43	25
1890	Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. 2012 , 30, 648-57	85
1889	Direct molecular tissue analysis by MALDI imaging mass spectrometry in the field of gastrointestinal disease. 2012 , 143, 544-549.e2	20
1888	Systemic treatment of advanced pancreatic cancer. 2012 , 38, 843-53	98
1887	Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. 2012 , 38, 566-79	92
1886	Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. 2012 , 23, 343-56	28
1885	Improving drug penetration to curb tumor drug resistance. 2012 , 17, 1139-46	24

1884	Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors. 2012 , 15, 211-22	16
1883	Sonic Hedgehog in pancreatic cancer: from bench to bedside, then back to the bench. 2012 , 152, S19-32	30
1882	Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development. 2012 , 33, 449-55	30
1881	The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. 2012 , 6, 111-27	118
1880	Omics and therapy - a basis for precision medicine. 2012 , 6, 128-39	30
1879	Genomics and pharmacogenomics of pancreatic adenocarcinoma. 2012 , 12, 1-9	10
1878	The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. 2012 , 9, 454-67	418
1877	The Role of Bone Marrow-Derived Progenitor Cells in Tumor Growth and Angiogenesis. 2012 , 45-54	
1876	The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. 2011 , 9, 44-54	113
1875	Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. 2012 , 18, 344-6; author reply 346	88
1874	Stromal cell-derived factor 1 α mediates resistance to mTOR-directed therapy in pancreatic cancer. 2012 , 14, 690-701	40
1873	Pathology and Genetics of Pancreatic Neoplasms. 2012 , 5, 941-59	
1872	Brain Tumor Models to Predict Clinical Outcome: Like the Phoenix?. 2012 , 3-20	1
1871	[New aspects of surgery for pancreatic cancer. Principles, results and evidence]. 2012 , 33 Suppl 2, 258-65	0
1870	Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. 2012 , 22, 295-305	52
1869	Patient-derived tumour xenografts as models for oncology drug development. 2012 , 9, 338-50	900
1868	Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. 2012 , 4, 271-9	51
1867	Energy Balance and Gastrointestinal Cancer. 2012 ,	1

1866	Molecular markers associated with outcome and metastasis in human pancreatic cancer. 2012 , 31, 68	51
1865	Arousal of cancer-associated stroma: overexpression of palladin activates fibroblasts to promote tumor invasion. 2012 , 7, e30219	68
1864	Feedback within the inter-cellular communication and tumorigenesis in carcinomas. 2012 , 7, e36719	15
1863	Unlike pancreatic cancer cells pancreatic cancer associated fibroblasts display minimal gene induction after 5-aza-2'-deoxycytidine. 2012 , 7, e43456	20
1862	Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. 2012 , 7, e49707	117
1861	Role of Wnt/ β -catenin signaling in drug resistance of pancreatic cancer. 2012 , 18, 2464-71	114
1860	Hedgehog pathway as a drug target: Smoothed inhibitors in development. 2012 , 5, 47-58	113
1859	Failure of Pancreatic Cancer Chemotherapy: Consequences of Drug Resistance Mechanisms. 2012 ,	1
1858	Novel therapeutic modalities and drug delivery in pancreatic cancer - an ongoing search for improved efficacy. 2012 , 2012, 212244	1
1857	Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis. 2012 , 122, 2092-103	84
1856	Hedgehog Signaling in Gastrointestinal Morphogenesis and Morphostasis. 2012 , 303-327	
1855	Cooperative Hedgehog-EGFR signaling. 2012 , 17, 90-9	44
1854	Tumor Microenvironment and Pancreatic Cancer. 2012 , 01,	1
1853	Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer. 2012 , 12, 15	96
1852	Integrative physical oncology. 2012 , 4, 1-14	25
1851	Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. 2012 , 18, 4019-25	57
1850	Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. 2012 , 227, 3373-80	51
1849	Magnetization transfer MRI in pancreatic cancer xenograft models. 2012 , 68, 1291-7	28

1848	Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. 2012 , 4, 675-84	164
1847	Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. 2012 , 131, 30-40	157
1846	Stromal interactions as regulators of tumor growth and therapeutic response: A potential target for photodynamic therapy?. 2012 , 52, 757-766	15
1845	Production of avian retroviruses and tissue-specific somatic retroviral gene transfer in vivo using the RCAS/TVA system. 2012 , 7, 1167-83	40
1844	The determinants of tumour immunogenicity. 2012 , 12, 307-13	248
1843	Peptides as targeting elements and tissue penetration devices for nanoparticles. 2012 , 24, 3747-56	311
1842	Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. 2012 , 64, 2724-33	110
1841	EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. 2012 , 18, 465-74	96
1840	Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. 2012 , 31, 195-208	383
1839	Identification of cancer stem cells provides novel tumor models for drug discovery. 2012 , 6, 112-21	3
1838	Chronic myeloid leukemia stem cell biology. 2012 , 7, 125-32	36
1837	How to improve exposure of tumor cells to drugs: promoter drugs increase tumor uptake and penetration of effector drugs. 2012 , 64, 53-68	69
1836	Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. 2012 , 21, 418-29	1309
1835	Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. 2012 , 21, 488-503	353
1834	Accessories to the crime: functions of cells recruited to the tumor microenvironment. 2012 , 21, 309-22	2685
1833	A tell-tail sign of chromatin: histone mutations drive pediatric glioblastoma. 2012 , 21, 329-31	17
1832	Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer?. 2012 , 21, 327-9	58
1831	Predictive in vivo animal models and translation to clinical trials. 2012 , 17, 253-60	80

1830	The immunological contribution of NF- κ B within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent. 2012 , 1825, 160-72	16
1829	Stroma and pancreatic ductal adenocarcinoma: an interaction loop. 2012 , 1826, 170-8	16
1828	Muscle wasting in animal models of severe illness. 2012 , 93, 157-71	38
1827	Metastatic disease: a drug discovery perspective. 2012 , 22, 261-71	7
1826	Targeting DNA damage and repair: embracing the pharmacological era for successful cancer therapy. 2012 , 133, 334-50	77
1825	Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. 2012 , 160, 245-53	43
1824	Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer. 2012 , 103, 1272-9	34
1823	Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells. 2012 , 27 Suppl 2, 69-74	108
1822	Aberrant signaling pathways in pancreatic cancer: a two compartment view. 2012 , 51, 25-39	43
1821	A starring role for stellate cells in the pancreatic cancer microenvironment. 2013 , 144, 1210-9	299
1820	Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer. 2013 , 8, 145-51	21
1819	Molecular Genetics of Pancreatic Cancer. 2013 ,	1
1818	Cancer Genomics. 2013 ,	4
1817	The use of HA oligosaccharide-loaded nanoparticles to breach the endogenous hyaluronan glycocalyx for breast cancer therapy. 2013 , 34, 6829-38	41
1816	Fibroblast-mediated drug resistance in cancer. 2013 , 85, 1033-41	105
1815	Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. 2013 , 13, 194	30
1814	Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. 2013 , 13, 154	73
1813	Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner. 2013 , 12, 66	109

1812	Translating discovery in zebrafish pancreatic development to human pancreatic cancer: biomarkers, targets, pathogenesis, and therapeutics. 2013 , 10, 132-46	6
1811	Bone marrow cells as precursors of the tumor stroma. 2013 , 319, 1650-6	21
1810	Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. 2013 , 108, 1-8	216
1809	Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs. 2013 , 228, 1834-43	7
1808	Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions. 2013 , 341, 132-8	18
1807	Ultrasound-targeted microbubble destruction for chemotherapeutic drug delivery to solid tumors. 2013 , 1, 10	73
1806	Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. 2013 , 20, 3787-93	36
1805	Roles for KRAS in pancreatic tumor development and progression. 2013 , 144, 1220-9	261
1804	Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. 2013 , 109, 926-33	208
1803	Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells. 2013 , 72, 553-63	42
1802	Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. 2013 , 71, 1485-91	10
1801	Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells. 2013 , 340, 113-23	103
1800	60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. 2013 ,	7
1799	Therapeutic advances in pancreatic cancer. 2013 , 144, 1316-26	220
1798	Relevance of animal models of pancreatic cancer and pancreatitis to human disease. 2013 , 144, 1194-8	38
1797	Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. 2013 , 15, 249-62	126
1796	Mechanistic insights into self-reinforcing processes driving abnormal histogenesis during the development of pancreatic cancer. 2013 , 182, 1078-86	14
1795	The role of pancreatic stellate cells in pancreatic cancer. 2013 , 13, 106-9	23

1794	Genetically engineered mouse models of pancreatic adenocarcinoma. 2013 , 7, 232-47	111
1793	Antifibrotic therapy in pancreatic diseases. 2013 , 62, 1244-5	4
1792	Unraveling the therapeutic potential of the Hedgehog pathway in cancer. 2013 , 19, 1410-22	409
1791	Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. 2013 , 145, 1121-32	310
1790	Influence of tumour micro-environment heterogeneity on therapeutic response. 2013 , 501, 346-54	1579
1789	Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer. 2013 , 30, 381-92	18
1788	Early expression of the fractalkine receptor CX3CR1 in pancreatic carcinogenesis. 2013 , 109, 2424-33	21
1787	Micro and Nano Flow Systems for Bioanalysis. 2013 ,	2
1786	A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. 2013 , 34, 725-38	68
1785	miR-210 regulates the interaction between pancreatic cancer cells and stellate cells. 2013 , 437, 433-9	70
1784	Molecular Pathology of Neoplastic Gastrointestinal Diseases. 2013 ,	2
1783	Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis. 2013 , 32, 83-107	26
1782	Cancer and Metastasis Reviews. Introduction. 2013 , 32, 3-4	5
1781	Pancreatic-carcinoma-cell-derived pro-angiogenic factors can induce endothelial-cell differentiation of a subset of circulating CD34+ progenitors. 2013 , 11, 314	12
1780	Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. 2013 , 65, 1731-47	189
1779	Microenvironment and tumor cell plasticity: an easy way out. 2013 , 341, 80-96	183
1778	HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects. 2013 , 172, 946-53	45
1777	Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. 2013 , 172, 782-94	657

1776	Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors. 2013 , 9, 777-88	5
1775	Understanding the stroma of pancreatic cancer: co-evolution of the microenvironment with epithelial carcinogenesis. 2013 , 231, 4-7	34
1774	Pancreatic cancer genomics: insights and opportunities for clinical translation. 2013 , 5, 26	18
1773	Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications. 2013 , 5, 101	36
1772	Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. 2013 , 62, 112-20	690
1771	The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. 2013 , 15, 203	72
1770	The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. 2013 , 48, 602-9	58
1769	A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma. 2013 , 13, 3965-75	43
1768	Targeting the K-Ras/PDE1 β protein-protein interaction: the solution for Ras-driven cancers or just another therapeutic mirage?. 2013 , 8, 1620-2	2
1767	Combining two strategies to improve perfusion and drug delivery in solid tumors. 2013 , 110, 18632-7	280
1766	Phosphorylation of ribosomal protein S6 attenuates DNA damage and tumor suppression during development of pancreatic cancer. 2013 , 73, 1811-20	58
1765	Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition. 2013 , 133, 225-34	27
1764	Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-Gli pathway. 2013 , 373, 217-27	119
1763	Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer. 2013 , 330, 11-21	38
1762	GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. 2013 , 330, 22-32	125
1761	Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma. 2013 , 73, 885-96	58
1760	Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status. 2013 , 54, 342-52	7
1759	Fibroblasts as architects of cancer pathogenesis. 2013 , 1832, 1070-8	172

1758	Autocrine IL-1 β /TRAF6 signalling promotes squamous cell carcinoma invasion through paracrine TNF β signalling to carcinoma-associated fibroblasts. 2013 , 32, 747-58	30
1757	Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma. 2013 , 132, 993-1003	66
1756	Toward a systems-level understanding of the Hedgehog signaling pathway: defining the complex, robust, and fragile. 2013 , 5, 83-100	9
1755	Assessment of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma. 2013 , 7, 1031-42	34
1754	Epithelial to mesenchymal transition and the generation of stem-like cells in pancreatic cancer. 2013 , 13, 114-7	20
1753	Correcting the misnomers of epithelial-mesenchymal relations. 2013 , 182, 36-9	2
1752	The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models. 2013 , 339, 135-43	25
1751	Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers. 2013 , 334, 319-27	59
1750	Current concepts and novel targets in advanced pancreatic cancer. 2013 , 62, 317-26	123
1749	Pancreatic Cancer. 2013 ,	1
1748	Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. 2013 , 182, 2037-47	42
1747	A historical perspective on clinical advances in pancreatic diseases. 2013 , 144, 1249-51	7
1746	Pancreaticobiliary surgery for the treatment of malignancy: spread the word. 2013 , 185, 513-5	2
1745	Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers. 2013 , 86, 143-9	34
1744	Overcoming the stromal barrier for targeted delivery of HPMA copolymers to pancreatic tumors. 2013 , 456, 202-11	21
1743	Tumor-stromal interactions in pancreatic cancer. 2013 , 13, 1-7	25
1742	Pancreatic cancer: a comprehensive review and update. 2013 , 59, 368-402	88
1741	Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1. 2013 , 7, 826-39	39

1740	Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. 2013 , 49, 593-603	89
1739	Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform. 2013 , 9, 474-91	291
1738	Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. 2013 , 23, 406-20	233
1737	Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. 2013 , 108, 755-61	114
1736	Biological rationale for the design of polymeric anti-cancer nanomedicines. 2013 , 21, 1-26	53
1735	Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. 2013 , 228, 1651-7	158
1734	Evolution and dynamics of pancreatic cancer progression. 2013 , 32, 5253-60	131
1733	Mouse models for studying angiogenesis and lymphangiogenesis in cancer. 2013 , 7, 259-82	88
1732	Analysis of transplanted bone marrow-derived cells in chronic pancreatitis. 2013 , 980, 291-300	
1731	Hedgehog signaling pathway and cancer therapeutics: progress to date. 2013 , 73, 613-23	54
1730	MicroRNA-100 regulates IGF1-receptor expression in metastatic pancreatic cancer cells. 2013 , 88, 397-402	21
1729	IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. 2013 , 19, 626-630	142
1728	Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. 2013 , 144, 512-27	481
1727	Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. 2013 , 25, 192-9	60
1726	Tumor Biology and Metastasis. 2013 , 30-50	1
1725	Quantification of murine pancreatic tumors by high-resolution ultrasound. 2013 , 980, 249-66	34
1724	Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. 2013 , 230, 107-17	94
1723	New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies. 2013 , 9, 681-97	6

1722	Carbonylation of propargyl carbamates with palladium(II) bisoxazoline catalysts: efficient synthesis of 5-methoxy-3(2H)-furanones. 2013 , 52, 7845-9	27
1721	'Cancer associated fibroblasts'--more than meets the eye. 2013 , 19, 447-53	251
1720	MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2. 2013 , 329, 228-35	17
1719	Biology and clinical applications of pancreatic cancer stem cells. 2013 , 144, 1241-8	85
1718	Strategies for optimizing the response of cancer and normal tissues to radiation. 2013 , 12, 526-42	255
1717	Recapitulating human cancer in a mouse. 2013 , 31, 392-5	5
1716	Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair. 2013 , 42, 2046-52	22
1715	Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype. 2013 , 779, 91-143	7
1714	Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. 2013 , 4, 56	66
1713	Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. 2013 , 110, 6700-5	169
1712	Stem cells & pancreatic cancer. 2013 , 13, 110-3	10
1711	Docetaxel conjugate nanoparticles that target β -smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. 2013 , 73, 4862-71	82
1710	Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. 2013 , 34, 2361-9	87
1709	The hitchhikers guide to cancer stem cell theory: markers, pathways and therapy. 2013 , 83, 62-71	36
1708	Complex behaviours--new targets against cancer. 2013 , 10,	1
1707	Menin/PRMT5/hedgehog signaling: a potential target for the treatment of multiple endocrine neoplasia type 1 tumors. 2013 , 5, 469-71	8
1706	An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κ B- and hypoxia-inducible factor 1 β -mediated up-regulation of CXCR4. 2013 , 288, 21197-21207	122
1705	Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy. 2013 , 344, 103-12	24

1704	Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma. 2013 , 3, 190	19
1703	Contribution of bone marrow derived cells to the pancreatic tumor microenvironment. 2013 , 4, 56	14
1702	Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer. 2013 , 4, 331	33
1701	Alteration of pancreatic cancer cell functions by tumor-stromal cell interaction. 2013 , 4, 318	20
1700	Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E ßocotrienol. 2013 , 34, 858-63	30
1699	Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. 2013 , 8, e76518	121
1698	Carcinoma-associated fibroblasts are a promising therapeutic target. 2013 , 5, 149-69	110
1697	Hedgehog signaling pathway in ovarian cancer. 2013 , 14, 1179-96	38
1696	Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. 2013 , 14, 19731-62	39
1695	Risk factors and therapeutic targets in pancreatic cancer. 2013 , 3, 282	28
1694	Pancreatic cancer: why is it so hard to treat?. 2013 , 6, 321-37	193
1693	A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. 2013 , 19, 258-67	132
1692	Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. 2013 , 73, 2221-34	39
1691	Deciphering the role of stroma in pancreatic cancer. 2013 , 29, 537-43	93
1690	Histological advantages of the tumor graft: a murine model involving transplantation of human pancreatic cancer tissue fragments. 2013 , 42, 1275-82	9
1689	A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. 2013 , 36, 151-6	86
1688	Determination of malignancy and characterization of hepatic tumor type with diffusion-weighted magnetic resonance imaging: comparison of apparent diffusion coefficient and intravoxel incoherent motion-derived measurements. 2013 , 48, 722-8	49
1687	Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor. 2013 , 42, 467-74	32

1686	Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma. 2013 , 2, e26837	6
1685	Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. 2013 , 19, 2766-74	125
1684	Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. 2013 , 73, 3381-92	73
1683	Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. 2013 , 73, 3235-47	136
1682	A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. 2013 , 19, 6286-95	321
1681	Snail cooperates with KrasG12D to promote pancreatic fibrosis. 2013 , 11, 1078-87	40
1680	Combining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis. 2013 , 12, 1038-48	45
1679	Evolving panorama of treatment for metastatic pancreas adenocarcinoma. 2013 , 31, 1621-3	4
1678	High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. 2013 , 19, 3396-403	58
1677	Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. 2013 , 73, 3007-18	267
1676	Prediction of effective drug combinations by chemical interaction, protein interaction and target enrichment of KEGG pathways. 2013 , 2013, 723780	24
1675	The tumor microenvironment and strategies to improve drug distribution. 2013 , 3, 154	79
1674	Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis. 2013 , 62, 310-6	44
1673	Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer. 2013 , 73, 4674-86	96
1672	Quantitative magnetization transfer MRI of desmoplasia in pancreatic ductal adenocarcinoma xenografts. 2013 , 26, 1688-95	12
1671	Poisonous plants: effects on embryo and fetal development. 2013 , 99, 223-34	27
1670	Advanced intravital subcellular imaging reveals vital three-dimensional signalling events driving cancer cell behaviour and drug responses in live tissue. 2013 , 280, 5177-97	9
1669	Recent progress in pancreatic cancer. 2013 , 63, 318-48	606

1668	Harnessing the antitumor potential of macrophages for cancer immunotherapy. 2013 , 2, e26860	67
1667	HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. 2013 , 10, 1312-23	46
1666	Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. 2013 , 110, 19513-8	56
1665	Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to Smoothened-targeting Hedgehog inhibition. 2013 , 288, 11824-33	77
1664	Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. 2013 , 73, 2345-56	134
1663	Microenvironment-mediated resistance to anticancer therapies. 2013 , 23, 179-81	31
1662	Exploiting inflammation for therapeutic gain in pancreatic cancer. 2013 , 108, 997-1003	57
1661	CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. 2013 , 110, 12325-30	181
1660	Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. 2013 , 73, 3927-37	125
1659	Hedgehog signaling pathway regulates human pancreatic cancer cell proliferation and metastasis. 2013 , 29, 1124-32	50
1658	Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor- κ B is associated with a poor prognosis of pancreatic cancer. 2013 , 85, 86-94	21
1657	Carbonylation of Propargyl Carbamates with Palladium(II) Bisoxazoline Catalysts: Efficient Synthesis of 5-Methoxy-3(2H)-furanones. 2013 , 125, 7999-8003	7
1656	Can mouse models of cancer reliably improve clinical trial outcome?. 2013 , 3, 119-130	1
1655	Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer. 2013 , 42, 160-7	20
1654	[Recent update of molecular targeted therapy in pancreatic cancer]. 2013 , 61, 147-54	2
1653	Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. 2013 , 7, 33-43	54
1652	Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. 2013 , 8, e67330	24
1651	Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens. 2013 , 8, e77065	52

1650	Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. 2013 , 8, e79167	156
1649	Hedgehog signaling in prostate cancer and its therapeutic implication. 2013 , 14, 13979-4007	70
1648	MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. 2013 , 8, e71978	117
1647	Targeting hedgehog signaling in cancer: research and clinical developments. 2013 , 6, 1425-35	49
1646	[Kras oncogene and pancreatic cancer: thirty years after]. 2013 , 29, 991-7	4
1645	Tumor stromal barrier and cancer stromal targeting therapy. 2013 , 6, 2-8	1
1644	Ras. 258-271	
1643	Pancreatic cancer. 557-568	
1642	Pathology, genetic alterations, and targets of differentially expressed microRNAs in pancreatic cancer. 2014 , 75	
1641	The impact of hypoxia in pancreatic cancer invasion and metastasis. 2014 , 2, 91-106	43
1640	Radiofrequency heat-enhanced chemotherapy for breast cancer: towards interventional molecular image-guided chemotherapy. 2014 , 4, 1145-52	14
1639	Attenuation of hedgehog acyltransferase-catalyzed sonic Hedgehog palmitoylation causes reduced signaling, proliferation and invasiveness of human carcinoma cells. 2014 , 9, e89899	29
1638	Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma. 2014 , 9, e94357	53
1637	Antiproliferative effects and mechanisms of liver X receptor ligands in pancreatic ductal adenocarcinoma cells. 2014 , 9, e106289	31
1636	Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer. 2014 , 9, e111481	3
1635	Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment. 2014 , 2014, 817613	81
1634	Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma. 2014 , 5, 87	21
1633	Assessment and optimization of electroporation-assisted tumoral nanoparticle uptake in a nude mouse model of pancreatic ductal adenocarcinoma. 2014 , 9, 4169-76	13

1632	Chemoresistance in Cancer Stem Cells and Strategies to Overcome Resistance. 2014 , 03,	3
1631	Assessing the role of the EGF receptor in the development and progression of pancreatic cancer. 2014 , 23	3
1630	Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer. 2014 , 9, 5653-65	11
1629	Therapeutic options for the management of pancreatic cancer. 2014 , 20, 11142-59	94
1628	Atm deletion with dual recombinase technology preferentially radiosensitizes tumor endothelium. 2014 , 124, 3325-38	54
1627	Emerging treatments for advanced pancreatic cancer: clinical potential of albumin-bound paclitaxel. 2014 , 89	
1626	Druggable Targets in Pancreatic Adenocarcinoma. 2014 , 5, 195-214	
1625	Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?. 2014 , 20, 2224-36	44
1624	. 2014 ,	4
1623	Hedgehog pathway inhibition in chondrosarcoma using the smoothed inhibitor IPI-926 directly inhibits sarcoma cell growth. 2014 , 13, 1259-69	51
1622	Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. 2014 , 74, 7003-13	109
1621	MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule. 2014 , 7, 672-80	10
1620	Synthesis and cytotoxicity studies of Hedgehog enzyme inhibitors SANT-1 and GANT-61 as anticancer agents. 2014 , 49, 641-7	8
1619	Brief overview of selected approaches in targeting pancreatic adenocarcinoma. 2014 , 23, 793-807	5
1618	Translational therapeutics in genetically engineered mouse models of cancer. 2014 , 2014, 131-43	9
1617	Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer. 2014 , 20, 3422-33	105
1616	New option for the initial management of metastatic pancreatic cancer?. 2014 , 32, 2405-7	12
1615	Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. 2014 , 20, 5937-5945	202

1614	Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. 2014 , 111, 318-25	16
1613	Stromal uncertainties in pancreatic cancer. 2014 , 7, 665-665	1
1612	A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. 2014 , 13, 3839-56	23
1611	What's up in nanomedicine?. 2014 , 6,	
1610	Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. 2014 , 19, 937-50	7
1609	Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models. 2014 , 5, 464	17
1608	Desmoplasia and chemoresistance in pancreatic cancer. 2014 , 6, 2137-54	85
1607	Cholangiocarcinoma: molecular pathways and therapeutic opportunities. 2014 , 34, 456-64	88
1606	Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. 2014 , 5, 2	45
1605	Altered Signaling Pathways and Potential Therapeutic Targets in Pancreatic Cancer. 2014 , 2265-2273	
1604	Perfusion in the tissue surrounding pancreatic cancer and the patient's prognosis. 2014 , 2014, 648021	11
1603	Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. 2014 , 2014, 925845	19
1602	Docetaxel-encapsulating small-sized polymeric micelles with higher permeability and its efficacy on the orthotopic transplantation model of pancreatic ductal adenocarcinoma. 2014 , 15, 23571-88	9
1601	Kras as a key oncogene and therapeutic target in pancreatic cancer. 2013 , 4, 407	92
1600	Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. 2014 , 5, 141	90
1599	Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression. 2014 , 5, 52	57
1598	Progress in the knowledge and treatment of advanced pancreatic cancer: from bedside to bedside. 2014 , 40, 1039-47	76
1597	Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation. 2014 , 9, 1181-92	37

1596	nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer. 2014 , 52, 360-6	23
1595	Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. 2014 , 20, 4326-38	97
1594	Dosage-dependent regulation of pancreatic cancer growth and angiogenesis by hedgehog signaling. 2014 , 9, 484-94	71
1593	Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer. 2014 , 234, 214-27	12
1592	Adenocarcinoma of the pancreas. 2014 , 31, 443-451	32
1591	Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. 2014 , 134, 9-20	33
1590	Development of a 'mouse and human cross-reactive' affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy. 2014 , 27, 179-90	23
1589	Re-adapting T cells for cancer therapy: from mouse models to clinical trials. 2014 , 257, 145-64	60
1588	Smarter drugs emerging in pancreatic cancer therapy. 2014 , 25, 1260-1270	62
1587	Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. 2014 , 6, 467-81	102
1586	Maspin influences response to doxorubicin by changing the tumor microenvironment organization. 2014 , 134, 2789-97	12
1585	SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. 2014 , 63, 974-83	112
1584	Hedgehog pathway as a potential treatment target in human cholangiocarcinoma. 2014 , 21, 607-15	34
1583	Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. 2014 , 135, 2294-304	45
1582	Lessons from patient-derived xenografts for better in vitro modeling of human cancer. 2014 , 79-80, 222-37	126
1581	Nanomedicine: the promise and challenges in cancer chemotherapy. 2014 , 811, 207-33	14
1580	SPOP suppresses tumorigenesis by regulating Hedgehog/Gli2 signaling pathway in gastric cancer. 2014 , 33, 75	42
1579	Targeting mTOR dependency in pancreatic cancer. 2014 , 63, 1481-9	93

1578	PEG-detachable lipid-polymer hybrid nanoparticle for delivery of chemotherapy drugs to cancer cells. 2014 , 25, 751-66	10
1577	Influence of the implantation site on the sensitivity of patient pancreatic tumor xenografts to Apo2L/TRAIL therapy. 2014 , 43, 298-305	9
1576	Molecular biology of pancreatic ductal adenocarcinoma. 2014 , 30, 506-10	1
1575	Diffusion-weighted magnetic resonance imaging of the pancreas: diagnostic benefit from an intravoxel incoherent motion model-based 3 b-value analysis. 2014 , 49, 93-100	58
1574	Neutralizing murine TGF β 2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. 2014 , 74, 4996-5007	44
1573	Cancer stem cells: a systems biology view of their role in prognosis and therapy. 2014 , 25, 353-67	29
1572	A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. 2014 , 1, 143-157	14
1571	Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. 2014 , 20, 3187-97	30
1570	Cancer cell metabolism as new targets for novel designed therapies. 2014 , 6, 1791-810	18
1569	Monitoring the dynamics of Src activity in response to anti-invasive dasatinib treatment at a subcellular level using dual intravital imaging. 2014 , 8, 478-86	7
1568	BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. 2014 , 13, 1907-17	74
1567	Human Pancreatic Cancer-Associated Stellate Cells Remain Activated after in vivo Chemoradiation. 2014 , 4, 102	24
1566	A modular and flexible ESC-based mouse model of pancreatic cancer. 2014 , 28, 85-97	56
1565	Genome-wide association study of survival in patients with pancreatic adenocarcinoma. 2014 , 63, 152-60	46
1564	Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu ®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance. 2014 , 7, 117-34	32
1563	Functional p38 MAPK identified by biomarker profiling of pancreatic cancer restrains growth through JNK inhibition and correlates with improved survival. 2014 , 20, 6200-11	29
1562	Cholecystikinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice. 2014 , 43, 1050-9	27
1561	The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling. 2014 , 187, 377-85	27

1560	Macromolecular therapeutics. 2014 , 190, 288-303	55
1559	Comparison of prophylactic and therapeutic immunisation with an ErbB-2 (HER2) fusion protein and immunoglobulin V-gene repertoire analysis in a transgenic mouse model of spontaneous breast cancer. 2014 , 32, 1012-8	5
1558	Inflammation and pancreatic cancer: disease promoter and new therapeutic target. 2014 , 49, 605-17	31
1557	Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. 2014 , 17, 471-94	489
1556	The stromal compartments in pancreatic cancer: are there any therapeutic targets?. 2014 , 343, 147-55	129
1555	Dynamic Interactions Between Cancer Stem Cells And Their Stromal Partners. 2014 , 2, 41-52	32
1554	Targeting tumour-supportive cellular machineries in anticancer drug development. 2014 , 13, 179-96	169
1553	Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. 2014 , 347, 183-90	38
1552	Nanoparticles containing insoluble drug for cancer therapy. 2014 , 32, 778-88	100
1551	Focal Controlled Drug Delivery. 2014 ,	15
1550	Developments in preclinical cancer imaging: innovating the discovery of therapeutics. 2014 , 14, 314-28	112
1549	The complex landscape of pancreatic cancer metabolism. 2014 , 35, 1441-50	86
1548	Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. 2014 , 345, 132-9	73
1547	Regulation of the anti-tumour immune response by cancer-associated fibroblasts. 2014 , 25, 69-77	147
1546	Mouse tumour models to guide drug development and identify resistance mechanisms. 2014 , 232, 103-11	24
1545	Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. 2014 , 74, 1032-44	62
1544	Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling. 2014 , 13, 386-98	15
1543	Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. 2014 , 74, 3512-24	84

1542	Quantitative synchrotron X-ray fluorescence study of the penetration of transferrin-conjugated gold nanoparticles inside model tumour tissues. 2014 , 6, 9774-82	26
1541	Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. 2014 , 106, djt346	39
1540	Intratumoral gene therapy versus intravenous gene therapy for distant metastasis control with 2-diethylaminoethyl-dextran methyl methacrylate copolymer non-viral vector-p53. 2014 , 21, 158-67	16
1539	Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions. 2014 , 40, 78-85	25
1538	Pathogenesis of pancreatic cancer: lessons from animal models. 2014 , 42, 217-28	27
1537	Chromosome instability and carcinogenesis: insights from murine models of human pancreatic cancer associated with BRCA2 inactivation. 2014 , 8, 161-8	12
1536	Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. 2014 , 20, 1204-1211	49
1535	Sensitizing protective tumor microenvironments to antibody-mediated therapy. 2014 , 156, 590-602	128
1534	In vitro models of tumor vessels and matrix: engineering approaches to investigate transport limitations and drug delivery in cancer. 2014 , 69-70, 205-216	55
1533	Multimodal Therapies for Pancreatic Cancer. 2014 , 39-73	
1532	Gene Expression Profiling in Pancreatic Cancer. 2014 , 151-167	
1531	Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression. 2014 , 289, 16516-25	16
1530	The extracellular matrix modulates the hallmarks of cancer. 2014 , 15, 1243-53	957
1529	A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. 2014 , 20, 1340-1347	149
1528	Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma. 2014 , 120, 537-47	33
1527	A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis. 2014 , 454, 144-50	8
1526	Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications. 2014 , 97, 515-24	32
1525	Nab-paclitaxel: a flattering facelift. 2014 , 92, 166-80	28

1524	Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma. 2014 , 23, 1499-515	14
1523	HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. 2014 , 27, 1361-70	17
1522	Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. 2014 , 41, 559-75	3
1521	Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1 β /VEGF mediated angiogenesis. 2014 , 355, 281-7	37
1520	Snapshots April-August 2014. 2014 , 14, 321-3	
1519	Targeting metabolic scavenging in pancreatic cancer. 2014 , 20, 6-8	7
1518	New chemical probes targeting cholesterylation of Sonic Hedgehog in human cells and zebrafish. 2014 , 5, 4249-4259	33
1517	Cancer stem-like cells and thyroid cancer. 2014 , 21, T285-300	44
1516	Reciprocal regulation of hypoxia-inducible factor 2 α and GLI1 expression associated with the radioresistance of renal cell carcinoma. 2014 , 90, 942-51	26
1515	Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. 2014 , 13, 2062-72	25
1514	Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?. 2014 , 122, 565-79	16
1513	Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment. 2014 , 35, 1671-9	95
1512	Fibroblast heterogeneity in the cancer wound. 2014 , 211, 1503-23	524
1511	Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. 2014 , 741, 8-16	306
1510	Stromal response to Hedgehog signaling restrains pancreatic cancer progression. 2014 , 111, E3091-100	337
1509	The role of mechanical forces in tumor growth and therapy. 2014 , 16, 321-46	527
1508	Systems Biology of Pancreatic Cancer Stem Cells. 2014 , 297-322	
1507	Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines. 2014 , 68, 737-43	39

1506	Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. 2014 , 26, 521-33	126
1505	Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. 2014 , 8, 1905-1918	339
1504	Stromal reengineering to treat pancreas cancer. 2014 , 35, 1451-60	84
1503	Inhibitory effects of prostaglandin E2 on collagen synthesis and cell proliferation in human stellate cells from pancreatic head adenocarcinoma. 2014 , 14, 413	21
1502	Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. 2014 , 61, 1397-406	113
1501	Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. 2014 , 59, 2397-402	85
1500	Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies. 2014 , 50, 2570-82	67
1499	Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. 2014 , 159, 80-93	650
1498	microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF- β actions. 2014 , 33, 4664-74	103
1497	Intratumoral Mistletoe (<i>Viscum album</i> L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis. 2014 , 13, 332-40	19
1496	Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. 2014 , 33, 3812-9	172
1495	Hedgehog signaling between cancer cells and hepatic stellate cells in promoting cholangiocarcinoma. 2014 , 21, 2684-98	31
1494	Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. 2014 , 63, 1769-81	202
1493	Stem Cells in Cancer: Should We Believe or Not?. 2014 ,	0
1492	Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. 2014 , 13, 1758-71	106
1491	A historical perspective of pancreatic cancer mouse models. 2014 , 27, 96-105	19
1490	Connective tissue of cervical carcinoma xenografts: associations with tumor hypoxia and interstitial fluid pressure and its assessment by DCE-MRI and DW-MRI. 2014 , 53, 6-15	17
1489	Fibrogenesis in pancreatic cancer is a dynamic process regulated by macrophage-stellate cell interaction. 2014 , 94, 409-21	53

1488	In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. 2014 , 13, 2040-9	75
1487	Functions and roles of a protein-associated factor. 2014 , 68, 577-82	
1486	The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. 2014 , 14, 41	131
1485	Modern Cancer Drug Discovery. 2014 , 3-53	5
1484	Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor. 2014 , 192, 29-39	35
1483	Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. 2014 , 91, 135-43	129
1482	Fluorescent imaging of cancerous tissues for targeted surgery. 2014 , 76, 21-38	82
1481	Mangostin inhibits hypoxia-driven ROS-induced PSC activation and pancreatic cancer cell invasion. 2014 , 347, 129-38	61
1480	Passive cavitation detection during pulsed HIFU exposures of ex vivo tissues and in vivo mouse pancreatic tumors. 2014 , 40, 1523-34	53
1479	Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression. 2014 , 7, 1143-55	57
1478	MicroRNAs in pancreatic malignancy: progress and promises. 2014 , 347, 167-74	45
1477	Animal models and the tumor microenvironment: studies of tumor-host symbiosis. 2014 , 41, 146-55	12
1476	Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. 2014 , 182, 90-6	90
1475	Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. 2014 , 40, 118-28	96
1474	Is arterial infiltration still a criterion for unresectability in pancreatic adenocarcinoma?. 2014 , 92, 305-15	4
1473	Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. 2014 , 25, 719-34	1332
1472	Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. 2014 , 25, 735-47	1235
1471	Improving the distribution of Doxil [®] in the tumor matrix by depletion of tumor hyaluronan. 2014 , 191, 105-14	62

1470	Alteration of the microRNA expression profile during the activation of pancreatic stellate cells. 2014 , 49, 323-31	41
1469	Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. 2014 , 25, 621-37	235
1468	Is Arterial Infiltration Still a Criterion for Unresectability in Pancreatic Adenocarcinoma?. 2014 , 92, 305-315	
1467	A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. 2014 , 89, 830-8	81
1466	A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. 2014 , 146, 1784-94.e6	95
1465	Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies. 2014 , 33, 1341-7	22
1464	Transport properties of pancreatic cancer describe gemcitabine delivery and response. 2014 , 124, 1525-36	144
1463	Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies. 2014 , 20, 2237-46	86
1462	Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action. 2014 , 37, 128-34	22
1461	Stem Cells and Pancreatic Cancer. 2014 , 209-222	
1460	Inhibition of the Hedgehog pathway induces autophagy in pancreatic ductal adenocarcinoma cells. 2014 , 31, 707-12	41
1459	Effect of resveratrol on proliferation and apoptosis of human pancreatic cancer MIA PaCa-2 cells may involve inhibition of the Hedgehog signaling pathway. 2014 , 10, 2563-7	26
1458	Feeding cancer's sweet tooth: specialized tumour vasculature shuttles glucose in pancreatic ductal adenocarcinoma. 2015 , 236, 133-5	
1457	Adenocarcinoma of the Pancreas. 2015 , 1761-1781	
1456	Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. 2015 , 7, 735-53	131
1455	Molecular Therapeutics: Pancreatic Cancer. 2015 , 255-262	
1454	An automated fitting procedure and software for dose-response curves with multiphasic features. 2015 , 5, 14701	83
1453	Inhibition of Lysyl Oxidases Improves Drug Diffusion and Increases Efficacy of Cytotoxic Treatment in 3D Tumor Models. 2015 , 5, 17576	22

1452	Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. 2015 , 7, 1063-76	172
1451	miRNAs As Diagnostic and Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: A Review. 2015 , 10, 113-24	6
1450	Therapie des Pankreaskarzinoms. 2015 , 10, 50-59	
1449	The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow. 2015 , 44, 528-34	21
1448	Tumor-induced solid stress activates E-cadherin signaling to drive malignant behavior in normal, tumor-adjacent cells. 2015 , 37, 1293-7	8
1447	Respiratory self-gating for free-breathing magnetization transfer MRI of the abdomen. 2015 , 73, 2249-54	3
1446	Primary and liver metastasis-derived cell lines from KrasG12D; Trp53R172H; Pdx-1 Cre animals undergo apoptosis in response to triptolide. 2015 , 44, 583-9	13
1445	A Plasmonic Gold Nanostar Theranostic Probe for In Vivo Tumor Imaging and Photothermal Therapy. 2015 , 5, 946-60	204
1444	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. 2015 , 6, 516	51
1443	Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer. 2015 , 2, 10	14
1442	Modeling Combined Chemotherapy and Particle Therapy for Locally Advanced Pancreatic Cancer. 2015 , 5, 145	21
1441	Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy. 2015 , 5, 214	81
1440	Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. 2015 , 9, 3529-45	101
1439	What are the macrophages and stellate cells doing in pancreatic adenocarcinoma?. 2015 , 6, 125	12
1438	An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. 2015 , 6, 24947-68	32
1437	TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. 2015 , 6, 7504-21	36
1436	Pancreatic cancer vaccine: a unique potential therapy. 2015 , 1	
1435	Tumor talk: understanding the conversation between the tumor and its microenvironment. 2015 , 2, e773	12

1434	Stromal biology and therapy in pancreatic cancer: a changing paradigm. 2015 , 64, 1476-84	345
1433	Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract. 2015 , 13, 115	48
1432	Pancreatic cancer stromal biology and therapy. 2015 , 2, 133-143	85
1431	Stroma, Stroma Everywhere (Far More Than You Think). 2015 , 21, 3366-8	12
1430	Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. 2015 , 75, 2800-2810	247
1429	Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. 2015 , 16, 43-51	44
1428	Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment. 2015 , 4, e978709	26
1427	Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression. 2015 , 21, 4482-93	58
1426	Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. 2015 , 7, 291ra94	186
1425	Breast cancer stem cells: current advances and clinical implications. 2015 , 1293, 1-49	67
1424	Pancreatic Stellate Cells. 2015 , 271-306	1
1423	Well-Differentiated Malignancies. 2015 ,	6
1422	Inflammatory Dysregulation and Cancer: From Molecular Mechanisms to Therapeutic Opportunities. 2015 , 375-395	1
1421	Cycloamine-loaded core-cross-linked polymeric micelles enhance radiation response in pancreatic cancer and pancreatic stellate cells. 2015 , 12, 2093-100	14
1420	Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection. 2015 , 274, 790-9	47
1419	Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. 2015 , 21, 1002-9	30
1418	Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation. 2015 , 14, 788-98	84
1417	Whole-genome characterization of chemoresistant ovarian cancer. 2015 , 521, 489-94	890

1416	Nanoparticle albumin-bound (nab)-paclitaxel for the treatment of pancreas ductal adenocarcinoma. 2015 , 11	4
1415	Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction. 2015 , 21, 299-306	55
1414	microRNA: Cancer. 2015 ,	1
1413	Distribution of Gemcitabine Is Nearly Homogenous in Two Orthotopic Murine Models of Pancreatic Cancer. 2015 , 30, 299-304	3
1412	CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus. 2015 , 75, 3583-95	48
1411	Gemcitabine resistance in pancreatic ductal adenocarcinoma. 2015 , 23, 55-68	173
1410	Mechanisms of Drug Resistance Related to the Microenvironment of Solid Tumors and Possible Strategies to Inhibit Them. 2015 , 21, 254-62	43
1409	Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer. 2016 , 9, 131-40	9
1408	A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling. 2015 , 149, 1685-8	4
1407	HEAL Project Aims to Regenerate Human Limbs by 2030. 2015 , 1, 50-57	
1406	Pancreatic Cancer. 2015 , 343-392	
1405	Pancreatic Cancer: a Challenge to Cure. 2015 , 77, 350-7	4
1404	Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy. 2015 , 889, 71-87	36
1403	Quoi de neuf en recherche fondamentale et translationnelle sur le cancer du pancréas ?. 2015 , 17, 535-540	
1402	Harmonic motion imaging for abdominal tumor detection and high-intensity focused ultrasound ablation monitoring: an in vivo feasibility study in a transgenic mouse model of pancreatic cancer. 2015 , 62, 1662-73	20
1401	Targeting Transcriptional and Epigenetic Reprogramming in Stromal Cells in Fibrosis and Cancer. 2015 , 80, 249-55	9
1400	Organoid models of human and mouse ductal pancreatic cancer. 2015 , 160, 324-38	1072
1399	Hedgehog acyltransferase as a target in pancreatic ductal adenocarcinoma. 2015 , 34, 263-8	43

1398	Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells. 2015 , 21, 505-13	102
1397	Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer. 2015 , 12, 1289-98	63
1396	Cancer stem cells, lymphangiogenesis, and lymphatic metastasis. 2015 , 357, 438-47	48
1395	Efficacy of Hedgehog pathway inhibitors in Basal cell carcinoma. 2015 , 14, 633-41	56
1394	The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. 2015 , 34, 97-114	51
1393	Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. 2015 , 27, 123-37	135
1392	A Novel CDC25B Promoter-Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models. 2015 , 21, 1665-74	8
1391	The Hedgehog pathway: role in cell differentiation, polarity and proliferation. 2015 , 89, 179-91	70
1390	Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. 2015 , 7, 68-84	104
1389	Molecular Pathogenesis of Pancreatic Adenocarcinoma. 2015 , 515-522.e2	
1388	Current adjuvant therapeutic approaches for pancreatic cancer. 2015 , 32, 42-56	6
1387	Gene and cell therapy for pancreatic cancer. 2015 , 15, 505-16	14
1386	Pancreatic disease in 2014: Pancreatic fibrosis and standard diagnostics. 2015 , 12, 68-70	12
1385	Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. 2015 , 236, 142-154	21
1384	Tenascin-C induces resistance to apoptosis in pancreatic cancer cell through activation of ERK/NF- κ B pathway. 2015 , 20, 843-57	31
1383	BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance. 2015 , 75, 732-41	36
1382	Can oncology recapitulate paleontology? Lessons from species extinctions. 2015 , 12, 273-85	24
1381	Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy. 2015 , 141, 1163-70	11

1380	Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer. 2015 , 36, 5617-26	43
1379	Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. 2015 , 62, 198-207	57
1378	Tumor cells, but not endothelial cells, mediate eradication of primary sarcomas by stereotactic body radiation therapy. 2015 , 7, 278ra34	58
1377	Modeling the effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors. 2015 , 77, 1-22	70
1376	Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. 2015 , 212, 333-49	89
1375	Dynamic contrast-enhanced (DCE) MRI assessment of microvascular characteristics in the murine orthotopic pancreatic cancer model. 2015 , 33, 737-60	10
1374	The role of pancreatic stellate cells in pancreatic cancer. 2015 , 24, 232-8	49
1373	Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer. 2015 , 75, 3738-46	54
1372	Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302). 2015 , 14, 2060-71	45
1371	[Advance in the biology of pancreatic of cancer]. 2015 , 102, S53-61	6
1370	Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?. 2015 , 59, 19-35	51
1369	Genetics and Biology of Pancreatic Ductal Adenocarcinoma. 2015 , 29, 595-608	46
1368	Mouse Models of Pancreatic Ductal Adenocarcinoma. 2015 , 29, 609-17	7
1367	Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. 2015 , 8, 196-203	21
1366	Conditionally immortalized human pancreatic stellate cell lines demonstrate enhanced proliferation and migration in response to IGF-I. 2015 , 330, 300-310	21
1365	Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. 2015 , 56, 2092-7	43
1364	Control of cancer formation by intrinsic genetic noise and microenvironmental cues. 2015 , 15, 499-509	44
1363	HSP47: The New Heat Shock Protein Therapeutic Target. 2015 , 197-219	1

1362	Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. 2015 , 112, 1782-90	144
1361	Pancreatic stellate cells: A dynamic player of the intercellular communication in pancreatic cancer. 2015 , 39 Suppl 1, S98-103	21
1360	BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. 2015 , 113, 425-32	55
1359	Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. 2015 , 3, 1096-107	47
1358	A patient-derived subrenal capsule xenograft model can predict response to adjuvant therapy for cancers in the head of the pancreas. 2015 , 15, 397-404	8
1357	Pathophysiological role of microRNA-29 in pancreatic cancer stroma. 2015 , 5, 11450	47
1356	Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. 2015 , 33, 1779-86	57
1355	Targeting tumor hypoxia with hypoxia-activated prodrugs. 2015 , 33, 1505-8	29
1354	Increased expression of PHD3 represses the HIF-1 signaling pathway and contributes to poor neovascularization in pancreatic ductal adenocarcinoma. 2015 , 50, 975-83	6
1353	Nanoparticle formulation of ormeloxifene for pancreatic cancer. 2015 , 53, 731-43	32
1352	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. 2015 , 3, 399-411	289
1351	Targeted Therapies for Solid Tumors. 2015 ,	1
1350	Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer. 2015 , 21, 1764-71	38
1349	The epithelial to mesenchymal transition in pancreatic cancer: A systematic review. 2015 , 15, 217-25	90
1348	Linking the future of anticancer metal-complexes to the therapy of tumour metastases. 2015 , 44, 8818-35	151
1347	Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer. 2015 ,	22
1346	Immune Therapy in GI Malignancies: A Review. 2015 , 33, 1745-53	29
1345	Exploring the tumor microenvironment with nanoparticles. 2015 , 166, 193-226	78

1344	Strategies to relieve immunosuppression in pancreatic cancer. 2015 , 7, 363-76	16
1343	Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. 2015 , 95, 318-36	17
1342	New trends in guided nanotherapies for digestive cancers: A systematic review. 2015 , 209, 288-307	68
1341	Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer. 2015 , 21, 3561-8	323
1340	Liposome-based engineering of cells to package hydrophobic compounds in membrane vesicles for tumor penetration. 2015 , 15, 2938-44	115
1339	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. 2015 , 12, 319-34	404
1338	Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma. 2015 , 68, 309-13	16
1337	Local iontophoretic administration of cytotoxic therapies to solid tumors. 2015 , 7, 273ra14	44
1336	Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. 2015 , 75, 2292-304	56
1335	Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy. 2015 , 17, e5	56
1334	Immune-mediated mechanisms influencing the efficacy of anticancer therapies. 2015 , 36, 198-216	93
1333	Pancreatic cancer: The microenvironment needs attention too!. 2015 , 15, S32-8	59
1332	Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma. 2015 , 21, 1215-24	59
1331	Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. 2015 , 206, 122-30	83
1330	MicroRNA Signaling Pathway Network in Pancreatic Ductal Adenocarcinoma. 2015 , 42, 563-577	17
1329	New avenues for improving pancreatic ductal adenocarcinoma (PDAC) treatment: Selective stroma depletion combined with nano drug delivery. 2015 , 369, 266-73	37
1328	Preclinical mouse cancer models: a maze of opportunities and challenges. 2015 , 163, 39-53	363
1327	Membrane-to-Nucleus Signals and Epigenetic Mechanisms for Myofibroblastic Activation and Desmoplastic Stroma: Potential Therapeutic Targets for Liver Metastasis?. 2015 , 13, 604-12	32

1326	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. 2015 , 21, 1163-71	275
1325	Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. 2015 , 42, 477-96	20
1324	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. 2015 , 33, 4284-92	323
1323	Animal Models of Gastrointestinal and Liver Diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics. 2015 , 309, G283-91	16
1322	The dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment. 2015 , 6, 123-33	32
1321	Minimal residual disease in cancer therapy--Small things make all the difference. 2015 , 21-22, 1-10	19
1320	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. 2015 , 15, 668-79	581
1319	T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. 2015 , 28, 638-652	129
1318	The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. 2015 , 17, 292-8	50
1317	Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. 2015 , 149, 1932-1943.e9	107
1316	Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation. 2015 , 33, 2893-902	26
1315	Elucidating steroid alkaloid biosynthesis in <i>Veratrum californicum</i> : production of verazine in Sf9 cells. 2015 , 82, 991-1003	32
1314	Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole. 2015 , 113, 864-71	45
1313	GEMMs as preclinical models for testing pancreatic cancer therapies. 2015 , 8, 1185-200	70
1312	Functional significance of macrophages in pancreatic cancer biology. 2015 , 36, 9119-26	12
1311	The crosstalk between acinar cells with mutations and M1-polarized macrophages leads to initiation of pancreatic precancerous lesions. 2015 , 4, e1008794	9
1310	Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer. 2015 , 75, 4582-92	18
1309	Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma. 2015 , 4, e1029698	26

1308	Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. 2015 , 47, 1168-78	893
1307	Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy. 2015 , 4, e177	108
1306	Therapeutic potential of ultrasound microbubbles in gastrointestinal oncology: recent advances and future prospects. 2015 , 8, 384-94	25
1305	Reverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models. 2015 , 93, 444-53	8
1304	Mapping dynamic mechanical remodeling in 3D tumor models via particle tracking microrheology. 2015 ,	
1303	Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer. 2015 , 75, 5058-69	28
1302	Cancer's Fuel Choice: New Flavors for a Picky Eater. 2015 , 60, 514-23	89
1301	The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings. 2015 , 42, 144-62	17
1300	Microenvironmental regulation of therapeutic response in cancer. 2015 , 25, 198-213	427
1299	Novel targets in pancreatic cancer research. 2015 , 42, 177-87	17
1298	Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. 2015 , 1855, 61-82	43
1297	Addressing the challenges of pancreatic cancer: future directions for improving outcomes. 2015 , 15, 8-18	277
1296	Improving drug delivery to solid tumors: priming the tumor microenvironment. 2015 , 201, 78-89	305
1295	Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor?. 2015 , 1855, 43-9	24
1294	E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin $\alpha 5 \beta 1$ and maintained through TGF β signalling. 2015 , 34, 704-16	37
1293	Epidemiological-molecular evidence of metabolic reprogramming on proliferation, autophagy and cell signaling in pancreas cancer. 2015 , 356, 281-8	21
1292	The impact of tumor stroma on drug response in breast cancer. 2015 , 31, 3-15	68
1291	Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. 2015 , 30, 689-721	79

1290	Stress Response Pathways in Cancer. 2015 ,	3
1289	miRNAs in pancreatic cancer: therapeutic potential, delivery challenges and strategies. 2015 , 81, 34-52	67
1288	Genetic Mouse Models of Cancer. 2015 , 145-154.e2	3
1287	Molecular pathogenesis of intrahepatic cholangiocarcinoma. 2015 , 22, 101-13	39
1286	Gli2 protein expression level is a feasible marker of ligand-dependent hedgehog activation in pancreatic neoplasms. 2016 , 67, 136-44	4
1285	Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer. 2016 , 12, 292-301	17
1284	Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. 2016 , 7, 27-43	58
1283	Investigating the Process of Renal Epithelial Repair to Develop New Therapies. 2016 , 381-393	1
1282	Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma. 2016 , 7, 81110-81122	45
1281	Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes. 2016 , 9, 2273-86	4
1280	CASTIN: a system for comprehensive analysis of cancer-stromal interactome. 2016 , 17, 899	8
1279	The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. 2016 , 7, 48265-48279	79
1278	Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. 2016 , 22, 2441-59	55
1277	Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?. 2016 , 7, 727-737	2
1276	Soluble factors from stellate cells induce pancreatic cancer cell proliferation via Nrf2-activated metabolic reprogramming and ROS detoxification. 2016 , 7, 36719-36732	26
1275	Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises. 2016 , 7, 487-94	33
1274	Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. 2016 , 7, 58649-58658	54
1273	Mesenchymal Stem/Stromal Cells in Stromal Evolution and Cancer Progression. 2016 , 2016, 4824573	54

1272	Systemic Chemotherapy in Advanced Pancreatic Cancer. 2016 , 10, 340-7	43
1271	Pancreatic Cancer from Molecular Pathways to Treatment Opinion. 2016 , 7, 1328-39	20
1270	Tertiary Lymphoid Organs in Cancer Tissues. 2016 , 7, 244	57
1269	Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal. 2016 , 6, 115	33
1268	The Effect of Stromal Integrin β -Deficiency on Two Different Tumors in Mice. 2016 , 8,	3
1267	Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothed and GLI Inhibitors. 2016 , 8,	367
1266	Diffusion-weighted and dynamic contrast-enhanced MRI of pancreatic adenocarcinoma xenografts: associations with tumor differentiation and collagen content. 2016 , 14, 161	27
1265	Theory and Experimental Validation of a Spatio-temporal Model of Chemotherapy Transport to Enhance Tumor Cell Kill. 2016 , 12, e1004969	46
1264	Animal models of pancreatic cancer and their application in clinical research. 2016 , Volume 6, 31-39	5
1263	The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse Hepatocarcinoma. 2016 , 7, 506	6
1262	The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. 2016 , 12, 273-82	70
1261	Pancreatic stellate cells contribute pancreatic cancer pain via activation of SHH signaling pathway. 2016 , 7, 18146-58	33
1260	miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma. 2016 , 45, 84-92	46
1259	Low Stromal Area and High Stromal Microvessel Density Predict Poor Prognosis in Pancreatic Cancer. 2016 , 45, 593-600	11
1258	Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+);LSL-Trp53(R172H/+);Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery. 2016 , 73, 14.39.1-14.39.20	88
1257	The cancer stem-cell signaling network and resistance to therapy. 2016 , 49, 25-36	98
1256	S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. 2016 , 113, 413-9	13
1255	Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. 2016 , 22, 851-60	516

1254	A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. 2016 , 45, 370-5	123
1253	3D Cancer Models on Hydrogels. 2016 , 207-256	1
1252	Obesity and Cancer: An Angiogenic and Inflammatory Link. 2016 , 23, 191-206	44
1251	Self-Assembled DNA Nanostructures for Drug Delivery. 2016 , 34, 265-272	15
1250	Echoes of the embryo: using the developmental biology toolkit to study cancer. 2016 , 9, 105-14	64
1249	The PRKD1 promoter is a target of the KRas-NF- κ B pathway in pancreatic cancer. 2016 , 6, 33758	12
1248	Hedgehog Signaling Plays a Dual Role in Pancreatic Carcinogenesis. 2016 , 1-22	
1247	Clinical Insights Into the Biology and Treatment of Pancreatic Cancer. 2016 , 12, 17-23	12
1246	Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer. 2016 , 65, 1838-1849	55
1245	Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer. 2016 , 8, 1309-1320	13
1244	Pancreatic cancer microenvironment, to target or not to target?. 2016 , 8, 80-2	36
1243	ATRA modulates mechanical activation of TGF- β by pancreatic stellate cells. 2016 , 6, 27639	48
1242	Challenges and Opportunities in Modeling Pancreatic Cancer. 2016 , 81, 231-235	6
1241	Commentary on "Epithelial-to-Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer". 2016 , 76, 7075-7077	1
1240	Intravital characterization of tumor cell migration in pancreatic cancer. 2016 , 5, e1261773	24
1239	Resveratrol inhibits hypoxia-driven ROS-induced invasive and migratory ability of pancreatic cancer cells via suppression of the Hedgehog signaling pathway. 2016 , 35, 1718-26	58
1238	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. 2016 , 17, 651-62	407
1237	Modeling pancreatic cancer with organoids. 2016 , 2, 176-190	134

1236	ARCI: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. 2016 , 119, 306-11	39
1235	Cancer-Associated Fibroblasts: Perspectives in Cancer Therapy. 2016 , 2, 277-279	46
1234	Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis. 2016 , 101, 108-120	22
1233	Regulation of the Namp1-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. 2016 , 379, 1-11	36
1232	CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. 2016 , 197, 179-87	37
1231	Heat Shock Protein Inhibitors. 2016 ,	
1230	Nucleoside analogs: ready to enter the era of precision medicine?. 2016 , 12, 865-77	5
1229	Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions. 2016 , 42, 80-93	86
1228	Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. 2016 , 22, 4259-70	28
1227	GM-CSF Mediates Mesenchymal-Epithelial Cross-talk in Pancreatic Cancer. 2016 , 6, 886-99	114
1226	A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. 2016 , 93, 71-82	27
1225	Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocity. 2016 , 165, 910-20	169
1224	Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma. 2016 , 150, 1545-1557.e2	71
1223	Hedgehog Signaling in Pancreatic Fibrosis and Cancer. 2016 , 95, e2996	23
1222	Macrophage-secreted granulins support pancreatic cancer metastasis by inducing liver fibrosis. 2016 , 18, 549-60	226
1221	Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. 2016 , 22, 497-505	338
1220	Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival. 2016 , 151, 180-193.e12	157
1219	Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment. 2016 , 16, 733-6	7

1218	Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. 2016 , 30, 1002-19	410
1217	Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. 2016 , 78, 1-12	99
1216	Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase. 2016 , 110, 2106-19	86
1215	Screening out irrelevant cell-based models of disease. 2016 , 15, 751-769	297
1214	KRAS-related proteins in pancreatic cancer. 2016 , 168, 29-42	97
1213	Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor-stromal cross-talk. 2016 , 37, 1052-1061	25
1212	Fibrosis and Cancer: Partners in Crime or Opposing Forces?. 2016 , 2, 279-282	29
1211	Calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer-stromal interactions in a mouse xenograft model. 2016 , 107, 1443-1452	17
1210	Emerging from their burrow: Hedgehog pathway inhibitors for cancer. 2016 , 25, 1153-66	18
1209	Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferation. 2016 , 29, 656-668	21
1208	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. 2016 , 142, 458-64	13
1207	Elasticity mapping of murine abdominal organs in vivo using harmonic motion imaging (HMI). 2016 , 61, 5741-54	17
1206	Available technologies and clinical applications of targeted chemotherapy in pancreatic cancer. 2016 , 209, 582-591	4
1205	Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer. 2016 , 26, 320-37	15
1204	Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. 2016 , 536, 479-83	589
1203	Cancer metabolism: Friendly neighbours feed tumour cells. 2016 , 536, 401-2	17
1202	Inflammation and cancer: tissue regeneration gone awry. 2016 , 43, 55-61	91
1201	The roles of tumor- and metastasis-promoting carcinoma-associated fibroblasts in human carcinomas. 2016 , 365, 675-89	65

1200	UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis. 2016 , 238, 423-33	34
1199	Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. 2016 , 239, 286-96	69
1198	Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality. 2016 , 27, 770-781	6
1197	The Tyrosine Kinase Inhibitor Imatinib Augments Extracellular Fluid Exchange and Reduces Average Collagen Fibril Diameter in Experimental Carcinoma. 2016 , 15, 2455-2464	12
1196	Impact by pancreatic stellate cells on epithelial-mesenchymal transition and pancreatic cancer cell invasion: Adding a third dimension in vitro. 2016 , 346, 206-15	22
1195	Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer. 2016 , 107, 514-20	17
1194	Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor- B activation. 2016 , 60, 27-38	46
1193	Fibroblast activation in cancer: when seed fertilizes soil. 2016 , 365, 607-19	130
1192	Human pancreatic cancer progression: an anarchy among CCN-siblings. 2016 , 10, 207-216	10
1191	New treatment strategy with nuclear factor- B inhibitor for pancreatic cancer. 2016 , 206, 1-8	12
1190	The biology and function of fibroblasts in cancer. 2016 , 16, 582-98	1824
1189	A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies. 2016 , 14, 57	30
1188	Bufalin suppresses cancer stem-like cells in gemcitabine-resistant pancreatic cancer cells via Hedgehog signaling. 2016 , 14, 1907-14	14
1187	Molecular and Cellular Mechanobiology. 2016 ,	1
1186	Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. 2016 , 13, 750-765	137
1185	Molecular and Cellular Mechanobiology of Cancer. 2016 , 277-290	1
1184	Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors. 2016 , 76, 6851-6863	144
1183	Generation of an in vitro 3D PDAC stroma rich spheroid model. 2016 , 108, 129-42	77

1182	Endosialin-Expressing Pericytes Promote Metastatic Dissemination. 2016 , 76, 5313-25	33
1181	IL-6/STAT3 axis initiated CAFs via up-regulating TIMP-1 which was attenuated by acetylation of STAT3 induced by PCAF in HCC microenvironment. 2016 , 28, 1314-24	41
1180	Pancreatic cancer biology and genetics from an evolutionary perspective. 2016 , 16, 553-65	235
1179	Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment. 2016 , 37, 993-1008	97
1178	Integrin-mediated mechanotransduction. 2016 , 215, 445-456	469
1177	Characterization of Hedgehog Acyltransferase Inhibitors Identifies a Small Molecule Probe for Hedgehog Signaling by Cancer Cells. 2016 , 11, 3256-3262	31
1176	Current and Emerging Targeting Strategies for Treatment of Pancreatic Cancer. 2016 , 144, 277-320	6
1175	Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer. 2016 , 18, 689-698	24
1174	Nanocarrier-Based Anticancer Therapies with the Focus on Strategies for Targeting the Tumor Microenvironment. 2016 , 67-122	
1173	Human pancreatic stellate cells modulate 3D collagen alignment to promote the migration of pancreatic ductal adenocarcinoma cells. 2016 , 18, 105	27
1172	Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. 2016 , 24, 672-684	170
1171	Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma. 2016 , 9, 431-437	29
1170	Pancreatic cancer. 2016 , 2, 16022	838
1169	Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature. 2016 , 76, 7181-7193	73
1168	Cancer Stem Cells. 2016 , 375-413	3
1167	ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion. 2016 , 7, 12630	148
1166	Metastatic progression is associated with dynamic changes in the local microenvironment. 2016 , 7, 12819	79
1165	Systemic Therapy in Pancreatic Cancer. 2016 , 247-273	1

1164	A Mimic of the Tumor Microenvironment: A Simple Method for Generating Enriched Cell Populations and Investigating Intercellular Communication. 2016,	5
1163	The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models. 2016, 6, 63	8
1162	Critical role of oncogenic KRAS in pancreatic cancer (Review). 2016, 13, 4943-9	23
1161	Evolution of novel therapeutic options for pancreatic cancer. 2016, 32, 401-407	13
1160	UEG Week 2016 Oral Presentations. 2016, 4, A1-A156	5
1159	Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. 2016, 6, 852-69	213
1158	Tumor-associated fibroblasts predominantly come from local and not circulating precursors. 2016, 113, 7551-6	77
1157	MYB Promotes Desmoplasia in Pancreatic Cancer through Direct Transcriptional Up-regulation and Cooperative Action of Sonic Hedgehog and Adrenomedullin. 2016, 291, 16263-70	14
1156	Photonanomedicine: a convergence of photodynamic therapy and nanotechnology. 2016, 8, 12471-503	119
1155	Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells. 2016, 151, 338-350.e7	44
1154	Halting the hallmarks: a cellular automaton model of early cancer growth inhibition. 2016, 15, 15-30	2
1153	Fibrin degradation by rtPA enhances the delivery of nanotherapeutics to A549 tumors in nude mice. 2016, 96, 63-71	23
1152	CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. 2016, 29, 832-845	442
1151	Integrin α modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas. 2016, 37, 12315-12327	13
1150	Combined targeting of TGF- β 1/EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. 2016, 379, 143-53	26
1149	Building up the tension between the epithelial and stromal compartment in pancreatic ductal adenocarcinoma. 2016, 23, 1265-6	2
1148	The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells. 2016, 119, 300-5	8
1147	Microenvironmental InterFereNce of metabolism regulates chemosensitivity. 2016, 26, 867-8	7

1146	Cyclopamine disrupts tumor extracellular matrix and improves the distribution and efficacy of nanotherapeutics in pancreatic cancer. 2016 , 103, 12-21	51
1145	Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. 2016 , 45, 425-33	10
1144	Early Detection and Treatment Opportunities in Pancreatic Adenocarcinoma. 2016 , 12, 31-2	
1143	Enhancement of Small Molecule Delivery by Pulsed High-Intensity Focused Ultrasound: A Parameter Exploration. 2016 , 42, 956-63	8
1142	Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility. 2016 , 372, 210-8	55
1141	Changing the course of pancreatic cancer--Focus on recent translational advances. 2016 , 44, 17-25	19
1140	Isolation and culture of primary human pancreatic stellate cells that reflect the context of their tissue of origin. 2016 , 401, 89-97	7
1139	Pancreatic cancer: Current research and future directions. 2016 , 1865, 123-32	51
1138	Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. 2016 , 30, 233-47	69
1137	Pathobiology of pancreatic cancer: implications on therapy. 2016 , 16, 219-27	2
1136	Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer. 2016 , 22, 415-25	66
1135	EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model. 2016 , 12, 589-600	36
1134	Hedgehog signaling: modulation of cancer properties and tumor microenvironment. 2016 , 15, 24	111
1133	Application of iron oxide nanoparticles in glioma imaging and therapy: from bench to bedside. 2016 , 8, 7808-26	82
1132	Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer. 2016 , 13, 1822-32	19
1131	Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer. 2016 , 30, 772-85	54
1130	TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis. 2016 , 76, 2525-39	110
1129	Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK. 2016 , 14, 437-47	38

1128	Preclinical models of pancreatic ductal adenocarcinoma. 2016 , 238, 197-204	71
1127	The Prognostic Significance of the Hedgehog Signaling Pathway in Colorectal Cancer. 2016 , 15, 116-27	22
1126	Cellular and molecular aspects of pancreatic cancer. 2016 , 118, 305-16	23
1125	Toward stratification of patients with pancreatic cancer: Past lessons from traditional approaches and future applications with physical biomarkers. 2016 , 381, 237-43	23
1124	Genetics and biology of pancreatic ductal adenocarcinoma. 2016 , 30, 355-85	288
1123	IFN γ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. 2016 , 6, 400-413	137
1122	MRI with hyperpolarised [1- ¹³ C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model. 2016 , 65, 465-75	54
1121	Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma. 2016 , 113, 2200-5	11
1120	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. 2016 , 44, 343-54	518
1119	Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer. 2016 , 15, 1145-52	22
1118	Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. 2016 , 381, 201-10	36
1117	Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. 2016 , 15, 439-47	68
1116	Suppression of CD51 in pancreatic stellate cells inhibits tumor growth by reducing stroma and altering tumor-stromal interaction in pancreatic cancer. 2016 , 48, 1499-508	20
1115	Organoids as Models for Neoplastic Transformation. 2016 , 11, 199-220	50
1114	Anti-Fc γ RIIIb antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response. 2016 , 5, e1112940	16
1113	Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. 2016 , 381, 259-68	26
1112	Nicotine induces self-renewal of pancreatic cancer stem cells via neurotransmitter-driven activation of sonic hedgehog signalling. 2016 , 52, 188-96	25
1111	Matrix control of pancreatic cancer: New insights into fibronectin signaling. 2016 , 381, 252-8	64

1110	Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. 2016 , 6, 256-69	133
1109	Prognostic and predictive markers in pancreatic adenocarcinoma. 2016 , 48, 223-30	83
1108	A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies. 2016 , 20, 53-65; discussion 65	21
1107	Key role of pancreatic stellate cells in pancreatic cancer. 2016 , 381, 194-200	76
1106	The role of hypoxia in pancreatic cancer: a potential therapeutic target?. 2016 , 10, 301-16	81
1105	Tumor microenvironment and cancer therapy resistance. 2016 , 380, 205-15	176
1104	The emerging roles of F-box proteins in pancreatic tumorigenesis. 2016 , 36, 88-94	15
1103	Evaluation of Tumor-associated Stroma and Its Relationship with Tumor Hypoxia Using Dynamic Contrast-enhanced CT and (18)F Misonidazole PET in Murine Tumor Models. 2016 , 278, 734-41	7
1102	Tumor-Priming Smoothed Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model. 2016 , 15, 84-93	19
1101	Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. 2016 , 150, 513-25.e10	66
1100	Model organoids provide new research opportunities for ductal pancreatic cancer. 2016 , 3, e1014757	42
1099	Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. 2016 , 20, 341-59	24
1098	Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. 2016 , 99, 186-196	247
1097	Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. 2016 , 65, 1710-20	131
1096	Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer. 2016 , 23 Suppl 2, S197-205	31
1095	Tumor evolution: Linear, branching, neutral or punctuated?. 2017 , 1867, 151-161	135
1094	Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma. 2017 , 6, 463-470	86
1093	Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer. 2017 , 140, 2101-2111	26

1092	Genomic insights in gynecologic cancer. 2017 , 41, 8-36	7
1091	Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. 2017 , 31, 5-19	200
1090	Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. 2017 , 116, 609-619	159
1089	Pancreatic cancer: Stroma and its current and emerging targeted therapies. 2017 , 391, 38-49	101
1088	Hedgehog signaling stimulates Tenascin C to promote invasion of pancreatic ductal adenocarcinoma cells through Annexin A2. 2017 , 11, 514-523	7
1087	Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies. 2017 , 232, 2931-2937	30
1086	ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. 2017 , 9, 198-218	83
1085	Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. 2017 , 49, 358-366	228
1084	Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma. 2017 , 36, 3232-3239	31
1083	Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. 2017 , 97, 302-317	24
1082	The Solid Mechanics of Cancer and Strategies for Improved Therapy. 2017 , 139,	75
1081	Extracellular Superoxide Dismutase Expression in Papillary Thyroid Cancer Mesenchymal Stem/Stromal Cells Modulates Cancer Cell Growth and Migration. 2017 , 7, 41416	21
1080	Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. 2017 , 214, 579-596	906
1079	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. 2017 , 174, 145-172	19
1078	Tumor Microenvironment and Differential Responses to Therapy. 2017 , 7,	170
1077	Refined strategies for the treatment of pancreatic carcinoma: targeting myeloid cells in order to overcome T cell exhaustion. 2017 , 66, 3-4	1
1076	Prometastatic mechanisms of CAF-mediated EMT regulation in pancreatic cancer cells. 2017 , 50, 121-128	18
1075	Hedgehog Signaling: From Basic Biology to Cancer Therapy. 2017 , 24, 252-280	186

1074	Pancreatic cancer stroma: controversies and current insights. 2017 , 52, 641-646	28
1073	Pancreatic ductal adenocarcinoma: is a cure possible?. 2017 , 13, 863-865	2
1072	Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer. 2017 , 17, 113	9
1071	Tackling pancreatic cancer with metronomic chemotherapy. 2017 , 394, 88-95	3
1070	PEG10 overexpression induced by E2F-1 promotes cell proliferation, migration, and invasion in pancreatic cancer. 2017 , 36, 30	27
1069	Biological determinants of radioresistance and their remediation in pancreatic cancer. 2017 , 1868, 69-92	43
1068	Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma. 2017 , 15, 47	8
1067	Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. 2017 , 77, 2647-2660	60
1066	Can diffusion-weighted imaging serve as a biomarker of fibrosis in pancreatic adenocarcinoma?. 2017 , 46, 393-402	20
1065	Genetically engineered mouse models in oncology research and cancer medicine. 2017 , 9, 137-153	218
1064	Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. 2017 , 392, 83-93	69
1063	Noninvasive characterization of pancreatic tumor mouse models using magnetic resonance imaging. 2017 , 6, 1082-1090	12
1062	Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. 2017 , 77, 951-965	12
1061	Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer. 2017 , 7, 470	42
1060	Therapeutic effects of Argyrin F in pancreatic adenocarcinoma. 2017 , 399, 20-28	7
1059	Hippo pathway mediates resistance to cytotoxic drugs. 2017 , 114, E3729-E3738	40
1058	Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. 2017 , 92, 47-66	168
1057	Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. 2017 , 44, 43-59	59

1056	Context-dependent intravital imaging of therapeutic response using intramolecular FRET biosensors. 2017 , 128, 78-94	26
1055	Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer. 2017 , 8, 15130	184
1054	Pancreatic cancer: a mechanobiology approach. 2017 , 3, 013001	6
1053	Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. 2017 , 66, 1037-1048	108
1052	The influence of anisotropic growth and geometry on the stress of solid tumors. 2017 , 119, 40-49	10
1051	IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma. 2017 , 16, 1898-1908	63
1050	O-GlcNAcylation of fumarase maintains tumour growth under glucose deficiency. 2017 , 19, 833-843	57
1049	Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. 2017 , 46, 3830-3852	500
1048	Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. 2017 , 546, 498-503	1093
1047	"Heat shock protein 70 in pancreatic diseases: Friend or foe". 2017 , 116, 114-122	18
1046	Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy. 2017 , 179, 158-170	92
1045	Runx3 and Cell Fate Decisions in Pancreas Cancer. 2017 , 962, 333-352	6
1044	Attenuating PI3K isoforms in pancreatic cancer: Focus on immune PI3K. 2017 , 41, 351-353	3
1043	MK2461, a Multitargeted Kinase Inhibitor, Suppresses the Progression of Pancreatic Cancer by Disrupting the Interaction Between Pancreatic Cancer Cells and Stellate Cells. 2017 , 46, 557-566	7
1042	The pancreatic cancer microenvironment: A true double agent. 2017 , 116, 7-15	44
1041	A mouse model for pain and neuroplastic changes associated with pancreatic ductal adenocarcinoma. 2017 , 158, 1609-1621	6
1040	Arl13b Promotes Gastric Tumorigenesis by Regulating Smo Trafficking and Activation of the Hedgehog Signaling Pathway. 2017 , 77, 4000-4013	21
1039	Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation. 2017 , 77, 2869-2880	14

1038	Development of anticancer agents targeting the Hedgehog signaling. 2017 , 74, 2773-2782	14
1037	Surface modulation of polymeric nanocarriers enhances the stability and delivery of proteins and small molecules. 2017 , 12, 729-743	4
1036	Fast lesion mapping during HIFU treatment using harmonic motion imaging guided focused ultrasound (HMIgFUS) in vitro and in vivo. 2017 , 62, 3111-3123	12
1035	Tumour tissue transport after intraperitoneal anticancer drug delivery. 2017 , 33, 534-542	21
1034	Circulating pancreatic stellate (stromal) cells in pancreatic cancer-a fertile area for novel research. 2017 , 38, 588-591	15
1033	Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. 2017 , 9,	159
1032	Strategies for Increasing Pancreatic Tumor Immunogenicity. 2017 , 23, 1656-1669	92
1031	Current and Emerging Therapies in Metastatic Pancreatic Cancer. 2017 , 23, 1670-1678	84
1030	Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked. 2017 , 23, 1647-1655	26
1029	U1 Adaptors Suppress the Oncogenic Axis in Human Pancreatic Cancer Xenografts. 2017 , 16, 1445-1455	8
1028	miR-202 Diminishes TGF β Receptors and Attenuates TGF β -Induced EMT in Pancreatic Cancer. 2017 , 15, 1029-1039	32
1027	Separation of Solid Stress From Interstitial Fluid Pressure in Pancreas Cancer Correlates With Collagen Area Fraction. 2017 , 139,	13
1026	Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. 2017 , 23, 4429-4440	108
1025	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. 2017 , 34, 331-357	6
1024	Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo. 2017 , 397, 72-82	15
1023	The role of stromal cancer-associated fibroblasts in pancreatic cancer. 2017 , 10, 76	201
1022	Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. 2017 , 31, 311-325	326
1021	Biosynthesis of Veratrum californicum specialty chemicals in Camelina sativa seed. 2017 , 11, 29-41	2

1020	Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. 2017 , 7, 44686	36
1019	Developments and future clinical outlook of taxane nanomedicines. 2017 , 253, 137-152	26
1018	New Interventional Treatment Model for Pancreatic Neoplasms Using Gemcitabine-Eluting Hydrogel Devices: In Vitro and In Vivo Results. 2017 , 40, 1246-1254	1
1017	Alteration of pancreatic carcinoma and promyeloblastic cell adhesion in liver microvasculature by co-culture of hepatocytes, hepatic stellate cells and endothelial cells in a physiologically-relevant model. 2017 , 9, 350-361	4
1016	Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters. 2017 , 17, 7-12	83
1015	Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. 2017 , 17, 175-186	74
1014	The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. 2017 , 12, 153-186	261
1013	Cholangiocarcinoma. 2017 , 116, 11-31	73
1012	Tumor Progression of Non-Small Cell Lung Cancer Controlled by Albumin and Micellar Nanoparticles of Itraconazole, a Multitarget Angiogenesis Inhibitor. 2017 , 14, 4705-4713	15
1011	Value of combining dynamic contrast enhanced ultrasound and optoacoustic tomography for hypoxia imaging. 2017 , 8, 15-27	8
1010	Resveratrol and cancer treatment: updates. 2017 , 1403, 59-69	75
1009	Elastographic Assessment of Xenograft Pancreatic Tumors. 2017 , 43, 2891-2903	9
1008	Soils and Seeds That Initiate Pancreatic Cancer Metastasis. 2017 , 7, 1067-1068	5
1007	Isolating and Analyzing Cells of the Pancreas Mesenchyme by Flow Cytometry. 2017 ,	8
1006	The Stromal Niche for Epithelial Stem Cells: A Template for Regeneration and a Brake on Malignancy. 2017 , 32, 404-410	41
1005	Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy. 2017 , 148, 69-80	64
1004	Engineering and physical sciences in oncology: challenges and opportunities. 2017 , 17, 659-675	153
1003	Tissue Force Programs Cell Fate and Tumor Aggression. 2017 , 7, 1224-1237	125

1002	Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?. 2017 , 60, 1114-1124	62
1001	The Roles of Matrix Metalloproteinases in Pancreatic Cancer. 2017 , 148, 339-354	35
1000	GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment. 2017 , 7, 13379	21
999	Integrated expression profiling of potassium channels identifies KCNN4 as a prognostic biomarker of pancreatic cancer. 2017 , 494, 113-119	24
998	Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. 2017 , 60, 32-43	93
997	Targeting Inflammation to Improve Tumor Drug Delivery. 2017 , 3, 621-630	19
996	Cancer Stem Cells and Metastasis. 2017 , 151, 137-176	32
995	Molecular MR imaging of fibrosis in a mouse model of pancreatic cancer. 2017 , 7, 8114	24
994	Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment. 2017 , 16, 2399-2409	19
993	Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis. 2017 , 7, 10374	24
992	Thermosensitive Liposomal Codelivery of HSA-Paclitaxel and HSA-Ellagic Acid Complexes for Enhanced Drug Perfusion and Efficacy Against Pancreatic Cancer. 2017 , 9, 25138-25151	39
991	Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review. 2017 , 8, 591-605	100
990	Retinoic acid, CYP26, and drug resistance in the stem cell niche. 2017 , 54, 17-25	18
989	Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance. 2017 , 144, 105-118	36
988	A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. 2017 , 31, 43-51	31
987	New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies. 2017 , 22, 223-233	14
986	Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. 2017 , 11, 8690-8706	88
985	Epigenetic regulation by the menin pathway. 2017 , 24, T147-T159	23

984	Chronic Pancreatitis. 2017 ,	0
983	Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. 2017 , 21, 2458-2470	86
982	Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. 2017 , 49, e406	75
981	Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma. 2017 , 7, 17038	21
980	Advances in the Genetics and Biology of Pancreatic Cancer. 2017 , 23, 315-320	14
979	The Pancreatic Cancer Microenvironment. 2017 , 23, 321-325	85
978	Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems. 2017 , 23, 326-332	3
977	Transport of drugs from blood vessels to tumour tissue. 2017 , 17, 738-750	332
976	Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance. 2017 , 38, 3335-3346	9
975	Radiofrequency heat-enhanced direct intratumoral chemotherapy for prostate cancer. 2017 , 14, 7250-7256	1
974	Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts. 2017 , 108, 2470-2477	13
973	Reverse Phase Protein Arrays elucidate mechanisms-of-action and phenotypic response in 2D and 3D models. 2017 , 23, 7-16	8
972	Lessons Learned from Two Decades of Anticancer Drugs. 2017 , 38, 852-872	53
971	SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients. 2017 , 34, 136	5
970	Genetics of pancreatic cyst-cancer progression: standing on the shoulders of giants. 2017 , 33, 404-410	3
969	Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. 2017 , 8, 16031	178
968	Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy. 2017 , 261, 105-112	47
967	Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts. 2017 , 56, 1754-1762	18

966	Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. 2017 , 77, 41-52	61
965	Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF- β /Gfi-1 axis. 2017 , 385, 65-74	27
964	Vascular enhancement pattern of mass in computed tomography may predict chemo-responsiveness in advanced pancreatic cancer. 2017 , 17, 103-108	12
963	Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. 2017 , 3, 774-783	157
962	NO and Pancreatic Cancer: A Complex Interaction with Therapeutic Potential. 2017 , 26, 1000-1008	5
961	Inhibition of Pancreatic Cancer Cell-Induced Paracrine Hedgehog Signaling by Liver X Receptor Agonists and Oxy16, a Naturally Occurring Oxysterol. 2017 , 118, 499-509	9
960	Clonal cooperativity in heterogenous cancers. 2017 , 64, 79-89	32
959	Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. 2017 , 36, 1770-1778	391
958	Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer. 2017 , 23, 1461-1470	41
957	Senescent Carcinoma-Associated Fibroblasts Upregulate IL8 to Enhance Prometastatic Phenotypes. 2017 , 15, 3-14	59
956	Patterns of Vasculature in Mouse Models of Lung Cancer Are Dependent on Location. 2017 , 19, 215-224	13
955	Sonoporation with Acoustic Cluster Therapy (ACT \square) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. 2017 , 245, 70-80	19
954	Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts. 2017 , 116, 50-57	14
953	Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents. 2017 , 10, 1179064417709287	19
952	Acquired chemotherapy resistance in ovarian cancer. 2017 , 28, viii13-viii15	77
951	In situ measurement of ECM rheology and microheterogeneity in embedded and overlaid 3D pancreatic tumor stroma co-cultures via passive particle tracking. 2017 , 10, 1742003	4
950	Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. 2017 , 127, 2007-2018	118
949	Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery. 2017 , 8, 952	78

948	Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma. 2017 , 51, 1239-1248	13
947	Nanoparticles for tumor targeting. 2017 , 221-267	4
946	EMT and Treatment Resistance in Pancreatic Cancer. 2017 , 9,	83
945	Toxic plants. 2017 , 903-923	
944	Seed-in-Soil: Pancreatic Cancer Influenced by Tumor Microenvironment. 2017 , 9,	16
943	Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. 2017 , 18,	42
942	Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. 2017 , 18,	267
941	Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. 2017 , 2017, 6012810	9
940	Inflammatory Cytokine Signaling during Development of Pancreatic and Prostate Cancers. 2017 , 2017, 7979637	10
939	LSL-KrasG12D; LSL-Trp53R172H/+; Ink4flox/+; Ptf1/p48-Cre mice are an applicable model for locally invasive and metastatic pancreatic cancer. 2017 , 12, e0176844	8
938	Fibromodulin deficiency reduces collagen structural network but not glycosaminoglycan content in a syngeneic model of colon carcinoma. 2017 , 12, e0182973	5
937	Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy. 2017 , 12, e0189051	25
936	Chemotherapy and tumor microenvironment of pancreatic cancer. 2017 , 17, 68	58
935	Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology. 2017 , 7, 16887	16
934	The IGF-I/IGF-IR Signaling System and Pancreatic Cancer. 2017 , 32, 131-136	3
933	Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene. 2017 , 8, 33393-33404	23
932	TGF-beta1, WNT, and SHH signaling in tumor progression and in fibrotic diseases. 2017 , 9, 31-45	24
931	Theranostic Role of P-ATP as Radiopharmaceutical for the Induction of Massive Cell Death within Avascular Tumor Core. 2017 , 7, 4399-4409	6

930	Cancer Biophysics. 2017 ,	2
929	Pirfenidone normalizes the tumor microenvironment to improve chemotherapy. 2017 , 8, 24506-24517	98
928	Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts. 2017 , 8, 19074-19088	18
927	Targeting Smoothed Sensitizes Gastric Cancer to Chemotherapy in Experimental Models. 2017 , 23, 1493-1500	7
926	Matrix-regulated integrin β maintains β -dependent desmoplastic traits prognostic of neoplastic recurrence. 2017 , 6,	61
925	Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma. 2017 , 8, 441-448	4
924	Coadministration of Polymeric Conjugates of Docetaxel and Cycloamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis. 2018 , 35, 17	3
923	Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. 2018 , 6, 389-401	42
922	Mechanotransduction in tumor progression: The dark side of the force. 2018 , 217, 1571-1587	140
921	Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma. 2018 , 11, 426-435	14
920	Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy. 2018 , 5, 1701070	52
919	Stroma - A Double-Edged Sword in Pancreatic Cancer: A Lesson From Targeting Stroma in Pancreatic Cancer With Hedgehog Signaling Inhibitors. 2018 , 47, 382-389	20
918	Biomimetic nanoparticles delivered hedgehog pathway inhibitor to modify tumour microenvironment and improved chemotherapy for pancreatic carcinoma. 2018 , 46, 1088-1101	13
917	Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. 2018 , 1869, 248-255	16
916	Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma. 2018 , 4, 239-255	52
915	Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. 2018 , 115, E3769-E3778	71
914	Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer. 2018 , 426, 14-24	17
913	Targeting the tumour stroma to improve cancer therapy. 2018 , 15, 366-381	421

912 Adenocarcinoma of the Pancreas. **2018**, 82-99

911 Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe-binding. **2018**, 9, 512 25

910 A Subset of Cancer-Associated Fibroblasts Determines Therapy Resistance. **2018**, 172, 643-644 45

909 Fibrogenesis of the Pancreas. **2018**, 117-122

908 Targeted Therapies for Pancreatic Cancer. **2018**, 865-871

907 Pathology of Exocrine Pancreatic Tumors. **2018**, 693-704

906 Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. **2018**, 115, E1147-E1156 84

905 Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis. **2018**, 36, 545-560 10

904 Functions of autophagy in the tumor microenvironment and cancer metastasis. **2018**, 285, 1751-1766 110

903 The hypoxic tumour microenvironment. **2018**, 7, 10 440

902 LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. **2018**, 78, 909-921 51

901 PTEN-Dependent Stabilization of MTSS1 Inhibits Metastatic Phenotype in Pancreatic Ductal Adenocarcinoma. **2018**, 20, 12-24 11

900 Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts. **2018**, 67, 90-106 76

899 Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. **2018**, 52, 241-252 9

898 Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. **2018**, 154, 820-838 118

897 Drug development and clinical trial design in pancreatobiliary malignancies. **2018**, 42, 73-94 4

896 The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone. **2018**, 18, 191-197 7

895 Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. **2018**, 159, 215-228 51

894	MicroRNA-494 regulates Gli3 expression and inhibits pancreatic cancer cells growth and migration. 2018 , 119, 5324-5331	4
893	Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer. 2018 , 9, 16	53
892	Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4. 2018 , 110,	83
891	CSF1R Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype. 2018 , 23, 1448-1460	105
890	The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma. 2018 , 17, 62	61
889	Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST. 2018 , 104, 49-57	9
888	Chronic pancreatitis and resectable synchronous pancreatic carcinoma: A survival analysis. 2018 , 18, 394-398	7
887	Therapeutic developments in pancreatic cancer: current and future perspectives. 2018 , 15, 333-348	423
886	Pancreatic Cancer Stem Cells. 2018 , 349-368	
885	Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis. 2018 , 369-382	
884	Stromal Inflammation in Pancreatic Cancer: Mechanisms and Translational Applications. 2018 , 481-508	
883	Development of Novel Therapeutic Response Biomarkers. 2018 , 1273-1304	
882	Multiparameter Modalities for the Study of Patients in the Setting of Individualized Medicine. 2018 , 1523-1549	
881	Precision Medicine Based on Next-Generation Sequencing and Master Controllers. 2018 , 1577-1611	0
880	Hedgehog Signaling Plays a Dual Role in Pancreatic Carcinogenesis. 2018 , 409-430	1
879	Mouse Models of Pancreatic Exocrine Cancer. 2018 , 509-538	
878	Emerging Therapeutic Targets in Pancreatic Adenocarcinoma. 2018 , 1613-1641	1
877	Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. 2018 , 81, 991-998	6

876	Current perspectives on the crosstalk between lung cancer stem cells and cancer-associated fibroblasts. 2018 , 125, 102-110	17
875	Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside. 2018 , 4, 292-319	229
874	Mesenchymal Cell Plasticity and Perfidy in Epithelial Malignancy. 2018 , 4, 273-277	5
873	Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. 2018 , 24, 2873-2885	25
872	Cyclopamine treatment disrupts extracellular matrix and alleviates solid stress to improve nanomedicine delivery for pancreatic cancer. 2018 , 26, 913-919	11
871	Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer. 2018 , 18, 2195-2208	16
870	Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. 2018 , 67, 508-520	63
869	Dynamic landscape of pancreatic carcinogenesis reveals early molecular networks of malignancy. 2018 , 67, 146-156	30
868	Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. 2018 , 67, 497-507	114
867	Pancreatic stellate cells reorganize matrix components and lead pancreatic cancer invasion via the function of Endo180. 2018 , 412, 143-154	20
866	Physical oncology: New targets for nanomedicine. 2018 , 150, 87-99	19
865	Molecular similarities and differences from human pulmonary fibrosis and corresponding mouse model: MALDI imaging mass spectrometry in comparative medicine. 2018 , 98, 141-149	12
864	Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?. 2018 , 75, 1001-1012	24
863	Tumor Heterogeneity in Pancreatic Adenocarcinoma. 2018 , 85, 64-71	53
862	Revisiting ovarian cancer microenvironment: a friend or a foe?. 2018 , 9, 674-692	20
861	New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. 2018 , 25, 131-142	30
860	Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice. 2018 , 154, 675-688	55
859	Triptonide potently suppresses pancreatic cancer cell-mediated vasculogenic mimicry by inhibiting expression of VE-cadherin and chemokine ligand 2 genes. 2018 , 818, 593-603	36

858	Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. 2018 , 68, 77-87	84
857	Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer. 2018 , 78, 475-488	42
856	Peptides as drug delivery vehicles across biological barriers. 2018 , 48, 89-111	39
855	Characterization of tumor vascular permeability using natural dextrans and CEST MRI. 2018 , 79, 1001-1009	26
854	HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH/Gli1 signaling pathway. 2018 , 415, 164-176	48
853	Experimental models of pancreatic cancer desmoplasia. 2018 , 98, 27-40	30
852	An overview of polyamine metabolism in pancreatic ductal adenocarcinoma. 2018 , 142, 1968-1976	12
851	Pancreas Embryology, Anatomy, and Physiology. 2018 , 143-160	
850	Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets. 2018 , 8,	10
849	Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. 2018 , 2018,	32
848	How does the tumor microenvironment play a role in hepatobiliary tumors?. 2018 , 9, 180-195	14
847	Astragaloside IV promotes the proliferation and migration of osteoblast-like cells through the hedgehog signaling pathway. 2019 , 43, 830-838	7
846	Evaluation of pancreatic tumor development in KPC mice using multi-parametric MRI. 2018 , 18, 41	8
845	HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. 2018 , 7,	35
844	Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review. 2018 , 35, 195-292	6
843	. 2018 ,	0
842	Biomechanics in Oncology. 2018 ,	3
841	Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. 2018 , 155, 1999-2013.e3	189

840	The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. 2018 , 6,	5
839	From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. 2018 , 19,	6
838	The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. 2018 , 8, 5072-5087	91
837	Deciphering cancer fibroblasts. 2018 , 215, 2967-2968	17
836	Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment. 2018 , 37, 577-597	86
835	Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer. 2018 , 32, 983-996	52
834	Dual-Responsive Doxorubicin-Conjugated Polymeric Micelles with Aggregation-Induced Emission Active Bioimaging and Charge Conversion for Cancer Therapy. 2018 , 29, 4050-4061	22
833	Preclinical characterization of therapeutic antibodies targeted at the carboxy-terminus of Sonic hedgehog. 2018 , 9, 14311-14323	7
832	Targeting the Oncoprotein Smoothed by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothed Inhibitors. 2018 , 7,	27
831	Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model. 2019 , 54, 537-549	7
830	Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype. 2018 , 4, e01055	22
829	Targeted Therapies for Pancreatic Cancer and Hurdles Ahead. 2018 , 38, 6591-6606	40
828	Development of photoactive Sweet-C for pancreatic cancer stellate cell therapy. 2018 , 13, 2981-2993	16
827	Chemoresistance and the Self-Maintaining Tumor Microenvironment. 2018 , 10,	88
826	Blocking Autophagy in Cancer-Associated Fibroblasts Supports Chemotherapy of Pancreatic Cancer Cells. 2018 , 8, 590	16
825	Enhancement of Tumor Homing by Chemotherapy-Loaded Nanoparticles. 2018 , 14, e1802886	14
824	Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance. 2018 , 6, 131	53
823	Advances in Gastrointestinal Surgery. 2018 , 177-221	

822	The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. 2018 , 9, 573	8
821	Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. 2018 , 8, 14008	15
820	Whole Exome Sequencing Identifies a Novel Hedgehog-Interacting Protein G516R Mutation in Locally Advanced Papillary Thyroid Cancer. 2018 , 19,	6
819	GI Surgery Annual. 2018 ,	
818	Advanced pancreatic cancer: The standard of care and new opportunities. 2018 , 12, 370	7
817	Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model. 2018 , 70, 1075-1087	10
816	Role of angiogenesis in pancreatic cancer biology and therapy. 2018 , 108, 1135-1140	29
815	Novel Targets in Pancreatic Cancer Therapy - Current Status and Ongoing Translational Efforts. 2018 , 41, 596-602	9
814	Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer. 2018 , 10,	21
813	Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma. 2018 , 13, e0194809	9
812	Computational fluid dynamics with imaging of cleared tissue and of in vivo perfusion predicts drug uptake and treatment responses in tumours. 2018 , 2, 773-787	54
811	Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. 2018 , 155, 1625-1639.e2	92
810	Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-Kras;Tp53 (KPC) mice, a genetically engineered model of pancreatic cancer. 2018 , 82, 1067-1080	6
809	Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance. 2018 , 19,	23
808	Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. 2018 , 10,	14
807	Image-Based Profiling of Patient-Derived Pancreatic Tumor-Stromal Cell Interactions Within a Micropatterned Tumor Model. 2018 , 17, 1533033818803632	
806	Extracellular Matrix Stiffness Exists in a Feedback Loop that Drives Tumor Progression. 2018 , 1092, 57-67	14
805	Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis. 2018 , 10,	10

804 Harmonic Motion Imaging. **2018**, 264-283

803 Jack of many trades: Multifaceted role of neuropilins in pancreatic cancer. **2018**, 7, 5036-5046 10

802 Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness. **2018**, 8, 1458-1473 83

801 Technical Note: In vivo Young's modulus mapping of pancreatic ductal adenocarcinoma during HIFU ablation using harmonic motion elastography (HME). **2018**, 45, 5244-5250 3

800 Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer. **2018**, 12, 9881-9893 43

799 The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship. **2018**, 10, 119

798 Reproducibility of academic preclinical translational research: lessons from the development of Hedgehog pathway inhibitors to treat cancer. **2018**, 8, 17

797 LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates. **2018**, 78, 4059-4072 73

796 Stromal heterogeneity in pancreatic cancer and chronic pancreatitis. **2018**, 18, 536-549 20

795 Ciliary signalling in cancer. **2018**, 18, 511-524 67

794 Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. **2018**, 8, 1112-1129 394

793 Immunotherapy for pancreatic cancer: Barriers and breakthroughs. **2018**, 2, 274-281 87

792 Mechanisms and impact of altered tumour mechanics. **2018**, 20, 766-774 109

791 Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer. **2018**, 130, 50-57 47

790 Hedgehog Signaling in Gastrointestinal Morphogenesis and Morphostasis. **2018**, 103-129

789 Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer. **2018**, 432, 227-236 25

788 Pharmacokinetics and Tissue Transport of Intraperitoneal Chemotherapy. **2018**, 27, 477-494 12

787 Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression. **2018**, 24, 4798-4807 39

786	Localized Controlled Delivery of Gemcitabine via Microsol Electrospun Fibers to Prevent Pancreatic Cancer Recurrence. 2018 , 7, e1800593	26
785	Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer. 2018 , 315, G27-G35	14
784	Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. 2018 , 13, 447-459	6
783	Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. 2018 , 208, 253-261	31
782	Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound. 2018 , 39, 1197-1206	4
781	FF-ATP Synthase Inhibitory Factor 1 in the Normal Pancreas and in Pancreatic Ductal Adenocarcinoma: Effects on Bioenergetics, Invasion and Proliferation. 2018 , 9, 833	3
780	New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment. 2018 , 286, 254-263	23
779	Genetic Alterations Featuring Biological Models to Tailor Clinical Management of Pancreatic Cancer Patients. 2020 , 12,	4
778	Loss of microRNA-21 leads to profound stromal remodeling and short survival in K-Ras-driven mouse models of pancreatic cancer. 2020 , 147, 2265-2278	8
777	The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. 2020 , 17, 527-540	221
776	Pancreatic Cancer and Its Microenvironment-Recent Advances and Current Controversies. 2020 , 21,	19
775	Modeling EV Kinetics for Use in Early Cancer Detection. 2020 , 4, e1900305	10
774	Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer. 2020 , 12,	13
773	Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer. 2020 , 12,	1
772	Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma. 2020 , 212, 107575	36
771	Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy. 2020 ,	9
770	The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives. 2020 , 24, 7706-7716	8
769	Pancreatic Cancer Associated Fibroblasts (CAF): Under-Explored Target for Pancreatic Cancer Treatment. 2020 , 12,	34

768	Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer. 2020 , 319, C233-C243	12
767	Antifibrotic therapy to normalize the tumor microenvironment. 2020 , 18, 207	25
766	Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy. 2020 , 33, 2026-2034	3
765	Desmoplasia and Biophysics in Pancreatic Ductal Adenocarcinoma: Can We Learn From Breast Cancer?. 2020 , 49, 313-325	8
764	Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation. 2020 , 29, 963689720929987	12
763	A novel pancreatic tumour and stellate cell 3D co-culture spheroid model. 2020 , 20, 475	20
762	Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models. 2020 , 12,	17
761	Killing the "BAD": Challenges for immunotherapy in pancreatic cancer. 2020 , 1874, 188384	6
760	Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer. 2020 , 22, 88	3
759	Ligand-Controlled Palladium-Catalyzed Carbonylation of Alkynols: Highly Selective Synthesis of β Methylene- γ Lactones. 2020 , 59, 21585-21590	9
758	Photocontrolled miR-148b nanoparticles cause apoptosis, inflammation and regression of Ras induced epidermal squamous cell carcinomas in mice. 2020 , 256, 120212	7
757	Ligand-Controlled Palladium-Catalyzed Carbonylation of Alkynols: Highly Selective Synthesis of β Methylene- γ Lactones. 2020 , 132, 21769-21774	4
756	The physiological characteristics of the basal microvilli microvessels in pancreatic cancers. 2020 , 9, 5535-5545	2
755	Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance. 2020 , 24, 314-339	14
754	Proteins and Molecular Pathways Relevant for the Malignant Properties of Tumor-Initiating Pancreatic Cancer Cells. 2020 , 9,	6
753	Fibroblasts as a Biological Marker for Curative Resection in Pancreatic Ductal Adenocarcinoma. 2020 , 21,	20
752	Glycogen synthase kinase-3 α novel therapeutic target for pancreatic cancer. 2020 , 24, 417-426	14
751	Integrin $\alpha 5 \beta 1$ -specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. 2020 , 10, 2930-2942	15

750	Engineered tumor models for cancer biology and treatment. 2020 , 423-443	1
749	Emerging Nano Drug Delivery Systems Targeting Cancer-Associated Fibroblasts for Improved Antitumor Effect and Tumor Drug Penetration. 2020 , 17, 1028-1048	25
748	O-GlcNAcylation of PFKFB3 is required for tumor cell proliferation under hypoxia. 2020 , 9, 21	13
747	Carcinogenesis of Pancreatic Ductal Adenocarcinoma. 2020 , 158, 2072-2081	33
746	[Organoids from pancreatic ductal adenocarcinoma]. 2020 , 36, 57-62	1
745	LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications. 2020 , 12,	7
744	Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes. 2020 , 10, 5420	34
743	Fibroblast Heterogeneity in the Pancreatic Tumor Microenvironment. 2020 , 10, 648-656	94
742	Cysteine depletion induces pancreatic tumor ferroptosis in mice. <i>Science</i> , 2020 , 368, 85-89	33.3 269
741	Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy. 2020 , 59, 775-782	17
740	OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models. 2020 , 26, 3420-3430	22
739	NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors. 2020 , 80, 1846-1860	81
738	Molecular imaging of extracellular matrix proteins with targeted probes using magnetic resonance imaging. 2020 , 12, e1622	9
737	Cancer-associated adipocytes promote pancreatic cancer progression through SAA1 expression. 2020 , 111, 2883-2894	22
736	MT1-MMP-Activated Liposomes to Improve Tumor Blood Perfusion and Drug Delivery for Enhanced Pancreatic Cancer Therapy. 2020 , 7, 1902746	11
735	The impact of molecular classification based on the transcriptome of pancreatic cancer: from bench to bedside. 2020 , 3, 67-75	
734	Fibroblast Reprogramming in Gastrointestinal Cancer. 2020 , 8, 630	11
733	Diffusion Kurtosis Imaging-A Superior Approach to Assess Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. 2020 , 12,	5

732	Agrobacterium-Mediated Genetic Transformation of the Medicinal Plant. 2020 , 9,	11
731	Hyperthermia and smart drug delivery systems for solid tumor therapy. 2020 , 163-164, 125-144	62
730	Developmental Morphogens and Adult Liver Repair. 2020 , 539-549	0
729	Paracrine and cell autonomous signalling in pancreatic cancer progression and metastasis. 2020 , 53, 102662	19
728	Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma. 2019 , 9, 1443	12
727	Small molecule inhibitors in pancreatic cancer. 2020 , 11, 164-183	8
726	Sonic Hedgehog Signaling in Organogenesis, Tumors, and Tumor Microenvironments. 2020 , 21,	52
725	A framework for advancing our understanding of cancer-associated fibroblasts. 2020 , 20, 174-186	790
724	A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma. 2020 , 16, e1905500	14
723	Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer. 2020 , 18, 623-631	17
722	Synthesis of the DEF-Ring Stereotriad Core of the Alkaloids. 2020 , 85, 6808-6814	4
721	Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. 2020 , 122, 1760-1768	4
720	The Role of Glypican-1 in the Tumour Microenvironment. 2020 , 1245, 163-176	16
719	Drug uptake-based chemoresistance in breast cancer treatment. 2020 , 177, 113959	38
718	Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. 2020 , 181, 424-441.e21	96
717	Renal clearable nanocarriers: Overcoming the physiological barriers for precise drug delivery and clearance. 2020 , 322, 64-80	16
716	Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. 2020 , 39, 4103-4117	16
715	SKA1 regulates actin cytoskeleton remodelling via activating Cdc42 and influences the migration of pancreatic ductal adenocarcinoma cells. 2020 , 53, e12799	8

714	CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy. 2020 , 9,	12
713	Radiolabeled Human Monoclonal Antibody 067-213 has the Potential for Noninvasive Quantification of CD73 Expression. 2020 , 21,	4
712	Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME). 2020 , 10, 4614-4626	12
711	Resveratrol in Cancer Patients: From Bench to Bedside. 2020 , 21,	32
710	Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response. 2020 , 26, 1297-1308	11
709	CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in Patients. 2020 , 159, 665-681.e13	22
708	Microenvironmental Determinants of Pancreatic Cancer. 2020 , 100, 1707-1751	62
707	Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy. 2020 , 19, 1308-1319	18
706	High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1. 2020 , 21, e48780	17
705	Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma. 2020 , 15, e0231745	4
704	MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype. 2020 , 10, 588-607	63
703	Diversity and Biology of Cancer-Associated Fibroblasts. 2021 , 101, 147-176	103
702	Extracellular matrix proteins in metastases to the liver - Composition, function and potential applications. 2021 , 71, 134-142	8
701	Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. 2021 , 1875, 188461	19
700	Predicting Gemcitabine Delivery by F-FAC PET in Murine Models of Pancreatic Cancer. 2021 , 62, 195-200	2
699	Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors. 2021 , 27, 75-90	2
698	Photodestruction of Stromal Fibroblasts Enhances Tumor Response to PDT in 3D Pancreatic Cancer Coculture Models. 2021 , 97, 416-426	6
697	Modulation of Cancer-Associated Fibrotic Stroma by An Integrin β -targeting Protein for Pancreatic Cancer Treatment. 2021 , 11, 161-179	7

696	Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF- β /Smad signaling pathways. 2021 , 37, 479-496	9
695	Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen. 2021 , 27, 107-119	23
694	Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer. 2021 , 25, 5-13	3
693	Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. 2021 , 20, 548-559	44
692	M2 Macrophage-Derived Exosomes Promote Angiogenesis and Growth of Pancreatic Ductal Adenocarcinoma by Targeting E2F2. 2021 , 29, 1226-1238	33
691	Nanoenabled Tumor Oxygenation Strategies for Overcoming Hypoxia-Associated Immunosuppression.. 2021 , 4, 277-294	1
690	Disease-induced immunomodulation at biomaterial scaffolds detects early pancreatic cancer in a spontaneous model. 2021 , 269, 120632	4
689	The rediscovery of platinum-based cancer therapy. 2021 , 21, 37-50	118
688	Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. 2021 , 160, 346-361.e24	24
687	Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblast-Driven Nutritional Support and Immunosuppression. 2021 , 11, 446-479	31
686	Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma. 2021 , 17, 675-688	2
685	Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy. 2021 , 69, 337-348	18
684	Collagenase-loaded pH-sensitive nanocarriers efficiently remodeled tumor stroma matrixes and improved the enrichment of nanomedicines. 2021 , 13, 9402-9414	0
683	Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer. 2021 , 11, 2182-2200	8
682	The Intricate Metabolism of Pancreatic Cancers. 2021 , 1311, 77-88	5
681	Stromal-driven and Amyloid E-dependent induction of neutrophil extracellular traps modulates tumor growth. 2021 , 12, 683	19
680	The vascular landscape of human cancer. 2021 , 131,	9
679	Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery. 2021 , 13,	36

678	Desmoplastic Crosstalk in Pancreatic Ductal Adenocarcinoma Is Reflected by Different Responses of Panc-1, MIAPaCa-2, PaTu-8902, and CAPAN-2 Cell Lines to Cancer-associated/Normal Fibroblasts. 2021 , 18, 221-243	3
677	Stromal Protein-Mediated Immune Regulation in Digestive Cancers. 2021 , 13,	5
676	Targeting TGF β signal transduction for cancer therapy. 2021 , 6, 8	62
675	Role of Stroma in Pancreatic Cancer. 2021 , 251-265	
674	STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer. 2021 , 12, 41-58	9
673	Hypoxic microenvironment induced spatial transcriptome changes in pancreatic cancer. 2021 ,	3
672	Combined chemotherapy and endoscopic ultrasound-guided intratumoral 32P implantation for locally advanced pancreatic adenocarcinoma: a pilot study. 2021 ,	3
671	Resectable, borderline, and locally advanced pancreatic cancer-"the good, the bad, and the ugly" candidates for surgery?. 2021 , 12, 2450-2460	1
670	The Hallmarks of Pancreatic Cancer. 2021 , 189-201	
669	Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer. 2021 , 11, 1693	9
668	The Prolyl Isomerase PIN1 Plays a Critical Role in Fibroblast Differentiation States to Support Pancreatic Cancer.	
667	Out-of-the-Box Nanocapsules Packed with On-Demand Hydrophobic Anticancer Drugs for Lung Targeting, Esterase Triggering, and Synergy Therapy. 2021 , 10, e2001803	4
666	Overcoming Therapeutic Challenges for Pancreatic Ductal Adenocarcinoma with xCT Inhibitors. 2021 , 1301, 7-24	
665	Lactoglobulin-gold nanoparticles interface and its interaction with some anticancer drugs - an approach for targeted drug delivery. 2021 , 1-25	1
664	Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. 2021 , 8, 2002147	14
663	Immuno-Oncology in Pancreatic Cancer. 2021 , 287-304	0
662	Cancer Cell Metabolism in Pancreatic Ductal Adenocarcinoma. 2021 , 219-234	
661	Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy. 2020 , 11, 586599	7

660	Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer. 2021 , 5, e1900236	2
659	Adaptive stimulation of macropinocytosis overcomes aspartate limitation in cancer cells under hypoxia.	1
658	Acquired radioresistance in cancer associated fibroblasts is concomitant with enhanced antioxidant potential and DNA repair capacity. 2021 , 19, 30	11
657	CEST MRI trackable nanoparticle drug delivery systems. 2021 , 16, 024103	2
656	Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic. 2021 , 22,	1
655	Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma. 2021 , 8, 2002545	11
654	Hyaluronic Acid Conjugated Metformin-Phospholipid Sonocomplex: A Biphasic Complexation Approach to Correct Hypoxic Tumour Microenvironment. 2021 , 16, 1005-1019	4
653	Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma.	0
652	Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma. 2021 , 11, e337	1
651	Role of endothelial cells in the regulation of mechanical microenvironment on tumor progression. 2021 , 37, 218-228	1
650	Theranostic Nanoparticles for Pancreatic Cancer Treatment. 2021 , 21, 203-214	5
649	Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. 2021 , 13,	14
648	Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology. 2021 , 13,	6
647	Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetration. 2021 , 16, 275-292	3
646	Adipose-derived mesenchymal stem cells differentiate into heterogeneous cancer-associated fibroblasts in a stroma-rich xenograft model. 2021 , 11, 4690	7
645	Application of Bionanomaterials in Tumor Immune Microenvironment Therapy. 2021 , 2021, 6663035	2
644	Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. 2020 , 11, 629722	15
643	Pancreatic cancer pathology viewed in the light of evolution. 2021 , 40, 661-674	3

642	Inhibitors of cullin-RING E3 ubiquitin ligase 4 with antitumor potential. 2021 , 118,	2
641	The matrix in cancer. 2021 , 21, 217-238	104
640	Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma. 2021 , 14,	2
639	Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies. 2021 , 27, 3825-3833	0
638	CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. 2021 , 20, 51	17
637	Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution. 2021 , 13,	7
636	Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. 2021 , 9, 641469	30
635	Progression of prostate carcinoma is promoted by adipose stromal cell-secreted CXCL12 signaling in prostate epithelium. 2021 , 5, 26	3
634	MicroRNA-Regulated Signaling Pathways: Potential Biomarkers for Pancreatic Ductal Adenocarcinoma. 2021 , 1, 30-47	3
633	Selecting the optimal parameters for sonoporation of pancreatic cancer in a pre-clinical model. 2021 , 22, 204-215	4
632	Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment. 2021 ,	10
631	In-Depth Characterization of Stromal Cells within the Tumor Microenvironment Yields Novel Therapeutic Targets. 2021 , 13,	4
630	Harnessing metabolic dependencies in pancreatic cancers. 2021 , 18, 482-492	17
629	Leveraging microenvironmental synthetic lethality to treat cancer. 2021 , 131,	6
628	Development of Facile and Versatile Platinum Drug Delivering Silicasome Nanocarriers for Efficient Pancreatic Cancer Chemo-Immunotherapy. 2021 , 17, e2005993	18
627	Fighting the Sixth Decade of the Cancer War with Better Cancer Models. 2021 , 11, 801-804	1
626	First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. 2021 , 27, 3556-3566	10
625	Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. 2021 , 4, 2000262	2

624	Research progress in tumor targeted immunotherapy. 2021 , 18, 1067-1090	4
623	The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities. 2021 , 13,	27
622	The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. 2021 , 9,	8
621	Metastasis-Initiating Cells and Ecosystems. 2021 , 11, 971-994	22
620	Targeting the Stromal Pro-Tumoral Hyaluronan-CD44 Pathway in Pancreatic Cancer. 2021 , 22,	3
619	Immune cell shuttle for precise delivery of nanotherapeutics for heart disease and cancer. 2021 , 7,	7
618	Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity. 2021 , 35, 109009	3
617	Type I collagen deletion in SMA myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. 2021 , 39, 548-565.e6	85
616	New Pharmacological Approaches for Pancreatic Cancer Therapy. 2021 , 564-572	
615	Dissecting FGF Signalling to Target Cellular Crosstalk in Pancreatic Cancer. 2021 , 10,	5
614	N-acetyl cysteine induces quiescent-like pancreatic stellate cells from an active state and attenuates cancer-stroma interactions. 2021 , 40, 133	2
613	Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy. 2021 , 11, 668731	11
612	Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?. 2021 , 13,	1
611	Mesenchymal Lineage Heterogeneity Underlies Non-Redundant Functions of Pancreatic Cancer-Associated Fibroblasts.	2
610	Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?. 2021 , 14, 101056	5
609	Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. 2021 , 302, 259-272	19
608	Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts. 2021 , 172, 37-51	6
607	Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma. 2021 , 22,	1

606	Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments. 2021 , 12, 2815	13
605	Cyclin B1 acts as a tumor microenvironment-related cancer promoter and prognostic biomarker in hepatocellular carcinoma. 2021 , 49, 3000605211016265	1
604	Tumor microenvironment remodeling-based penetration strategies to amplify nanodrug accessibility to tumor parenchyma. 2021 , 172, 80-103	14
603	Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy. 2021 , 10,	10
602	Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. 2021 , 27, 2105-2121	4
601	MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer. 2021 , 21, 340-355	2
600	missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. 2021 , 118,	9
599	Applications of single-cell sequencing in cancer research: progress and perspectives. 2021 , 14, 91	17
598	Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. 2021 , 6, 218	41
597	Stem Cells in the Exocrine Pancreas during Homeostasis, Injury, and Cancer. 2021 , 13,	1
596	The biological underpinnings of therapeutic resistance in pancreatic cancer. 2021 , 35, 940-962	13
595	Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer. 2021 , 44, 937-950	7
594	A bird's eye view of fibroblast heterogeneity: A pan-disease, pan-cancer perspective. 2021 , 302, 299-320	9
593	TNF- β induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma. 2021 , 12, 649	7
592	Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer. 2021 , 11,	3
591	Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment. 2021 , 302, 241-258	11
590	TGF- β -activated cancer-associated fibroblasts promote breast cancer invasion, metastasis and epithelial-mesenchymal transition by autophagy or overexpression of FAP- β 2021 , 188, 114527	4
589	Cancer-Associated Fibroblasts in Breast Cancer Treatment Response and Metastasis. 2021 , 13,	4

588	The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. 2021 , 13,	13
587	Long Distance From Microvessel to Cancer Cell Predicts Poor Prognosis in Non-Small Cell Lung Cancer Patients. 2021 , 11, 632352	1
586	Mechanical stress in pancreatic cancer: Signaling pathway adaptation activates cytoskeletal remodeling and enhances cell migration.	0
585	Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach. 2021 , 68, 103396	1
584	Biomarkers in Pancreatic Cancer as Analytic Targets for Nanomediated Imaging and Therapy. 2021 , 14,	1
583	Remodeling tumor microenvironment with nanomedicines. 2021 , 13, e1730	5
582	Immunotherapy in Pancreatic Adenocarcinoma: Beyond "Copy/Paste". 2021 , 27, 6287-6297	5
581	The Cellular and Biological Impact of Extracellular Vesicles in Pancreatic Cancer. 2021 , 13,	1
580	Conversion of cancer-associated fibroblasts from pro- to antitumor improves the sensitivity of pancreatic cancer to chemotherapeutics.	2
579	Collagenase-Expressing Targets Major Collagens in Pancreatic Cancer Leading to Reductions in Immunosuppressive Subsets and Tumor Growth. 2021 , 13,	2
578	Emerging Treatment Strategies in Pancreatic Cancer. 2021 , 50, 773-787	0
577	Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities. 2021 , 14,	3
576	The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. 2021 , 11, 688377	8
575	Identification of the prognostic value of elevated ANGPTL4 expression in gallbladder cancer-associated fibroblasts. 2021 , 10, 6035-6047	3
574	The dual role of complement in cancers, from destroying tumors to promoting tumor development. 2021 , 143, 155522	1
573	Distinct forms of the actin cross-linking protein F-actinin support macropinosome internalization and trafficking. 2021 , 32, 1393-1407	0
572	Increased expression of yes-associated protein/YAP and transcriptional coactivator with PDZ-binding motif/TAZ activates intestinal fibroblasts to promote intestinal obstruction in Crohn's disease. 2021 , 69, 103452	1
571	Natural killer cells and cytotoxic T lymphocytes are required to clear solid tumor in a patient-derived xenograft. 2021 , 6,	1

570	Apoptosis in the Pancreatic Cancer Tumor Microenvironment-The Double-Edged Sword of Cancer-Associated Fibroblasts. 2021 , 10,	2
569	Cancer-Associated Fibroblasts: Implications for Cancer Therapy. 2021 , 13,	6
568	Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. 2021 , 9, 655152	11
567	Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?. 2021 , 13,	14
566	Pulsed focused ultrasound can improve the anti-cancer effects of immune checkpoint inhibitors in murine pancreatic cancer. 2021 , 18, 20210266	4
565	Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models. 2021 , 174, 265-293	13
564	Targeting the Stroma in the Management of Pancreatic Cancer. 2021 , 11, 691185	2
563	Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance. 2021 , 13,	6
562	Physalin A, 13,14-Seco-16, 24-Cyclo-Steroid, Inhibits Stemness of Breast Cancer Cells by Regulation of Hedgehog Signaling Pathway and Yes-Associated Protein 1 (YAP1). 2021 , 22,	2
561	The Role of the Hedgehog Pathway in Chemoresistance of Gastrointestinal Cancers. 2021 , 10,	4
560	Gemcitabine-loaded microbubble system for ultrasound imaging and therapy. 2021 , 130, 385-394	5
559	Enzyme-Activated Prodrug-Based Smart Liposomes Specifically Enhance Tumor Hemoperfusion with Efficient Drug Delivery to Pancreatic Cancer Cells and Stellate Cells. 2100605	2
558	Modeling pancreatic cancer in mice for experimental therapeutics. 2021 , 1876, 188554	5
557	Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma. 2021 , 13,	4
556	T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGF β 1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer. 2021 , 20, 1926-1940	3
555	High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. 2021 , 9,	7
554	Emerging strategies against tumor-associated fibroblast for improved the penetration of nanoparticle into desmoplastic tumor. 2021 , 165, 75-83	1
553	Characterization of Tumor-immune Microenvironment by High-throughput Image Analysis of CD8 Immunohistochemistry Combined With Modified Masson's Trichrome. 2021 , 69, 611-615	0

552	Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. 2021 , 77, 144-166	7
551	YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation. 2021 , 74, 2605-2621	5
550	Engineering stromal heterogeneity in cancer. 2021 , 175, 113817	2
549	The Role of Smoothed-Dependent and -Independent Hedgehog Signaling Pathway in Tumorigenesis. 2021 , 9,	2
548	The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis. 2021 , 13,	9
547	The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions. 2021 , 40, 675-689	4
546	Prediction and identification of synergistic compound combinations against pancreatic cancer cells. 2021 , 24, 103080	1
545	The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options. 2021 , 13,	6
544	Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models. 2021 , 161, 996-1010.e1	3
543	Mesenchymal Lineage Heterogeneity Underlies Non-Redundant Functions of Pancreatic Cancer-Associated Fibroblasts. 2021 ,	12
542	Defining the Role of GLI/Hedgehog Signaling in Chemoresistance: Implications in Therapeutic Approaches. 2021 , 13,	2
541	Single EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer.	
540	Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. 2021 , 39, 1227-1244.e20	32
539	Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum. 2021 , 11, 699401	1
538	Clinical and therapeutic relevance of cancer-associated fibroblasts. 2021 , 18, 792-804	27
537	Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer. 2021 , 16, 6313-6328	2
536	New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth. 2021 ,	3
535	Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer. 2021 , 13,	0

534	The Cellular Origins of Cancer-Associated Fibroblasts and Their Opposing Contributions to Pancreatic Cancer Growth. 2021 , 9, 743907	9
533	Engineering strategies to capture the biological and biophysical tumor microenvironment in vitro. 2021 , 176, 113852	2
532	Metabolic reprogramming due to hypoxia in pancreatic cancer: Implications for tumor formation, immunity, and more. 2021 , 141, 111798	8
531	Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications. 2021 , 14, 141	10
530	Nrf2 expression in pancreatic stellate cells promotes progression of cancer. 2021 , 321, G378-G388	4
529	Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. 2021 , 7, eabh0363	5
528	Pathology and Molecular Characteristics of Pancreatic Cancer. 2021 , 30, 609-619	0
527	The transformation of cancer-associated fibroblasts: Current perspectives on the role of TGF- β CAF mediated tumor progression and therapeutic resistance. 2021 , 520, 222-232	5
526	Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. 2021 , 27, 2023-2037	54
525	The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives. 2020 , 10, 621937	15
524	Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer. 2021 , 28, 1400-1406	2
523	Tumor-Antagonizing Fibroblasts Secrete Prolargin as Tumor Suppressor in Hepatocellular Carcinoma.	
522	Nano-pharmacokinetics: interface of physics, chemistry and biology. 2021 , 29-54	
521	Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. 2021 , 20, 15330338211042139	1
520	High Frequency Ultrasound for the Visualization and Quantification of the Microcirculation. 293-312	0
519	Emerging Roles of Electrospun Nanofibers in Cancer Research. 2018 , 7, e1701024	75
518	Tumour-Promoting Stromal Myofibroblasts in Human Carcinomas. 2010 , 325-349	1
517	Cyclopamine and Its Derivatives for Cancer Therapeutics. 2011 , 187-212	3

516	The Hedgehog Signaling Pathway in Cancer Pathogenesis and Therapy. 2012 , 55-79	1
515	Integrating Omics Data for Quantitative and Systems Pharmacology in Translational Oncology. 2013 , 187-206	1
514	The Role of Non-cancerous Cells in Cancer: Pancreatic Ductal Adenocarcinoma as a Model to Understand the Impact of Tumor Microenvironment on Epithelial Carcinogenesis. 2013 , 309-333	1
513	Models for Evaluation of Targeted Therapies of Invasive and Metastatic Disease. 2011 , 447-495	1
512	Mechanisms Underlying Metastatic Pancreatic Cancer. 2019 , 1164, 3-10	5
511	Resistance to Anti-Cancer Therapeutics. 2019 , 65-82	1
510	Therapeutic Targeting of Stromal Components. 2020 , 157-168	1
509	The role of inflammation in pancreatic cancer. 2014 , 816, 129-51	59
508	Cancer Stem Cells and Chemoresistance: Strategies to Overcome Therapeutic Resistance. 2015 , 477-518	2
507	Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance. 2017 , 45-64	1
506	Pancreatic Cancer Genomics. 2013 , 219-253	1
505	Mouse Models of Pancreatic Cancer. 2013 , 57-91	1
504	Hedgehog signaling promotes angiogenesis directly and indirectly in pancreatic cancer. 2020 , 23, 479-492	24
503	Hedgehog signaling and pancreatic tumor development. 2011 , 110, 1-17	34
502	Hypoxia and pancreatic ductal adenocarcinoma. 2020 , 484, 9-15	19
501	Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer. 2020 , 91-92, 8-18	17
500	Pancreatic cancer heterogeneity and response to Mek inhibition. 2017 , 36, 5639-5647	14
499	Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. 2020 , 40,	9

498	Stromal Amyloid Drives Neutrophil extracellular trap formation to augment tumour growth.	2
497	Inflammation promotes tumor aggression by stimulating stromal cell-dependent collagen crosslinking and stromal stiffening.	4
496	T2 heterogeneity provides a sensitive measure of early tumor response to radiotherapy.	1
495	NK cells and CTLs are required to clear solid tumor in a novel model of patient-derived-xenograft.	2
494	PYCR1-dependent proline synthesis in cancer-associated fibroblasts is required for the deposition of pro-tumorigenic extracellular matrix.	3
493	Hyaluronic Acid Fuels Pancreatic Cancer Growth.	4
492	Transcriptional deconvolution reveals consistent functional subtypes of pancreatic cancer epithelium and stroma.	1
491	Netrin G1 promotes pancreatic tumorigenesis through cancer associated fibroblast driven nutritional support and immunosuppression.	7
490	Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer.	2
489	Quantification of microenvironmental metabolites in murine cancer models reveals determinants of tumor nutrient availability.	1
488	Myc instructs and maintains pancreatic adenocarcinoma phenotype.	1
487	Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors. 2017 , 22, 1-9	10
486	Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. 2020 , 12,	77
485	Cancer-Induced Muscle Wasting Requires p38MAPK Activation of p300. 2021 , 81, 885-897	6
484	eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer. 2019 , 4,	16
483	BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo. 2017 , 2, e88032	34
482	Misactivation of Hedgehog signaling causes inherited and sporadic cancers. 2019 , 129, 465-475	38
481	Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. 2020 , 130, 451-465	57

480	Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. 2020 , 130, 4704-4709	44
479	Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. 2011 , 121, 4106-17	191
478	Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. 2012 , 122, 639-53	474
477	Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. 2012 , 122, 4025-36	33
476	Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. 2012 , 122, 4118-29	139
475	New cast for a new era: preclinical cancer drug development revisited. 2013 , 123, 3639-45	63
474	Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF- β to promote proliferation. 2014 , 124, 338-52	51
473	Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. 2016 , 126, 4140-4156	127
472	Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance. 2016 , 126, 4460-4468	30
471	The fibrotic tumor stroma. 2018 , 128, 16-25	116
470	Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier. 2017 , 127, 1622-1624	7
469	Back to the drawing board: Re-thinking the role of GLI1 in pancreatic carcinogenesis. 2014 , 3, 238	1
468	The reg4 gene, amplified in the early stages of pancreatic cancer development, is a promising therapeutic target. 2009 , 4, e7495	18
467	Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells. 2010 , 5, e8824	65
466	Increased fibrosis and interstitial fluid pressure in two different types of syngeneic murine carcinoma grown in integrin β -subunit deficient mice. 2012 , 7, e34082	11
465	Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer. 2012 , 7, e40420	21
464	Evaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancer. 2012 , 7, e40611	12
463	Involvement of host stroma cells and tissue fibrosis in pancreatic tumor development in transgenic mice. 2012 , 7, e41833	24

462	K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. 2012 , 7, e44146	53
461	Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression. 2013 , 8, e64566	43
460	Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. 2013 , 8, e66371	31
459	Hypoxic tumor environments exhibit disrupted collagen I fibers and low macromolecular transport. 2013 , 8, e81869	14
458	Down-regulation of Gli transcription factor leads to the inhibition of migration and invasion of ovarian cancer cells via integrin α -mediated FAK signaling. 2014 , 9, e88386	55
457	Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models. 2015 , 10, e0123761	21
456	TGF- β Blockade Reduces Mortality and Metabolic Changes in a Validated Murine Model of Pancreatic Cancer Cachexia. 2015 , 10, e0132786	47
455	Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. 2015 , 10, e0139049	23
454	Epithelial to Stromal Re-Distribution of Primary Cilia during Pancreatic Carcinogenesis. 2016 , 11, e0164231	6
453	Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer. 2017 , 12, e0183871	42
452	FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. 2020 , 12, e12010	24
451	Chemotherapy and Targeted Therapy with Management of Related Complications in Pancreatic Cancer. 2015 , 20, 5-13	1
450	Role of the tumor microenvironment in digestive neuroendocrine tumors. 2018 , 25, R519-R544	8
449	Tumor-stromal interactions in pancreatic cancer. 2013 , 18, 135-51	52
448	Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. 2018 , 9, 78-86	41
447	A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. 2016 , 7, 53783-53796	21
446	Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin. 2016 , 7, 56395-56407	1
445	Novel regulatory role of neuropilin-1 in endothelial-to-mesenchymal transition and fibrosis in pancreatic ductal adenocarcinoma. 2016 , 7, 69489-69506	27

444	Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. 2016 , 7, 61469-61484	49
443	Quantification of nucleic acid quality in postmortem tissues from a cancer research autopsy program. 2016 , 7, 66906-66921	13
442	Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. 2016 , 7, 78396-78411	36
441	Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential. 2016 , 7, 71635-71650	45
440	Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. 2016 , 7, 72819-72832	11
439	The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. 2016 , 7, 75081-75093	10
438	Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. 2017 , 8, 4399-4409	11
437	Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection. 2016 , 7, 76197-76213	100
436	Loss of MTSS1 results in increased metastatic potential in pancreatic cancer. 2017 , 8, 16473-16487	12
435	32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. 2017 , 8, 20729-20740	21
434	Extra-pancreatic invasion induces lipolytic and fibrotic changes in the adipose microenvironment, with released fatty acids enhancing the invasiveness of pancreatic cancer cells. 2017 , 8, 18280-18295	38
433	The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. 2017 , 8, 21609-21625	62
432	Lymph node metastasis and the physicochemical micro-environment of pancreatic ductal adenocarcinoma xenografts. 2017 , 8, 48060-48074	8
431	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. 2010 , 1, 515-529	12
430	Drug discovery approaches to target Wnt signaling in cancer stem cells. 2010 , 1, 563-577	138
429	Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer. 2017 , 8, 76722-76739	37
428	Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. 2017 , 8, 102721-102738	29
427	Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer. 2017 , 8, 106405-106414	11

426	A dual mechanism of activation of the Sonic Hedgehog pathway in anaplastic thyroid cancer: crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma. 2018 , 9, 4496-4510	13
425	Stroma-derived extracellular vesicles deliver tumor-suppressive miRNAs to pancreatic cancer cells. 2018 , 9, 5764-5777	19
424	PKC δ and YAP1 are crucial in promoting pancreatic tumorigenesis. 2018 , 9, 32736-32750	9
423	Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma. 2018 , 9, 30837-30846	11
422	Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer. 2018 , 9, 37439-37457	57
421	Low dose photodynamic therapy harmonizes with radiation therapy to induce beneficial effects on pancreatic heterocellular spheroids. 2019 , 10, 2625-2643	22
420	Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. 2015 , 6, 9999-10015	52
419	Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. 2015 , 6, 15524-39	33
418	Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications. 2015 , 6, 39140-50	17
417	Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. 2015 , 6, 15788-801	39
416	Targeting autophagy addiction in cancer. 2011 , 2, 1302-6	131
415	Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. 2015 , 6, 18545-57	50
414	Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells. 2015 , 6, 27312-31	40
413	Hypoxia-induced endoplasmic reticulum stress characterizes a necrotic phenotype of pancreatic cancer. 2015 , 6, 32154-60	25
412	Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes. 2016 , 7, 323-41	28
411	Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?. 2012 , 3, 1335-47	12
410	The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma. 2016 , 7, 4183-94	65
409	Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells. 2016 , 7, 9046-59	24

408	CEST theranostics: label-free MR imaging of anticancer drugs. 2016 , 7, 6369-78	36
407	MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor. 2016 , 7, 16396-408	60
406	Neuraminidase-1: a novel therapeutic target in multistage tumorigenesis. 2016 , 7, 40860-40881	45
405	Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution. 2016 , 7, 32100-12	40
404	PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction. 2016 , 7, 28218-34	17
403	Targeting tumor-associated macrophages to combat pancreatic cancer. 2016 , 7, 50735-50754	63
402	Pancreatic cancer from bench to bedside: molecular pathways and treatment options. 2016 , 4, 165	16
401	Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer.	1
400	Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment. 2012 , 18, 2404-15	54
399	Mucin-based targeted pancreatic cancer therapy. 2012 , 18, 2472-81	71
398	Recent Advances in Strategies for Extracellular Matrix Degradation and Synthesis Inhibition for Improved Therapy of Solid Tumors. 2020 , 26, 5456-5467	3
397	Disruption of stromal hedgehog signaling initiates RNF5-mediated proteasomal degradation of PTEN and accelerates pancreatic tumor growth. 2018 , 1, e201800190	20
396	Development of CAST therapy based on the EPR effect: lesson from clinical trials.. 2018 , 33, 139-149	2
395	The Impact of Hedgehog Signaling Pathway on DNA Repair Mechanisms in Human Cancer. 2015 , 7, 1333-48	24
394	Non-Canonical Hh Signaling in Cancer-Current Understanding and Future Directions. 2015 , 7, 1684-98	42
393	Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge. 2015 , 7, 1785-805	18
392	Direct Interaction between Carcinoma Cells and Cancer Associated Fibroblasts for the Regulation of Cancer Invasion. 2015 , 7, 2054-62	78
391	Advances in Smoothed-muscle-targeting therapies for pancreatic cancer: implication for drug discovery from herbal medicines. 2012 , 10, 256-63	5

390	Functional magnetic resonance imaging in an animal model of pancreatic cancer. 2010 , 16, 3292-8	4
389	Pancreatic cancer: translational research aspects and clinical implications. 2012 , 18, 1417-24	19
388	Role of taxanes in pancreatic cancer. 2012 , 18, 4457-65	7
387	Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?. 2012 , 18, 4944-58	57
386	Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma. 2014 , 20, 4128-40	28
385	Personalising pancreas cancer treatment: When tissue is the issue. 2014 , 20, 7849-63	18
384	Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation. 2014 , 20, 8471-81	33
383	Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts. 2014 , 20, 10769-77	17
382	Novel therapeutic targets for pancreatic cancer. 2014 , 20, 10825-44	60
381	Pancreatic cancer and its stroma: a conspiracy theory. 2014 , 20, 11216-29	90
380	Pathology of pancreatic ductal adenocarcinoma: facts, challenges and future developments. 2014 , 20, 13833-41	50
379	Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. 2015 , 21, 4788-801	48
378	New targeted therapies in pancreatic cancer. 2015 , 21, 6127-45	38
377	Perspectives in the treatment of pancreatic adenocarcinoma. 2015 , 21, 9297-316	92
376	Cancer immunotherapy for pancreatic cancer utilizing Hgal epitope/natural anti-Gal antibody reaction. 2015 , 21, 11396-410	10
375	Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. 2016 , 22, 776-89	37
374	FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. 2016 , 22, 6987-7005	52
373	Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. 2016 , 22, 2678-700	143

372	ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?. 2018 , 24, 3222-3238	45
371	p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. 2018 , 24, 3709-3723	21
370	Typing of pancreatic cancer-associated fibroblasts identifies different subpopulations. 2018 , 24, 4663-4678	14
369	Translational pancreatic cancer research: A comparative study on patient-derived xenograft models. 2018 , 24, 794-809	7
368	Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. 2015 , 27, 376-91	11
367	Preoperative therapies for resectable and borderline resectable pancreatic cancer. 2011 , 2, 136-42	22
366	Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies. 2013 , 2, 130-144	23
365	Molecular characteristics of pancreatic ductal adenocarcinoma. 2011 , 2011, 620601	33
364	Preclinical screening methods in cancer. 2016 , 48, 481-486	30
363	Pancreatic cancer - lessons from the past decade. 2015 , 36, 73-6	3
362	Shattering the castle walls: Anti-stromal therapy for pancreatic cancer. 2018 , 10, 202-210	16
361	Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. 2020 , 12, 173-181	50
360	Molecular predictors of gemcitabine response in pancreatic cancer. 2011 , 3, 153-64	54
359	Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?. 2015 , 7, 172-7	6
358	Genomic alterations in pancreatic cancer and their relevance to therapy. 2015 , 7, 250-8	21
357	State of the art biological therapies in pancreatic cancer. 2016 , 8, 55-66	17
356	Molecular therapeutics in pancreas cancer. 2016 , 8, 366-79	16
355	Targeting inflammation in pancreatic cancer: Clinical translation. 2016 , 8, 380-8	15

354	Tumor initiating cells in pancreatic cancer: A critical view. 2009 , 1, 8-10	10
353	What are the current and potential future roles for endoscopic ultrasound in the treatment of pancreatic cancer?. 2016 , 8, 319-29	7
352	Differential role of Hedgehog signaling in human pancreatic (patho-) physiology: An up to date review. 2016 , 7, 199-210	15
351	Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator. 2020 , 14, 521-528	3
350	Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations. 2011 , 2, 195-202	21
349	Impact of tumour associated macrophages in pancreatic cancer. 2013 , 46, 131-8	59
348	Epigenetic regulation of mammalian Hedgehog signaling to the stroma determines the molecular subtype of bladder cancer. 2019 , 8,	14
347	Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. 2019 , 8,	178
346	Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. 2019 , 8,	59
345	Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. 2020 , 9,	31
344	Cancer systems immunology. 2020 , 9,	3
343	Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. 2020 , 9,	26
342	Deciphering the role of hedgehog signaling in pancreatic cancer. 2016 , 30, 353-360	34
341	Silencing GS Homeobox 2 Alleviates Gemcitabine Resistance in Pancreatic Cancer Cells by Activating SHH/GLI1 Signaling Pathway. 2021 , 1	2
340	Pre-clinical Models of Metastasis in Pancreatic Cancer. 2021 , 9, 748631	2
339	The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies. 2021 , 11, 751311	13
338	Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature. 2021 , 11,	0
337	Marker-free lineage tracing reveals an environment-instructed clonogenic hierarchy in pancreatic cancer. 2021 , 37, 109852	1

- 336 Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. **2021**, 22, 5
- 335 The Role of Cancer-Associated Fibroblast as a Dynamic Player in Mediating Cancer Stemness in the Tumor Microenvironment. **2021**, 9, 727640 2
- 334 Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation. **2021**, 11, 738534 0
- 333 Heterogeneity in Pancreatic Cancer Fibroblasts-TGF β s a Master Regulator?. **2021**, 13, 3
- 332 Using Organotypic Tissue Slices to Investigate the Microenvironment of Pancreatic Cancer: Pharmacotyping and Beyond. **2021**, 13, 1
- 331 Genetically-engineered mouse pancreatic cancer models. **2010**, 25, 28-34
- 330 Mosaic Cancer Mouse Models and Functional Oncogenomics in Hepatocellular Carcinoma. **2010**, 189-196 1
- 329 The Medical butterfly effect; how a discovery in a rare disease can have large effects elsewhere.. **2010**,
- 328 Genetically Engineered Mouse Models of Pancreatic Ductal Adenocarcinoma. **2011**, 377-395
- 327 Mouse phenotyping with MRI. **2011**, 771, 595-631 1
- 326 Cancer Stem Cells in Pancreatic Cancer. **2011**, 79-97
- 325 Global Molecular and Cellular Measurement Technologies. **2011**, 97-126
- 324 Obesity and Pancreatic Cancer. **2012**, 93-109
- 323 Abstract IA5: Developing therapeutics in mice with ductal pancreatic cancer. **2012**, 18, IA5-IA5
- 322 Pancreatic Cancer (Exocrine). **2013**, 119-131
- 321 Molecular Mechanisms of Tumor Metastasis. **2013**, 213-228
- 320 Neue Therapieprinzipien beim Pankreaskarzinom: Zweitlinientherapie/Second Line, Targeted Therapies. **2013**, 394-400
- 319 Anatomy, Physiology, and Embryology of the Pancreas. **2013**, 1110-1122

- 318 Molecular Targeted Therapies in Pancreatic Cancer. **2013**, 117-144
- 317 Innovative Technologies in the Molecular Characterization of Pancreatic Cancer. **2013**, 209-228
- 316 Mouse Models of Pancreatic Ductal Adenocarcinoma. **2013**, 145-170 1
- 315 Polymer-Based Drug Delivery Systems for Solid Tumor Treatment. **2014**, 511-534 0
- 314 Stem Cells in Pancreatic Cancer. **2014**, 167-189
- 313 Hedgehog as a New Paradigm in Cancer Treatment. **2014**, 67-84
- 312 Carcinoma of the Pancreas. **2014**, 1397-1415.e7 1
- 311 Gastrointestinal System, Pancreatobiliary Tract and Liver. **2015**, 99-131
- 310 Liver Metastases from Pancreatic Adenocarcinoma. **2015**, 95-109
- 309 Targeted Therapies for Pancreatic Cancer. **2015**, 127-135
- 308 Models and Mechanisms of High-Fat Diet (HFD) Promotion of Pancreatic Cancer. **2015**, 197-215
- 307 Pancreatic Cancer Stem Cells. **2015**, 247-271
- 306 Lung Cancer Stem Cells. **2015**, 199-225
- 305 Targeting Cancer Stem Cells and the Tumor Microenvironment. **2015**, 445-476
- 304 Self-Renewal Pathways in Mammary Stem Cells and Carcinogenesis. **2015**, 155-174
- 303 Emerging Therapeutic Targets in Pancreatic Adenocarcinoma. **2016**, 1-29
- 302 Strategies to Target Pancreatic Cancer. **2016**, 1-20
- 301 Pancreatic Cancer Stem Cells. **2016**, 1-20

300 Back to the drawing board: Re-thinking the role of GLI1 in pancreatic carcinogenesis. **2014**, 3, 238

299 Novel Therapeutic Modalities for Metastatic Pancreatic Cancer. **2016**, 21, 185-190

1

298 Chronic Pancreatitis and Pancreatic Cancer. **2017**, 179-190

297 Development of Novel Therapeutic Response Biomarkers. **2017**, 1-32

296 Targeting Cancer Stem Cells-A Renewed Therapeutic Paradigm. **2017**, 13, 45-55

1

295 Multiparameter Modalities for the Study of Patients in the Setting of Individualized Medicine. **2017**, 1-27

294 Mouse Models of Pancreatic Exocrine Cancer. **2017**, 1-30

293 Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis. **2017**, 1-14

292 IGF-I/IGF-IR signalling. **2017**, 35, 83

291 Stromal Inflammation in Pancreatic Cancer: Mechanisms and Translational Applications. **2017**, 1-28

290 Molecularly Targeted Therapies in Pancreatic Cancer. **2018**, 219-233

289 Targeting the Tumor Microenvironment. **2018**, 235-256

288 Combining optical imaging of cleared tissue with mathematical modelling to predict drug delivery and therapeutic response.

287 Precision Medicine Based on Next Generation Sequencing and Master Controllers. **2018**, 1-35

286 HNF1A is a Novel Oncogene and Central Regulator of Pancreatic Cancer Stem Cells.

285 HDGF supports anti-apoptosis and pro-fibrosis in pancreatic stellate cells of pancreatic cancer.

284 SuperCT: A supervised-learning-framework to enhance the characterization of single-cell transcriptomic profiles.

0

283 Principle of CAST Strategy. **2019**, 255-267

0

282 Treatment of Advanced Pancreatic Carcinoma. **2019**, 255-268

281 Pancreatic Cancer. **2019**, 421-470

280 Targeting tumor-intrinsic metabolic node sensitizes pancreatic cancer to anti-PD1 therapy.

279 CAST Therapy. **2019**, 269-288

278 Stromal Barriers Within the Tumor Microenvironment and Obstacles to Nanomedicine. **2019**, 57-89 0

277 Novel Targeted Treatment Approaches in Pancreatic Cancer. **2019**, 479-491

276 Pancreatic Stellate Cells Secrete Deoxycytidine Conferring Resistance to Gemcitabine in PDAC. 1

275 A deeper understanding of the tumor microenvironment in pancreatic cancer: the key to developing effective immunotherapies. **2019**, 7, 162 1

274 Stromal Hedgehog pathway activation by IHH suppresses lung adenocarcinoma growth and metastasis by limiting reactive oxygen species.

273 Severe disseminated intravascular coagulation and tumor lysis syndrome in a patient with pancreatic adenocarcinoma treated with gemcitabine and nab-paclitaxel: a case report. **2019**, 34, 232-238

272 Cancer-associated fibroblasts as a potential target in oncology therapy. **2019**, 73, 536-549 0

271 Induction of pancreatic tumor-selective ferroptosis through modulation of cystine import

270 Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation.

269 Stories of drug repurposing for pancreatic cancer treatmentPast, present, and future. **2020**, 231-272 1

268 Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice.

267 Deeper insights into long-term survival heterogeneity of Pancreatic Ductal Adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses. 0

266 Targeting desmoplasia in pancreatic cancer as an essential first step to effective therapy. **2020**, 11, 3486-3488 2

265 Harnessing the predictive power of preclinical models for oncology drug development. **2021**, 3

264	Role of Physicochemical Factors on the Efficacy and Safety of Lipid-based Nanosystems as potential drug carriers.	0
263	Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy. 2021 , e2101428	10
262	Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. 2021 , 118,	1
261	Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions. 2020 , 3,	2
260	SKA3 overexpression predicts poor outcomes in skin cutaneous melanoma patients. 2021 , 15, 101253	0
259	Subtypes of Pancreatic Adenocarcinoma. 2020 , 3-16	
258	Circulating Tumor Cells as Biomarkers in Pancreatic Cancer. 2020 , 129-143	
257	CHAPTER 10. Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities. 2020 , 259-306	
256	GOT1 Inhibition Primes Pancreatic Cancer for Ferroptosis through the Autophagic Release of Labile Iron.	2
255	Dissecting cell type-specific metabolism in pancreatic ductal adenocarcinoma.	
254	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. 2021 , 221554211056853	1
253	Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance. 2021 , 13,	6
252	Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?. 2020 , 12, e10909	
251	Cancer cells are sensitive to wild-type IDH1 inhibition under nutrient limitation.	
250	Emerging therapies in pancreas cancer. 2011 , 2, 93-103	9
249	Emerging tactical strategies for fighting the war on cancer based on the genetic landscape. 2011 , 3, 251-8	1
248	Cancer associated fibroblasts: the dark side of the coin. 2011 , 1, 482-97	257
247	Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. 2011 , 1, 787-805	22

246	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. 2010 , 1, 515-29	7
245	Hedgehog signalling pathway: carcinogenesis and targeted therapy. 2013 , 6, 36-43	3
244	Arterial resection for pancreatic cancer: a modern surgeon should change its behavior according to the new therapeutic options. 2014 , 35, 5-14	2
243	Antiproliferative effects of curcumin analog L49H37 in pancreatic stellate cells: a comparative study. 2015 , 28, 391-398	14
242	Radiation promotes epithelial-to-mesenchymal transition and invasion of pancreatic cancer cell by activating carcinoma-associated fibroblasts. 2016 , 6, 2192-2206	33
241	A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma. 2017 , 7, 657-672	3
240	Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a mouse model. 2019 , 9, 1757-1765	6
239	FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. 2019 , 9, 2650-2664	10
238	Overexpression of hydroxyproline via EGLN/HIF1A is associated with distant metastasis in pancreatic cancer. 2020 , 10, 2570-2581	2
237	From Screening to Treatment of Pancreatic Cancer: A Comprehensive Review. 2021 , 22, 70-79	
236	Magneto-mechanical destruction of cancer-associated fibroblasts using ultra-small iron oxide nanoparticles and low frequency rotating magnetic fields.	3
235	The Immune Landscape in a Long-Term Survival Pancreatic Adenocarcinoma Patient Highly Responsive to a Multidisciplinary Approach With Chemo-Radio Treatments. 2021 , 50, e76-e78	
234	Targeting Tumor-Stromal Interactions in Pancreatic Cancer: Impact of Collagens and Mechanical Traits.. 2021 , 9, 787485	3
233	Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma. 2021 ,	3
232	Anticancer Effect of Heparin-Taurocholate Conjugate on Orthotopically Induced Exocrine and Endocrine Pancreatic Cancer. 2021 , 13,	
231	Tumor Architecture and Targeted Delivery. 2022 , 237-247	
230	Uncovering key targets of success for immunotherapy in pancreatic cancer. 2021 ,	1
229	Tumour Microenvironment Stress Promotes the Development of Drug Resistance. 2021 , 10,	4

228	Peptide dendrimers as potentiators of conventional chemotherapy in the treatment of pancreatic cancer in a mouse model. 2021 , 170, 121-121	3
227	Cell Lineage Infidelity in PDAC Progression and Therapy Resistance.. 2021 , 9, 795251	1
226	Cancer Cell Mechanobiology: A New Frontier for Cancer Research. 2021 ,	1
225	Potential of PAR-4 as a Therapeutic Target for Pancreatic Cancer. 2021 , 161-170	
224	Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging.. 2022 ,	0
223	Medikamentöse Tumorthherapie des Pankreaskarzinoms. 2015 , 1-9	
222	TGF β Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGF β Induced EMT in PDAC.. 2021 , 13,	2
221	Jerveratrum-Type Steroidal Alkaloids Inhibit β 1,6-Glucan Biosynthesis in Fungal Cell Walls.. 2022 , e0087321	2
220	Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma.. 2022 , 14,	1
219	PEGPH20, a PEGylated Human Hyaluronidase, Induces Radiosensitization by Reoxygenation In Pancreatic Cancer Xenografts. A Molecular Imaging Study.	
218	HIF-1 and NRF2; Key Molecules for Malignant Phenotypes of Pancreatic Cancer.. 2022 , 14,	1
217	Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma.. 2022 ,	1
216	Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment.. 2022 ,	1
215	Oxysterol-Binding Protein 2 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Epithelial-Mesenchymal Transition.. 2021 , 11, 762233	
214	Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion.. 2022 , 38, 110227	5
213	Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer.. 2022 , 1-14	2
212	Contrast-enhanced ultrasound for evaluating response to pulsed-wave high-intensity focused ultrasound therapy in advanced pancreatic cancer.. 2022 ,	1
211	Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer.. 2022 , 14,	1

210	Leveraging cellular mechano-responsiveness for cancer therapy.. 2021,	2
209	Targeting hedgehog signaling in pancreatic ductal adenocarcinoma.. 2022, 108107	4
208	2-Cl-IB-MECA regulates the proliferative and drug resistance pathways, and facilitates chemosensitivity in pancreatic and liver cancer cell lines.. 2022, 49,	
207	Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma.. 2021,	2
206	Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells.. 2022, 13, 114	0
205	Matrix stiffening and acquired resistance to chemotherapy: concepts and clinical significance.. 2022	1
204	Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth.. 2022, 3, 119-136	2
203	Local Release of TGF- β Inhibitor Modulates Tumor-Associated Neutrophils and Enhances Pancreatic Cancer Response to Combined Irreversible Electroporation and Immunotherapy.. 2022, e2105240	3
202	Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia.. 2021, 13,	3
201	Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches. 2021, 13,	5
200	Hyaluronic acid fuels pancreatic cancer cell growth.. 2021, 10,	4
199	Recent advances of SIRT1 and implications in chemotherapeutics resistance in cancer. 2021, 11, 5233-5248	1
198	Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance. 2022,	0
197	Patient-Derived In Vitro and In Vivo Models of Cancer.. 2022, 1361, 215-233	0
196	PTEN in cancer associated fibroblasts.. 2022, 154, 203-226	0
195	Long Noncoding RNA Acting as Therapeutic Target for Oxidative Stress-Induced Pancreatic Cancer. 2022, 1-33	
194	Origin, activation and heterogeneity of fibroblasts associated with pancreas and breast cancers.. 2022, 154, 169-201	
193	Prognostic Relevance of Transforming Growth Factor- β Receptor Expression and Signaling in Glioblastoma, Isocitrate Dehydrogenase-Wildtype.. 2022,	0

192	The Role of Mesenchymal Stem Cells in the Induction of Cancer-Stem Cell Phenotype.. 2022 , 12, 817971	2
191	Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets.. 2022 , 14,	5
190	The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation.. 2022 , 10,	0
189	Gasdermin E mediates resistance of pancreatic adenocarcinoma to enzymatic digestion through a YBX1-mucin pathway.. 2022 , 24, 364-372	0
188	The case for cancer-associated fibroblasts: essential elements in cancer drug discovery?.	0
187	Bcl-xL enforces a slow-cycling state necessary for survival in the nutrient-deprived microenvironment of pancreatic cancer.. 2022 ,	0
186	Photodynamic stromal depletion (PSD) improves tumor response to PDT and enhances nanoparticle drug delivery in 3D co-culture models of pancreatic ductal adenocarcinoma (PDAC). 2022 ,	
185	Uncovering Pharmacological Opportunities for Cancer Stem Cells-A Systems Biology View.. 2022 , 10, 752326	1
184	Overcoming Vascular Barriers to Improve the Theranostic Outcomes of Nanomedicines.. 2022 , e2103148	0
183	Analysis of capecitabine metabolites in conjunction with digital autoradiography in a murine model of pancreatic cancer suggests extensive drug penetration through the tumor.. 2022 , 10, e00898	
182	Potential Therapeutic Applications of N-Cadherin Antagonists and Agonists.. 2022 , 10, 866200	2
181	Oncogene-induced matrix reorganization controls CD8+ T cell function in the tumor microenvironment.	
180	Exploiting LRRC15 as a novel therapeutic target in cancer.. 2022 ,	1
179	HIF-2 in cancer associated fibroblasts polarizes macrophages and creates an immunosuppressive tumor microenvironment in pancreatic cancer.. 2022 ,	0
178	High throughput screen in a co-culture model to uncover therapeutic strategies to potentiate the cancer-inhibiting properties of the tumor-stroma in pancreatic cancer.	
177	Cancer therapy that targets the Hedgehog signaling pathway considering the cancer microenvironment (Review).. 2022 , 47,	1
176	Distinct Response of Circulating microRNAs to the Treatment of Pancreatic Cancer Xenografts with FGFR and ALK Kinase Inhibitors.. 2022 , 14,	1
175	Targeting CAFs to overcome anticancer therapeutic resistance.. 2022 ,	4

174	Pancreatic Stellate Cells and Metabolic Alteration: Physiology and Pathophysiology.. 2022 , 13, 865105	1
173	B-Lymphocytes in the Pathophysiology of Pancreatic Adenocarcinoma.. 2022 , 13, 867902	0
172	Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair.. 2022 ,	1
171	The biology of pancreatic cancer morphology. 2021 ,	1
170	Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cancer.. 2022 ,	0
169	Endoscopic ultrasound guided interventions in the management of pancreatic cancer. 2022 , 14, 191-204	
168	EMT alterations in the solute carrier landscape uncover SLC22A10/A15 imposed vulnerabilities in pancreatic cancer.. 2022 , 25, 104193	1
167	GANT61 elevates chemosensitivity to cisplatin through regulating the Hedgehog, AMPK and cAMP pathways in ovarian cancer.. 2022 , 14, 479-500	0
166	Strategies to improve the EPR effect: A mechanistic perspective and clinical translation.. 2022 , 345, 512-536	2
165	Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs. 2021 , 1	0
164	Macrophage and Neutrophil Interactions in the Pancreatic Tumor Microenvironment Drive the Pathogenesis of Pancreatic Cancer.. 2021 , 14,	1
163	A Noncanonical Hedgehog Signaling Exerts a Tumor-Promoting Effect on Pancreatic Cancer Cells Via Induction of Osteopontin Expression.. 2021 ,	2
162	PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?. 2021 , 9, 787249	1
161	Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). 2021 , 59,	2
160	Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting.. 2021 , 22,	4
159	Emerging Trends and Research Foci in Tumor Microenvironment of Pancreatic Cancer: A Bibliometric and Visualized Study.. 2022 , 12, 810774	0
158	Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics.. 2022 ,	6
157	Tumor fibrosis correlates with the survival of patients with pancreatic adenocarcinoma and is predictable using clinoradiological features.. 2022 , 1	1

156	Presentation_1.PDF. 2018 ,	
155	Image_1.tiff. 2018 ,	
154	Single-EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer.. 2022 , 8, eabm3453	3
153	Modeling Pancreatic Cancer with Patient-Derived Organoids Integrating Cancer-Associated Fibroblasts.. 2022 , 14,	2
152	Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer.. 2022 , 119, e2200143119	
151	The expression and prognostic value of toll-like receptors (TLRs) in pancreatic cancer patients treated with neoadjuvant therapy.. 2022 , 17, e0267792	0
150	Increased glucose availability sensitizes pancreatic cancer to chemotherapy.	1
149	Current Pathology Model of Pancreatic Cancer.. 2022 , 14,	1
148	Ym1+ macrophages orchestrate fibrosis, lesion growth, and progression during development of murine pancreatic cancer. 2022 , 25, 104327	0
147	Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer.	0
146	Cancer-associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets.. 2022 ,	4
145	Synergistic autophagy blockade and VDR signaling activation enhance stellate cell reprogramming in pancreatic ductal adenocarcinoma.. 2022 , 539, 215718	0
144	PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study.. 2022 , 30, 100793	0
143	Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells. 2022 , 23, 5536	1
142	Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer.. 2022 ,	0
141	Engineered extracellular matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids.	0
140	Mass transport model of radiation response: calibration and application to chemoradiation for pancreatic cancer. 2022 ,	
139	The Role of Cancer-Associated Fibroblasts in Ovarian Cancer. 2022 , 14, 2637	4

138 Pathology of Pancreatic Cancer. **2022**, 91-97

137 Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. **2022**, 14, 2486 3

136 Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer. **2022**, 15, 1

135 Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. **2022**, 187, 114357 0

134 Extracellular Matrix in Tumor Angiogenesis.

133 Photodynamic Stromal Depletion (PSD) Enhances Therapeutic Nanoparticle Delivery in 3D Pancreatic Ductal Adenocarcinoma (PDAC) Tumor Models. 1

132 Nanomedicine Penetration to Tumor: Challenges, and Advanced Strategies to Tackle This Issue. **2022**, 14, 2904 2

131 Adaptive stimulation of macropinocytosis overcomes aspartate limitation in cancer cells under hypoxia. 4

130 Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment (Review). **2022**, 61, 2

129 EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance.

128 Remediating Desmoplasia with EGFR-Targeted Photoactivable Multi-Inhibitor Liposomes Doubles Overall Survival in Pancreatic Cancer. 2104594 1

127 Editorial: The Microenvironment in Pancreatic Cancer and Therapeutic Strategies Targeting Microenvironment. 12,

126 Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions. **2022**, 240, 108231 1

125 Pancreatic tumors activate arginine biosynthesis to adapt to myeloid-driven amino acid stress. 0

124 The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis. 2

123 Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care. **2022**, 14, 3239 2

122 Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors. 2

121 Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses. **2022**, 12, 0

120	Context Matters: Response Heterogeneity to Collagen-Targeting Approaches in Desmoplastic Cancers. 2022 , 14, 3132	1
119	Immunomodulatory antitumor effect of interferon-beta combined with gemcitabine in pancreatic cancer. 2022 , 61,	1
118	Personalized tumor vaccine for pancreatic cancer.	0
117	Facts and Hopes in Immunotherapy of Pancreatic Cancer. OF1-OF12	3
116	Tumor microenvironmental 15-PGDH depletion promotes fibrotic tumor formation and angiogenesis in pancreatic cancer.	0
115	Multimodal Therapies Against Pancreatic Ductal Adenocarcinoma: A Review on Synergistic Approaches Towards Ultimate Nanomedicine Treatments. 2200079	2
114	Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1). 12,	0
113	Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy. 2022 , 28, 3297-3313	0
112	The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities. 2022 , 14, 3293	2
111	ADAR1-Mediated RNA Editing and Its Role in Cancer. 10,	0
110	Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. 2022 , 18, e1010315	0
109	Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer. 2201931	
108	The Extracellular Matrix: A Key Accomplice of Cancer Stem Cell Migration, Metastasis Formation, and Drug Resistance in PDAC. 2022 , 14, 3998	2
107	Mouse Tumor Homografts Recapitulate Human Molecular Pathogenesis. 2022 , 75-106	
106	Metabolic profiling of induced acute pancreatitis and pancreatic cancer progression in a mutant Kras mouse model. 9,	1
105	Canonical Hedgehog Pathway and Noncanonical GLI Transcription Factor Activation in Cancer. 2022 , 11, 2523	1
104	Cancer-associated Fibroblasts: Origin, Function, Imaging, and Therapeutic Targeting. 2022 , 114504	0
103	Heterogeneity of Cancer-Associated Fibroblasts and the Tumor Immune Microenvironment in Pancreatic Cancer. 2022 , 14, 3994	1

102	Patient-Derived Pancreatic Cancer Cells Induce C2C12 Myotube Atrophy by Releasing Hsp70 and Hsp90. 2022 , 11, 2756	2
101	Modulating cancer-stroma crosstalk by a nanoparticle-based photodynamic method to pave the way for subsequent therapies. 2022 , 289, 121813	0
100	Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. 2022 , 14, 175883592211180	180
99	Long Noncoding RNA Acting as Therapeutic Target for Oxidative Stress-Induced Pancreatic Cancer. 2022 , 1525-1557	0
98	Organoids. 2022 , 51, 608-616	0
97	Collagenase-Loaded H-TiO ₂ Nanoparticles Enhance Ultrasound Imaging-Guided Sonodynamic Therapy in a Pancreatic Carcinoma Xenograft Model via Digesting Stromal Barriers. 2022 , 14, 40535-40545	4
96	Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies. 2022 , 14, 4257	1
95	Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. 2022 , 14, 4209	1
94	Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer. 2022 , 11,	1
93	Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. 2022 , 64, 100864	0
92	Comparative proteomic analysis identifies key metabolic regulators of gemcitabine resistance in pancreatic cancer. 2022 , 100409	0
91	Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation. 2022 , 58, 1298	0
90	Sustained degradation of hyaluronic acid using an in situ forming implant.	0
89	Increasing cancer permeability by photodynamic priming: from microenvironment to mechanotransduction signaling.	0
88	XDec-CHI reveals immunosuppressive interactions in pancreatic ductal adenocarcinoma. 2022 , 105249	0
87	Serum levels of ICAF-derived osteoglycin predict favorable outcome in pancreatic cancer.	0
86	Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy. 2022 ,	0
85	NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1.	0

84	Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization.	0
83	Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. 2023 , 18,	2
82	Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy. 2022 , 14, 2033	0
81	Early Drug Development in Pancreatic Cancer. 2022 , 291-297	0
80	Translational alterations in pancreatic cancer: a central role for the integrated stress response. 2022 , 4,	0
79	Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system. 2022 , 41,	1
78	Stromal Homeostasis-Restoring Nanomedicine Enhances Pancreatic Cancer Chemotherapy.	0
77	Multiphasic Heterogeneity of Fibroblasts in the Microenvironment of Pancreatic Ductal Adenocarcinoma: Dissection and the Sum of the Dynamics. 2022 , 14, 4880	1
76	The role of cancer-associated fibroblasts in tumorigenesis of gastric cancer. 2022 , 13,	2
75	Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. 12,	0
74	Modeling Obesity-Driven Pancreatic Carcinogenesis: A Review of Current In Vivo and In Vitro Models of Obesity and Pancreatic Carcinogenesis. 2022 , 11, 3170	0
73	PD-L1-directed PLGF/VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer. 2022 , 13,	0
72	Targeting TNF- α -producing macrophages activate antitumor immunity in pancreatic cancer through IL33 signaling.	0
71	The importance of being CAFs (in cancer resistance to targeted therapies). 2022 , 41,	0
70	Targeting the tumor stroma for cancer therapy. 2022 , 21,	3
69	Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma. 1-24	0
68	Research advances and treatment perspectives of pancreatic adenosquamous carcinoma.	0
67	Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy. 2022 , 191, 114585	0

66	Nuclear FGFR1 promotes pancreatic stellate cell-driven invasion through up-regulation of Neuregulin 1.	0
65	Advances of Veratrum nigrum L. Steroid Alkaloids. 2023 , 191, 115946	0
64	Periplocin exerts antitumor activity by regulating Nrf2-mediated signaling pathway in gemcitabine-resistant pancreatic cancer cells. 2023 , 157, 114039	1
63	Effect of tocopherol conjugation on polycation-mediated siRNA delivery to orthotopic pancreatic tumors. 2023 , 145, 213236	0
62	Epithelial to Mesenchymal Transition as Mechanism of Progression of Pancreatic Cancer: From Mice to Men. 2022 , 14, 5797	0
61	Epithelial and stromal co-evolution and complicity in pancreatic cancer.	0
60	Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models. 2022 , 13,	1
59	Dual-targeted near-infrared photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in the tumor microenvironment. 2022 , 12,	0
58	Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives.	1
57	Cancer-Associated Fibroblast Diversity Shapes Tumor Metabolism in Pancreatic Cancer. 2023 , 15, 61	0
56	Liposome-based diagnostic and therapeutic applications for pancreatic cancer. 2022 ,	1
55	Dual Role of Fibroblasts Educated by Tumour in Cancer Behavior and Therapeutic Perspectives. 2022 , 23, 15576	3
54	Notch signaling regulates vasculogenic mimicry and promotes cell morphogenesis and the epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma. 2022 , 17, e0279001	0
53	Pancreatic Cancer: Beyond Brca Mutations. 2022 , 12, 2076	1
52	Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer.	4
51	Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. OF1-OF20	0
50	Nanocarriers-Based Targeted Therapies for Pancreatic Cancer and Challenges Ahead. 2022 , 129-148	0
49	Long-circulating magnetoliposomes as surrogates for assessing pancreatic tumour permeability and nanoparticle deposition. 2023 ,	0

- 48 Notch signaling regulates immunosuppressive tumor-associated macrophage function in pancreatic cancer. ○
- 47 Physical Activity Delays Obesity-Associated Pancreatic Ductal Adenocarcinoma in Mice and Decreases Inflammation. ○
- 46 Pre-treatment of oncolytic reovirus improves tumor accumulation and intratumoral distribution of PEG-liposomes. **2023**, 354, 35-44 ○
- 45 Resveratrol Loaded Liposomes Disrupt Cancer Associated Fibroblast Communications within the Tumor Microenvironment to Inhibit Colorectal Cancer Aggressiveness. **2023**, 13, 107 ○
- 44 Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI. **2023**, 15, 120 ○
- 43 HROP68: A rare case of medullary pancreatic cancer—characterization and chemosensitivity of the first patient-derived cell line. 12, ○
- 42 Cancer-associated fibroblasts: The chief architect in the tumor microenvironment. 11, 1
- 41 Perspective Chapter: Critical Role of Hedgehog in Tumor Microenvironment. ○
- 40 The Microbiome-TIME Axis: A Host of Possibilities. **2023**, 11, 288 ○
- 39 Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment. **2023**, 15, 724 ○
- 38 Targeting Periostin Expression Makes Pancreatic Cancer Spheroids More Vulnerable to Natural Killer Cells. **2023**, 11, 270 ○
- 37 Dual Drug Loaded Nanotheranostic Platforms as a Novel Synergistic Approach to Improve Pancreatic Cancer Treatment. 2200138 ○
- 36 Gene Therapy with p14/tBID Induces Selective and Synergistic Apoptosis in Mutant Ras and Mutant p53 Cancer Cells In Vitro and In Vivo. **2023**, 11, 258 ○
- 35 Quantitative proteomics analysis in small cell carcinoma of cervix reveals novel therapeutic targets. **2023**, 20, ○
- 34 Pancreatic cancer: Advances and challenges. **2023**, 186, 1729-1754 ○
- 33 Correlation between hypoxia and HGF/c-MET expression in the management of pancreatic cancer. **2023**, 1878, 188869 ○
- 32 A Novel 3DNA \square Nanocarrier effectively delivers payloads to pancreatic tumors. **2023**, 32, 101662 ○
- 31 Pharmacologically targeting KRASG12D in PDAC models: tumor cell intrinsic and extrinsic impact. ○

- 30 Pancreatic Cancer Treatment by Using Theragnostic Nanoparticles. **2022**, 149-168 ○
- 29 IL18 Receptor Signaling Inhibits Intratumoral CD8+ T-Cell Migration in a Murine Pancreatic Cancer Model. **2023**, 12, 456 ○
- 28 Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL). **2023**, 24, 2962 ○
- 27 Emerging Role of Cancer-Associated Fibroblasts in Progression and Treatment of Hepatocellular Carcinoma. **2023**, 24, 3941 ○
- 26 Photochemical Internalization Using Natural Anticancer Drugs, Antimetabolites, and Nanoformulations: A Systematic Study against Breast and Pancreatic Cancer Cell Lines. **2023**, 20, 1818-1841 ○
- 25 Direct cellular targets and anticancer mechanisms of the natural product oridonin. **2023**, 2, ○
- 24 Development of anti-cancer drug effect enhancers by transforming cancer-associated fibroblasts. **2023**, 38, 37-43 ○
- 23 Surface modification of TiO₂ nanoparticles with organic molecules and their biological applications. **2023**, 11, 2334-2366 ○
- 22 Pancreatic cancer stromal heterogeneity characterized by multiplex immunohistochemistry-based image analyses. **2023**, 38, 28-36 ○
- 21 Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond. **2023**, 45, 1914-1949 1
- 20 The upregulation of keratocan promotes the progression of human pancreatic cancer. ○
- 19 BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma. ○
- 18 Cancer-associated fibroblasts: Is it a key to an intricate lock of tumorigenesis?. **2023**, 47, 859-893 ○
- 17 Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression□ ○
- 16 The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. **2023**, 41, 374-403 ○
- 15 Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation. **2023**, 45, 2505-2520 ○
- 14 Ras-dependent activation of BMAL2 regulates hypoxic metabolism in pancreatic cancer. ○
- 13 Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy. ○

- 12 The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets. 13,
- 11 The Gut Microbiome and Pancreatic Cancer Development and Treatment. **2023**, 29, 49-56
- 10 Fibroblasts as Turned Agents in Cancer Progression. **2023**, 15, 2014
- 9 Tumor microenvironment signaling and therapeutics in cancer progression.
- 8 Recent advances in targeted therapy for pancreatic adenocarcinoma. 15, 571-595
- 7 An agarose-alginate microfluidic device for the study of spheroid invasion, ATRA inhibits CAFs-mediated matrix remodeling.
- 6 Fibroblasts in cancer: Unity in heterogeneity. **2023**, 186, 1580-1609
- 5 Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities. **2023**, 15, 2354
- 4 Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression.
- 3 Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity. **2023**, 5,
- 2 Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions. **2023**,
- 1 USP7 - a crucial regulator of cancer hallmarks. **2023**, 1878, 188903